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Abstract 
NMDA receptors are ionotropic, glutamate receptors which mediate fast excitatory 
transmissions within the central nervous system. They form tetrameric or 
pentameric heterologous complexes from seven NMDA receptor subunits NRI, 
NR2A-D and NR3A-B which each convey distinct expression patterns, functional 
and pharmacological properties to the receptor complex. Due to its involvement in 
excitatory transmission, over-excitation of the NMDA receptor, particularly the 
NR2B subunit, has been the focus of pharmaceutical therapeutic targeting for 
neurodegenerative conditions and chronic pain. This thesis discusses the potential 
importance and clinical effectiveness of targeting NMDA receptors and the 
difficulties in drug development arising from the receptor's heteromeric nature. 
The work herein focuses on the pharmacological characterisation of two novel 
NR2B-selective antagonists Compound A and Compound B, the physiological and 
pharmacological effects of NR3 subunit inclusion in the NMDA receptor complex, 
and the modifications of NMDA receptor physiology and subunit expression during 
chronic pain states. 
This research provides novel evidence to suggest that Compound A and Compound 
B bind with a high selectivity and affinity towards NR1/NR2B containing receptors. 
It provides novel evidence for a differential cytoprotective effect of the NR3 subunits 
showing significant cytoprotection in NR1/NR2B, but not NR1/NR2A, receptors and 
shows that NR3B inclusion in the receptor can differentially modulate the binding 
affinities ofNR2B-selective antagonists. 
This study also shows evidence for increased activity of spinal and supra-spinal 
NR2B'-containing receptors iridicating"NMDAreceptor modUiailon and involvement 
in a chronic pain model. 
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90minutes. Non-specific binding was defined with ketamine 
(1mM). 
Chapter4 
Schematic diagram of immunoglobulin structure 
Immunoblot showing recombinant NR3B, NR3A and NR1 
subunits expressed in HEK 293 cells. Probed with anti-
rodent NR3B (2~g/ml). Representative from n=3 
experiments. 
Immunoblot showing adult rat forebrain (1) and spinal cord 
(2) membranes (30~g) and recombinant NR3B expressed in 
HEK 293 cells (3+4), probed with anti-rodent NR3B 
(2~g/ml). Representative from n=3 experiments. 
Immunoblot showing adult rat forebrain (1+4) and spinal 
cord (2+5) (30~g, respectively), and recombinant NR3B 
(3+6) subunits expressed in HEK 293 cells probed overnight 
with anti-rodent NR3B (2~g/ml). Representative from n=2 
experiments. 
Immunoblot showing post-mortem human putamen 
membranes (1) (50~g) and adult rat forebrain membranes 
(2) (30~g) probed with anti-human NR3B (2~g/ml). 
representative from n=3 experiments. 
Immunoblot (n=1) showing adult rat spinal cord 
meinbranes. (1+6), aduft' ~rat 'f'()rellrain membra-nes (2+ 7) 
(30~g) and human putamen membranes (4,5,8+9)(50~g) 
probed with anti-human NR3B (2~g/ml). Lane 3 was loaded 
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with sample buffer. 
Representative immunoblot (n=2) showing adult rat 
forebrain membranes (1) and adult rat spinal cord 
membranes (2) (301lg) and recombinant NR3B expressed in 
HEK 293 cells (3+4) probed with commercial anti-NR3B 
(1:1000). 
Representative immunoblots (n=3) showing adult rat 
forebrain membranes (251lg) (Lane 1) and adult rat spinal 
cord membranes (251lg) (Lane 2), probed overnight with 
anti-rNR1 (21lgfml) (A), anti-rNR2A (21lgfml) and anti-
rNR2B (21lg/ml). 
Schematic diagram showing the laminae layers in the dorsal 
and ventral regions of the rodent lumbar spinal cord. 
Control sections showing the immunoreactivity in tissue in 
the absence of primary antibodies in the cervical dorsal 
horn (A), the lumbar dorsal horn (B) and the thoracic 
ventral horn (C). Low resolution image of the cervical cord 
showing NR1 immunostaining (Bigini et al., 2006) with red 
arrows highlighting the dorsal and ventral areas of the cord 
focused upon in this study. 
Expression of NR1 (probed anti-rNR1 21lg/ml) (A), NR3B 
(commercial anti-rNR3B 1:1000) (B) in the dorsal horns 
laminae I, 11, Ill and ventral horns showing the motor 
neurons (MN) of the cervical rat spinal cord (n=2). Scale 
bars represent 100jlm. 
Expression of NR2A (anti-rNR2A 21lgfml) (C) and NR2B 
(anti-rNR2B 21lg/ml) (D) in the dorsal horn laminae I, 11, Ill 
and ventral horns showing the motor neurons (MN) of the 
cervical rat spinal cord (n=2). 
Expression of NR1 (probed anti-rNR1 11lg/ml) (A), NR3B 
(commercial anti-rNR3B 1:1000) (B) in the dorsal horn 
laminae I, 11, Ill and ventral horns .. showing--the motor 
neurons (MN) of the thoracic rat spinal cord (n=2). Scale 
bars represent 100jlm. 
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Expression of NR2A (anti-rNR2A 2Jlgfml) (C) and NR2B 
(anti-rNR2B 2Jlg/ml) (D) in the dorsal horn laminae I, 11, Ill 
and ventral horns showing the motor neurons (MN) of the 
thoracic rat spinal cord (n=2). Scale bars represent 100Jlm. 
Expression of NR1 (probed anti-rNR1 1Jlg/ml) (A), NR3B 
(commercial anti-rNR3B 1:1000) (B) in the dorsal horn 
laminae I, 11, Ill and ventral horns showing the motor 
neurons (MN) of the lumbar rat spinal cord (n=2). Scale 
bars represent 100Jlm. 
Expression of NR2A (anti-rNR2A 2Jlg/ml) (C) and NR2B 
(anti-rNR2B 2Jlg/ml) (D) in the dorsal horn laminae I, 11, Ill 
and ventral horns showing the motor neurons (MN) of the 
lumbar rat spinal cord (n=2). Scale bars represent 100Jlm. 
Expression of NR1 (probed anti-hNR1 1Jlg/ml) (A), NR3B 
(commercial anti-rNR3B 1:1000) (B) in the dorsal horn 
laminae I, 11, Ill and ventral horns showing the motor 
neurons (MN) of the cervical human spinal cord (n=1). 
Scale bars represent 100Jlm. 
Expression of NR2A (anti-rNR2A 2Jlg/ml) (C) and NR2B 
(anti-rNR2B 2Jlg/ml) (D) in the dorsal horn laminae I, 11, Ill 
and ventral horns showing the motor neurons (MN) of the 
cervical human spinal cord (n=1). Scale bars represent 
100Jlm. 
Representative immunoblots (n=2) showing solubilised 
membranes (lane 1) and unsolubilised membranes (lane 2) 
probed overnight with anti-rNR1 (2Jlg/ml) (A), anti-rNR2B 
(2Jlg/ml) (B), anti-rNR2A (2Jlgfml) (C) and anti-rNR3B 
(1:1000) (D). 
Immunoblot showing adult rat spinal cord homogenate 
(25Jlg/ml) (SC), solubilised membranes (S), unsolubilised 
membranes (DT), unbound material (UB) and elutions 1-5 
(E1-5), probed overnight with anti-NR1 (2Jlg/ml), anti-
NR2A (2Jlg/ml), anti:-NR2B (2Jlg/ml) and anti:.NR3B 
(1:iOOO). . Representative immunoblots from n=3 
experiments. 
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4.21 Immunoblots (n=1) showing solubilised and unsolubilised 138 
membranes at 0.75% [SOS] (1+2), solubilised and 
unsolubilised membranes at 0.5% [SOS] (3+4), solubilised 
and unsolubilised membranes at 0.25% [SOS] (5+6), 
solubilised and unsolubilised membranes at 0.1% [SOS] and 
solubilised and unsolubilised membranes at 0.05% [SOS]. 
Probed with anti-NR1 (2~g/ml) (A), anti-NR2A (2~g/ml) 
(B), anti-NR2B (2~g/ml) and anti-NR3B (1:1000). 
4.22 Immunoblots (n=1) showing solubilised and unsolubilised 139 
membranes at 0.5% [SOS] (1 +2), solubilised and 
unsolubilised membranes at 0.4% [SOS] (3+4), solubilised 
and unsolubilised membranes at 0.3% [SOS] (5+6), 
solubilised and unsolubilised membranes at 0.2% [SOS]. 
Probed with anti-NR1 (2~g/ml) (A), anti-NR2A (2~g/ml) 
(B), anti-NR2B (2~gjml) and anti-NR3B (1:1000). 
4.23 Representative immunoblots (n=2) showing purified 141 
fractions from an anti-NR1 affinity column. Spinal cord 
homogenate (25~gjml) (SC), solubilised membranes (S), 
unsolubilised membranes (OT), unbound material (UB) and 
elutions 1-5 (E1-5). Probed with anti-NR1 (2~g/ml) (A), 
anti-NR2A (2~g/ml) (B), anti-NR2B (2~g/ml) and anti-NR3B 
(1:1000). 
4.24 Representative immunoblots (n=2) showing purified 142 
fractions from an anti-NR2A affinity column. Spinal cord 
homogenate (25~g/ml) (SC), solubilised membranes (S), 
unsolubilised membranes (DT), unbound material (UB) and 
elutions 1-5 (E1-5). Probed with anti-NR1 (2~gjml) (A), 
anti-NR2A (2~g/ml) (B), anti-NR2B (2~g/ml) and anti-NR3B 
(1:1000). 
4.25 Representative immunoblots (n=3) showing adult rat 144 
forebrain membranes (20~g) (1), adult rat cervical cord 
membranes (20~g) (2) and adult rat thoracic/lumbar cord 
membranes (20~g) (3). Probed with anti-rNR2A (2~g/ml), 
anti-rNR2B (2~g/ml) and anti-rNR3B (1:1000). 
4.26 Re-probing the immunoblots in figure 4.f2 witl:utntj-:_mouse . 144 
~-actin (1:1000). >lhu:iiurfoblot.siio\Zi~g'~-d~lt rat forebrain 
membranes (20~g) (1), adult rat cervical cord membranes 
(20~g) (2) and adult rat thoracic/lumbar cord membranes 
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(20~g) (3). 
Chapter 5 
Schematic diagram representing electrode position and cell 
placement in the microscope bath beneath the barrels used 
for rapid agonist and antagonist application (From Jon 
Spencer, GSK). 
The percentage cytotoxicity of HEK 293 cells expressing 
various combinations of NMDA receptor subunits *p<0.05, 
**p<O.Ol, ***p<O.OOl one way ANOVA. 
Electrophysiological traces of peak amplitudes (pA) 
obtained from recombinant NR1/NR2B (A), 
NR1/NR2B/NR3B (B) and NR1 (C) receptors. Histogram 
(D) and data range charts (E) show the mean ± SD for 25 
individual experiments. 
Current/voltage (IV) relationships for NR1/NR2B (A) and 
NR1/NR2B/NR3B (B) receptors expressed in HEK 293 cells, 
showing no statistical differences between channel 
characteristics. 
Calcium permeability experiments, measuring the shift in 
reversal potential of the receptor channel between 0.3 and 
30mM extracellular calcium. 
Characterisation of magnesium sensitivity of recombinant 
NR1/NR2B (A) (n=8) and NR1/NR2B/NR3B (B) (n=6) 
receptors using current/voltage (1/V) relationships. 
Electrophysiological traces depicting the sensitivity of 
NR1/NR2B (A) and NR1/NR2B/NR3B (B) receptors 
towards lOOuM concentrations of magnesium and a 
histogram (C) representing the mean ± SD of data from all 
experiments. 
Electrohysiological traces representing the signals 
measured from NR1/NR2B (A) and NR1/NR2B/NR3B (B) 
receptor complexes when. expo~ed .to. 2Q~M AnC1gnesium 
chloride, -~m(f ·a. 'histog;~~;; ~(c)- sh~~-ng-the mean± so of all 
data sets. 
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Differential cytoprotective effects of the NR2B-selective 
antagonists ifenprodil (A), COMPOUND B (B) and 
COMPOUND A (C) upon NR1/NR2B and NR1/NR2B/NR3B 
receptor complexes * p=<0.05, **p=<0.01 Two-tailed T-Test. 
Electrophysiological traces representing inhibition of 
signals from recombinant NR1/NR2B (A) and 
NR1/NR2B/NR3B (B) receptors. Figure C represents the 
mean ± SO of percentage inhibition from all data sets. 
Electrophysiological traces representing the inhibition of 
NR1/NR2B (A) and NR1/NR2B/NR3B (B) receptor activity 
by 300nM CP-101606. Figure C shows the mean ± SO of 
percentage inhibition from all data sets. 
Electrophysiological traces representing the inhibition of 
NR1/NR2B (A) and NR1/NR2B/NR3B (B) receptor activity 
by 300nM CP-101606. Figure C shows the mean ± SO of 
percentage inhibition from all data sets. 
Electrophysiological traces representing the inhibition of 
NR1/NR2B (A) and NR1/NR2B/NR3B (B) receptor activity 
by 30nM CP-101606. Figure C shows the mean ± SO of 
percentage inhibition from all data sets. 
Electrophysiological traces showing the inhibition of 
NR1/NR2B (A) and NR1/NR2B/NR3B (B) receptor activity 
by the NR2B-selective antagonist Ro 256981 (101J.M 10 
seconds). Figure C shows the mean ± SO of percentage 
inhibition from all data sets. 
Electrophysiological traces showing the inhibition of 
NR1/NR2B (A) and NR1/NR2B/NR3B (B), by recombinant 
receptor activity by Ro-256981 (30nM, 60seconds). Figure 
C, shows signal from NR1/NR2B receptors before antagonist 
application, Figure E, shows signal from NR1/NR2B/NR3B 
receptors before antagonist application. Figure D, shows 
the mean ± SO of percentage inhibition from all data sets. 
Conmeq9on bindJJlg ~l"lowing.~o:-site displacementof [3H] 
CP-101606 by COMPOUND A in recombinant NR1/NR2B 
and NR1/NR2B/NR3B receptors. The results displayed are 
mean ± SO of three individual experiments and non-specific 
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binding was defined using 1mM ifenprodil. 
Competition binding experiments showing the displacement 
of [3H] CP-101606 by COMPOUND Bin recombinant 
NR1/NR2B and NR1/NR2B/NR3B receptors. Data shown is 
mean ± SD for two individual experiments and non-specific 
binding was defined using 1mM ifenprodil. 
Histogram representing specific binding data for [3H] Ro-
256981 in recombinant NR1/NR2B and NR1/NR2B/NR3B 
receptors. The data shown is mean ± SD for two individual 
experiments. Non-specific binding was defined using 1mM 
ifenprodil. 
Histogram to represent the specific binding data for [3H] CP-
101606 in recombinant NR1/NR2B and NR1/NR2B/NR3B 
receptors. The data shows the mean ± SD for two individual 
experiments. Non-specific binding was defined with 1mM 
ifenprodil 
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6.1 Schematic (Tolle et al., 1993) and low resolution images (Liu 201 
et al., 1994) of the cord highlighting the dorsal (outer 
lamina) and ventral regions (motor neurons) investigated in 
this study (A) and control sections showing the 
immunoreactivity in tissue in the absence of primary 
antibodies in the lumbar dorsal horn (B), the lumbar ventral 
horn (C), the thoracic dorsal horn (D) and the thoracic 
ventral horn (E). 
6.2 Expression of NR1 protein in the dorsal (A) and ventral (B) 202 
horns of the thoracic cord in a sham animal probed with 
anti-NR1 (1J..Lg/ml). The outer laminae I, 11, Ill are labelled 
in the dorsal horn (A) and cell bodies of motor neurons 
(MN) in laminae IX in the ventral horn (B). Scale bar 
represents 100nm. 
6.3 Expression of NR2A protein in the ventral horns of lumbar 203 
spinal cord in sham (A) and FCA model (B) animals, probed 
with anti-NR2A (2J..Lgfml). The cell bodies of the motor 
neurons (MN) within laminae IX show high levels of NR2A 
Heather Chaffey 
protein expression. Scale bar represents 100nm. 
6.4 Expression of phosphorylated NR2A subunit at tyrosine 205 
residue 1325 in the dorsal horn of sham (A) and FCA (B) 
lumbar cord tissue. Weak immunoreactivity is present 
particularly in the outer laminae (1, 11 and Ill) of the dorsal 
horn. Scale bar represents 100nm. 
6.5 Expression of phosphorylated NR2A subunit at tyrosine 205 
1387 in the dorsal horn of sham (A) and FCA (B) lumbar 
cord tissue. Initial evidence for increased phosphorylation 
of NR2A at tyrosine 1387 in the outer laminae (I, 11 and Ill) 
during the inflammatory response. Scale bar represents 
100nm. 
6.6 Expression of NR2B protein within the dorsal horns of 206 
lumbar spinal cord in sham (A) and FCA (B) tissue. NR2B 
shows expression in the outer laminae (I, 11 and Ill) in both 
sham and model tissue showing involvement in sensory 
inputs to the cord. Scale bar represents 100nm. 
6. 7 Expression of phosphorylated NR2B at tyrosine 1252 within 207 
the dorsal horn of lumbar sham (A) and FCA (B) tissue. 
6.8 
6.9 
Similar levels of immunoreactivity suggest no alteration in 
phosphorylation of Nr2B at this residue in the outer laminae 
I, 11 and Ill of the dorsal horns. Scale bar represents 100nm. 
Expression of phosphorylated NR2B at residue y1336 
within the dorsal horn of lumbar sham (A) and FCA (B) 
tissue. Initial evidence for increased phosphorylation of 
NR2B at this residue in the outer laminae I, 11 and Ill, 
suggesting potentiation of sensory NR2B-mediated 
transmission. Scale bar represents 100nm. 
Expression of phosphorylated NR2B at residue y1472 
within the dorsal horn of lumbar sham (A) and FCA (B) 
tissue. Initial evidence for enhanced phosphorylation of the 
NR2B subu'nit at residue 1472, in outer laminae I, 11 and Ill, 
important for blockade~ of receptof 'internalisation. Scale bar 
represents 100nm. 
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Expression of NR3B protein within the dorsal horns of the 
lumbar spinal cord in sham (A) and FCA (B) tissue. Initial 
evidence for increased NR3B expression in outer laminae I, 
11 and Ill following onset of the inflammatory response. 
Scale bar represents 100nm. 
209 
6.11 Expression of PSD-95 within the ventral horns of the lumbar 210 
cord in sham (A) and FCA (B) tissue. Initial evidence for 
increased expression of PSD-95 in the motor neuronal soma 
6.12 
(MN) of FCA model tissue (B) in comparison with sham 
tissue (A). Scale bar represents 100nm. 
Representative autoradiograms of adult rat lumbar spinal 
cord using (3H] Ro-256981 in sham (A) and FCA treated (B) 
animals. Representative image showing non-specific 
binding defined using ifenprodil (1mM) (C). 
213 
6.13 Autoradiographical data showing [3H] Ro-256981 binding 215 
within the dorsal and ventral horns of sham and FCA spinal 
cord. 
Data shown are the mean values ± standard deviation for 
n=4 sham and n=4 FCA spinal cords. Sham and FCA tissue is 
compared in the dorsal horn of the lumbar cord (A), the 
ventral horn of the lumbar cord (B), the dorsal horn of the 
thoracic cord (C) and the ventral horn of the thoracic cord 
(D). Levels of [3H] Ro-256981 binding are higher in the 
lumbar region than the thoracic region, consistent with 
NR2B immunoreactivities in IHC experiments. 
6.14 Representative horizontal (A+B) and coronal (C+D) 217 
autoradiograms showing [3H] Ro-256981 binding within 
sham and FCA-treated rat brains. Non-specific binding was 
defined using 1mM ifenprodil (E). 
6.15 Autoradiographical data showing [3H] Ro-256981 binding 219 
within the whole brain of sham and FCA-treated animals. 
Data shown are the means ± standard deviation of between 
n=3/4 sham and n=3/4 FCA whole brains. Sham and FCA 
tissue ··is compared· in 1° sorrfatoserisory coite:X fAr the zo 
somatosensory cortex (B), the cingulate cortex (C), the 
periaqueductal grey (D). 
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6.16 Autoradiographical data showing (3H] Ro-256981 binding 220 
within the whole brains of sham and FCA treated animals. 
Data shown are the means ± standard deviation of between 
n=3/4 sham and n=3/4 FCA whole brains. Sham and FCA 
tissue is compared in hippocampal regions CA1 (E), CA2 (F), 
CA3 (G), the dentate gyrus (H).* p=< 0.05 Unpaired Two-
tailed T-Test. 
6.17 Autoradiographical data showing [3H] Ro-256981 binding 221 
within the whole brains of sham and FCA-treated animals. 
Data shown are the means ± standard deviation of between 
n=3/4 sham and n=3/4 FCA whole brains. Sham and FCA 
tissue is compared in the thalamus (I) and all brain regions 
in both hemispheres combined (p=0.05) (J). * p=<0.05 
Unpaired Two tailed T-Test. 
Chapter 7 
7.1 Schematic diagram showing the binding affinities and 234 
selectivity towards NR2B-containing receptors of Ro-
256981, CP-101606, COMPOUND A and COMPOUND B, and 
the potential allosteric interaction of COMPOUND B with the 
channel pore. 
7.2 A schematic diagram showing the differential protective 236 
effect of the NR3 subunits upon the proposed NMDA-
mediated calcium toxicity in NR1/NR2A and NR1/NR2B 
receptors. 
7.3 A schematic diagram showing that the inclusion of an NR3B 240 
subunit into the receptor complex may have an allosteric 
7.4 
effect upon the LIVBP binding domain of the NR2B-selective 
antagonists. 
A schematic diagram showing the pathway of chronic pain 
transmission from the spinal cord, through the brainstem 
and into the cortex (Analgesia, UK) and the changes in the 
NMDA receptor which may contribute to the persistent 
response. 
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Chapter 1 
Introduction 
1.1 Neurotransmitters within the central nervous system 
Essential signalling mechanisms within the central nervous system (CNS) rely upon 
selective release of neurotransmitters and their interactions with specific receptors. 
As the primary excitatory neurotransmitter in the CNS, glutamate and its receptors 
are a major target for combating ·many disease states, which can manifest due to 
hyper or hypo-activation of these receptors. Widely expressed throughout the CNS, 
the N-methyl-D-aspartate (NMDA) receptor is a glutamate receptor that mediates 
neurotransmission via calcium influx upon neuronal depolarisation. As such it is 
vital for normal neuronal function and any modulations to this balanced system -may 
cause disease. 
This introduction will discuss the NMDA receptor, its multiple subunit structure, 
distribution, eo-assembly, physiology and pharmacology in detail with particular 
focus on the specific properties ofNR2B and NR3 subunits. 
1.2 Glutamate receptors within the central nervous system 
The amino acid L-glutamate is the most ubiquitous excitatory neurotransmitter in the 
central nervous system, mediating its effects via a large family of ionotropic and 
metabotropic receptors. 
Metabotropic glutamate receptors are seven transmembrane-domain G-protein-
coupled receptors that control intracellular signalling cascades (Nakanishi, 1994; 
Jordan et al., 1999; Roche et al., 1999; Chan et al., 2001) and provide modulatory 
and regulatory roles in neurotransmission (Takanishi et al., 1993; Malherbe et al., 
1999; Kew and Kemp, 2005). Eight family members (mGluR1-8) have been 
@ 
Chapter 1 Heather Chaffey 
identified to date, which have subsequently been divided into three groups according 
to sequence homology, secondary messenger coupling and pharmacology. As 
shown in Figure 1, group I, containing mGluRl and R5, predominantly couple to 
phospholipase C (PLC), whereas groups II (mGlu-R2 and R3) and m (mGlu-R4, R6, 
R 7 and R8) regulate adenylyl cyclase activity (Kew and Kemp, 2005). 
Ionotropic glutamate receptors (iGluRs) are ligand-gated channels divided into three 
groups (AMP A, Kainate and NMDA) and named according to the pharmacological 
tools used to selectively activate them. AMP A and kainate receptors display 
predominance for sodium and potassium permeability, whereas NMDA receptors are 
predominantly calcium permeable. 
lonotropic receptors (!GiuRs) 
AM PAR NMDAR 
K K K 
rvv 
Metabotropic receptors (mGiuRs) 
!Group I 
mGiuR5 
ea release 
.. 
Goups 11 , Ill 
AMP cAMP 
mGiuR2 
mG!uR3 
mGJuR4 
rnG!uR6 
mGiuR7 
mGiuR8 
Figure 1.1 A schematic diagram representing the two classes of glutamate receptor (A) 
(Verkhratsky and Kirchoff, 2007). 
2 
Chapter 1 Heather Chaffey 
1.3 The NMDA receptor 
Located throughout the central nervous system, the NMDA receptor forms a major 
subclass of excitatory L-glutamate receptor (Chazot and Stephenson, 1997; 
Stephenson 2001). NMDA receptors are heterologous complexes of essential and 
modulatory subunits, eo-assembled in various tetrameric or pentameric arrangements 
(Wafford et al., 1993; Sheng et al., 1994; Chazot et al., 1994). Seven NMDA 
receptor subunits have been identified to date, each providing specific modulatory 
influences on the receptor complex. Initial cloning of the NR1 subunit by Moriyoshi 
et al., 1991 was followed rapidly by the identification and cloning of the four NR2 
subunits NR2A, NR2B, NR2C and NR2D (Kutsuwada et al., 1992; Monyer et al., 
1992; Ishii et al., 1993) and the two NR3 subunits: NR3A (Ciabarra et al., 1995; 
Sucher et al., 1995) and NR3B (Nishi et al., 2001; Matsuda et al., 2002). 
The NR1 subunit is obligatory for NMDA receptor function and at least one NR1 
subunit is therefore always incorporated into the receptor complex. The NR1 
combines with at least one modulatory NR2 (A-D) subunit and more infrequently a 
modulatory NR3 (A-B) subunit. 
This heterologous nature confers a huge potential capacity for flexible modulation of 
the nervous system with different heteromers displaying individual biological and 
pharmacological characteristics. 
1.3.1 NMDA receptor activation and modulatory binding sites 
In addition to the complexity of NMDA receptors arising from multiple subunit eo-
assembly, two co-agonists glutamate and glycine, must be present in order to activate 
the receptor channel. 
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Early research expressing homomeric NR1 subunits (Boeckman et al., 1994) and 
homomeric NR2 subunits (Kutsuwada et al., 1992) failed to produce functional 
receptors fuelling the theory that neither subunit possessed the ability to function in 
isolation and that they must form heteromeric complexes. Research using site 
directed mutagenesis has since shown that the glycine binding site is present on the 
NR1 subunit (Kuryatov et al., 1994), with the glutamate binding site on the NR2 
subunit (Laube et al., 1998). It is thought that the agonists bind to the S 1 and S2 
regions (see section 1.3.3), inducing conformational changes and folding of the 
proteins, inducing channel opening (Priestley, 2002). 
The synthetic compound N-methyl-D-aspartate, an analogue of L-glutamate is 
frequently used as an agonist for research and it was the initial activation of these 
receptors by NMDA which led to its nomenclature. 
The receptor complex also has many other binding sites available for allosteric 
modulators such as a redox site, Zn2+ and endogenous polyamine binding sites. 
There are also multiple phosphorylation and glycosylation sites on the cytoplasmic 
tail, which are very important for regulation of NMDA activity (Zigmond et al., 
1999; Kew and Kemp, 2005). 
1.3.2 NMDA channel kinetics 
NMDA receptors are membrane-bound, ligand-gated, non-selective cation channels 
characterised by voltage-dependent activity, high calcium permeability and 
comparatively slow activation/deactivation kinetics (Cull-Candy et al., 2001; 
Stephenson, 2001; Takai et,al~, 2003). NMDA receptor channel kinetics are largely 
influenced by subunit combination with each NR2 and NR3 subunit conferring 
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different modulatory properties on the receptor complex (see table 1.1). For example 
NR1/NR2A receptors show very fast (millisecond) deactivation following excitatory 
currents, whereas NR1/NR2D receptors deactivate much more slowly (seconds) 
(Cull-Candy et al., 2001; Wyllie et al, 1998). 
NR2A Fast deactivation High principal 
('t decay ~90ms) conductance state High sensitivity 
High permeability Ca2+ ~SOpS 
NR2B Slower deactivation High principal 
('t decay ~370-400ms) conductance state High sensitivity 
High permeability Ca2+ ~SOpS 
NR2C Slower deactivation, Lower principal 
('t decay ~370-400ms) conductance state Reduced 
Lowered permeability ~30pS sensitivity 
Ca2+ 
NR2D Very slow deactivation Lower principal 
('t decay ~800ms) conductance state Reduced 
Lowered permeability ~30pS sensitivity 
Ca2+ 
NR3AIB Low permeability Ca2+ Lower conductance Reduced 
sensitivity 
Table 1.1 Modulatory properties inferred by the various NR2 and NR3 subunits on the 
receptor complex, data obtained from Gibb and Colquhoun, (1991), Cull-Candy et al., 
2001 and Priestley, (2002). 
At negative membrane potentials, current flux through the NMDA receptors is vastly 
reduced in the presence of micromolar concentrations of magnesium, forming a 
voltage-dependent magnesium block (Nowak and Wright 1992) which is relieved 
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when the membrane is depolarized beyond ----4-0mV. An asparagine residue in the 
pore-forming region has been shown to play a major role in the magnesium 
sensitivity particularly in the NR2 subunits where NR2A and NR2B-containing 
receptors display higher sensitivities towards magnesium blockade than NR2C and 
NR2D-containing receptors (Cull-Candy et a/, 2001). Research by Williams et al., 
1998 also showed the importance of a tryptophan residue in the same region of the 
M2 domain for Mg2+ sensitivity, with mutations to this residue greatly attenuating 
the magnesium blockade ofNR2B-containing receptors. 
The voltage dependence and degree of Mg2+ inhibition can be modulated by 
permeant ions (Qian and Johnson, 2006; Antonov and Johnson, 1999), a factor 
which is thought to be important in receptor function and modulation of synaptic 
transmissions. Studies by Hori and Carpenter, (1994) and Zhang et al., (1996) show 
that large fluctuations in the concentration of permeant ions under pathological 
conditions can also alter Mg2+ inhibition (Qian and Johnson, 2006), thereby 
modulating receptor role and function. 
1.3.3 NMDA receptor subunit structure 
Structurally, NMDA receptor subunits have a large extracellular N-terminal region 
followed by three transmembrane domains (M1, 3, 4) and a pore-forming domain 
(M2) which forms a re-entrant loop (Dingledine et al., 1999). The M2 domain 
contains an asparagine residue in a sequence of three amino acids, the QRN site 
(amino acid position between 598 and 612 depending on specific subunit) which is 
critical for Ca2+ permeability and Mg2+ sensitivity (Nishi et al., 2001; Stephenson, 
2001; Matsuda et al., 2002). Th~ third and fourth_ transmembrane domains,share a 
large extracellular loop (S2 region), which forms the agonist binding domain with 
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the extracellular N-terminal (S 1 region) (Armstrong et al., 1998; Dingledine et al., 
1999; Kew and Kemp, 2005; Stephenson, 2001). The cytoplasmic C-terminus varies 
in size depending on the subunit and contains multiple sites for interaction with 
intracellular proteins (Dingledine et al., 1999). 
A B 
Channel closed 
Subunit 
Channel open _A 
G ~ 
Figure 1.2 Schematic diagram showing an NMDA receptor channel in the closed and open 
positions (A) and the predicted transmembrane topology of individual subunit (B) 
showing the extracellular amino terminals, the intracellular carboxyl terminals , the 
membrane domains (Ml-4) and the agonist and NR2B-selective antagonist binding sites. 
1.3.3.1 The NR1 subunit structure 
The 120KDa NRI subunit is essential for channel formation and incorporates the 
binding site for the receptor eo-agonist glycine. The NR1 gene consists of22 exons 
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that give rise to eight distinct splice variants, namely NR1-1a, NR1-1b to NR1-4a 
and NR1-4b, due to three sites of alternative splicing (Stephenson, 2001; Cull-Candy 
et al., 2001; Blahos and Wenthold, 1996). The splice variants can be characterised 
by the presence or absence of exon 5 (21 amino acid sequence) in theN-terminal 
region and by differential splicing of exons 21 (Cl) and 22 (C2) in the C-terminal 
region (Stephenson, 2001 ). Studies investigating the influence of each variant have 
shown that different splice variants can co-exist within the same receptor complex 
(Chazot and Stephenson, 1997b) and that there is no preferential assembly ofNR2 
subunits and particular NRl variants (Blahos and Wenthold, 1996). Research has 
shown the existence of intracellular pools of unassembled NR1-C2-exon-containing 
NRl subunits (Chazot and Stephenson, 1997b) and that homomeric complexes of 
NRl subunits containing the C2 exon can be expressed at the cell surface (Standley 
et al., 2000) and bind the NMDA selective antagonist MK.-801 (Chazot et al., 1991) 
fuelling speculation that they can form glycine receptors that function independently 
of glutamate binding (Stephenson, 2001 ). 
1.3.3.2 The NR2 subunit structure 
In order to form a functional NMDA receptor, NRl must eo-assemble with at least 
one of four modulatory NR2 subunits (2A-D), which are essential for glutamate 
binding. The NR2 subunits are larger than NR1, with molecular masses of~ 170-
180KDa for NR2A and NR2B (Kopke et al., 1993; McBain and Mayer, 1994) and 
~150KDa for NR2C and NR2D (Akesson et al., 2000). The quaternary structure of 
the NMDA receptor is therefore potentially very large, with masses ranging from 
630-850 KDa (Wenthold et al., 1992; Brose et al., 1993; Chazot et al., 1994; Blahos 
and Wenthold, 1996). There is approximately 70% amino acid sequence homology 
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between the NR2A and NR2B subunits, with a similar degree of homology between 
the NR2C and NR2D subunits (see figure 1.3A). However, this homology decreases 
to approximately 55% between the two pairs of subunits. (Stephenson 2001). Both 
the NR2C and NR2D subunit genes undergo alternative splicing to form two 
isoforms (Ishii et al. 1993; Suchanek et al. 1995) though the functional significance 
ofthese variations is largely unknown (see figure 1.3B). 
1.3.3.3 The NR3 subunit structure 
NR3A and NR3B make up the most recently discovered NMDA receptor subunit 
family. NR3A was first identified from the mouse genome in 1995 (Ciabarra et al., 
1995; Sucher et al., 1995) and was so named due to its similarity to known NMDA 
receptor subunits (27% homology to NR1 and NR2). The human NR3A gene 
(GRIN3A) shows 92.7% sequence identity to rat NR3A and is localized to 
chromosome 9q34 in the region 13-34 and translates into a protein with a molecular 
mass ~100KDa (Andersson et al., 2001). NR3B was then discovered in 2001 in the 
human and mouse genomes (Nishi et al., 2001; Matsuda et al., 2002) following 
identification of a unique sequence showing significant homology to the glutamate 
receptor family (Nishi et al., 2001) and particularly with NR3A with which it shares 
62% homology (Matsuda et al., 2002). The human gene (GRIN3B) contains eight 
coding exons, is localised to chromosome 19p 13.3 and the protein product has a 
molecular weight of~ 1 OOKDa (Andersson et al., 2001 ). 
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A .----------------------------------- NR1 
-
_Q:.1_ 
B 
* NR1 1 ~ 1 
NR2A I I I 
NR2B I l i l 
* * NR2C I 1' 1 
NR2D I I f I 
NR3A I I I 
NR3B I I I 
I,----- NR2A 
~~----NR2B 
.--------- NR2C 
'-------- NR2D 
.------NR3A I 
I 
'-------- NR3B 
* * I 
I 
I 
I 
* I 
* I 
I 200 amino acids 
Figure 1.3 Phylogenic tree (A) showing NMDA receptor subunit homology and 
polypeptide sequences (B) showing transmembrane domains (black and grey boxes) and 
regions of alternative splicing (asterisks). Taken from Cull-Candy et al., 2 001. 
1.4 Regional distribution of the NMDA receptor subunits 
In the early 90's the regional expression ofNMDA receptor subunits was a focus for 
many research groups (Monyer et al. 1992; Buller et al., 1994, Akazawa et al., 1994 
and Sucher et al., 1995) using in situ hybridisation and immunohistochemical 
techniques. Since then, studies have been carried out using genetic, immunological 
and pharmacological probes to investigate NMDA receptor subunit expression and 
eo-association in different regions of the CNS. 
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1.4.1 NR1 expression 
The NR1 subunit is ubiquitously expressed throughout the central nervous system in 
mature tissue. In situ hybridisation studies to map NR1 mRNA levels throughout 
development found that in the foetal brain, NR1 expression was low and restricted to 
the cortex and hippocampus but expression increased and became more widespread 
as development progressed (Takai et al., 2003). 
1.4.2 NR2A expression 
NR2 subunits display distinct expression patterns throughout development: NR2A 
subunit mRNA expression shows a similar distribution pattern to that of the NRI 
subunit; it is highly expressed throughout the forebrain in the hippocampus, cerebral 
cortex, thalamus and in the cerebellum (Monyer et al., 1992; Wenzel et al., 1996). 
At embryonic days 18-20, NR2A expression was evident throughout forebrain 
regions with expression increasing into the neonate and adult (Takai et al., 2003). In 
the cerebellum, low expression levels in the neonate increase steadily, reaching adult 
levels by post-natal day 22 (Wang et al., 1995). In the rodent (Nagy et al., 2004) and 
human lumbar spinal cord (Sundstrom et al., 1997), NR2A mRNA and protein 
expression have been shown in the dorsal horn, particularly laminae III-IV with 
varying levels in the ventral horn. 
1.4.3 NR2B expression 
NR2B is expressed predominantly in forebrain areas in adult tissue, particularly in 
the hippocampus, cerebral cortex and thalamic regions. In situ hybridisation studies 
show high levels of NR2B mRNA expression by ~mbryonic day 17 in 1he cerebral 
cortex, thalamus and spinal cord, with levels increasing after birth in these regions 
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and the hippocampus, olfactory bulbs and striatum (Monyer et al., 1994; Wang et al., 
1995). Protein expression studies show a similar distribution of the NR2B subunit 
(Loftis and Janowsky, 2003). Laurie et al., 1997 showed that NR2B protein 
expression increased from birth to postnatal day 20 before declining slightly in 
whole neonatal rat brains. NR2B expression in the cerebellum is present until 
postnatal day 22 when levels are no longer detectable (Wang et al., 1995). Loftis 
and Janowsky, 2003 suggest a developmental role for granule cell maturation from 
this early down-regulation of NR2B expression which seemingly is replaced with 
NR2C expression (Monyer et al., 1994). 
In the rodent and primate spinal cord, NR2B shows expression in the superficial 
laminae of the lumbar dorsal horn and the motor neurons of the ventral horn (Nagy 
et al., 2004; Mutel et al., 1998; Rigby et al., 2002). Although overall, NR2B is 
expressed to a lesser extent than NR2A. 
1.4.4 NR2C expression 
The NR2C subunit is almost exclusively expressed in the cerebellum, particularly in 
Purkinje and granule cells (Rigby et al., 2002; Kew and Kemp, 2005; Stephenson, 
2001) with almost no expression in forebrain regions. Tolle et al., (1993) describe 
very weak detection ofNR2C mRNA in the dorsal horn of the rat spinal cord and in 
the periaqueductal grey. One study by Sundstrom et al., (1997) detected NR2C 
expression in human lumbar-sacral cord via immunoblotting, possibly suggesting 
differences in expression between species. 
1.4.5 NR2D expression 
The NR2D subunit is expressed highly in the embryo and newly-born rat, but 
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expression levels decline with maturity with low levels in the adult brainstem, 
midbrain thalamus, subthalamic nucleus and substantia nigra (Wenzel et al. 1996; 
Wenzel et al. 1995; Monyer et al., 1992). Primate studies show NR2D expression in 
the adult thalamus (Jones et al., 1998) and human hippocampus (Scherzer et al., 
1998). Rodent studies show weak but diffuse NR2D expression in the spinal cord 
(Watanabe et al., 1994; Rigby et al., 2002), with a similar intensity of expression and 
distribution in human studies (Sundstrom et al., 1997; Rigby et al., 2002). 
1.4.6 NR3A-B expression 
Differing expression patterns of NR3A and NR3B suggest separate roles and 
importance throughout various stages of development. In the rat, NR3A is widely 
expressed during development particularly in the cortex, midbrain and hippocampus 
(Al-Hallaq et al., 2002) reaching peak expression between postnatal days 7 and 10 
thereafter decreasing substantially in adult animals with limited expression in nuclei 
in the thalamus, amygdala and the olfactory tract (Nishi et al., 2001; Ciabarra et al., 
1995; Sucher et al., 1995). Expression has also been detected in the mouse 
cerebellum at post-synaptic sites where it may form symmetrical synapses between 
climbing fibre terminals and cerebellar interneurons (Fukaya and Watanabe, 2007). 
A recent study revealed some interesting species differences between rodent and 
human expression ofNR3A. Eriksson et al., (2002) show that NR3A is expressed in 
both embryonic and adult human brain tissue, with a similar distribution pattern to a 
post -natal rat, calling into question the accuracy and comparable nature of rodent 
models with human receptors. 
NR3B is highly expressed in somatic motor neurons in the brain, brainstem and 
spinal cord beginning at postnatal day 1 0-14 and continuing to maximal levels into 
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adulthood (Fukaya et al., 2005; Matsuda et al., 2003; Nishi et al., 2001). Expression 
within the motor neurons is mainly concentrated within the neuronal cell bodies 
rather than the dendrites which may indicate areas of intracellular NR3B storage 
(Matsuda et al., 2003) or an extrasynaptic location of NR3B containing receptors 
which may be activated following synaptic stimulation (Clark and Cull Candy 2002). 
A recent immunolocalisation study revealed evidence for more widespread 
expression of NR3B in the cortex, cerebellum, hippocampus and in spiny projection 
neurons of the striatum (Wee et al., 2007). 
1.5 NMDA receptor subunit eo-assembly 
The specific expression patterns of the NMDA receptor subunits suggests that 
specific NMDA receptor subunit eo-assembly is regulated in a spatio-temporal 
manner to fulfil specialised roles throughout the CNS enhancing the complexity and 
heterologous nature ofthe receptor. 
Many studies have investigated the subunits contained within native receptor 
assemblies, particularly in the rodent forebrain to look at the influence of specific 
sub-populations. According to these studies native NMDA receptors are composed 
of at least one NR1 subunit, one or more NR2 subunits (e.g NR1/NR2B or 
NR1/NR2A/NR2B) (Luo et al., 1997; Chazot and Stephenson, 1997) and possibly 
one or more NR3 subunits (e.g. NR1/NR2BINR3B) (Al-Hallaq et al., 2002) with 
some debate as to whether the subunits eo-assemble to form tetrameric and/or 
pentameric structures (Chazot, 2004). 
In forebrain structures immunoprecipitation and immunopurification studies have 
shown eo-association between NR1/NR2A, NR1/NR2B, NR1/NR2AINR2B (Chaiot 
and Stephenson, 1997; Blahos and Wenthold, 1996) and NR1/NR2D, 
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NR1/NR2AINR2D, NR1/NR2B/NR2D (Dunah et al., 1998; Stephenson, 2001). 
Research into subunit combinations in the spinal cord has been more limited. One 
group used solubilisation and immunoprecipitation ofNMDA receptors from human 
lumbar-sacral regions finding eo-associations between NR1, NR2A, NR2C and 
NR2D (Sundstrom et al., 1997). The native associations of the NR3 subunits and 
the other subunits with which they assemble have yet to be elucidated but would 
provide important information about NMDA receptor function and pharmacology. 
1.6 Physiological and functional properties of NR28 and NR3B receptors 
1.6.1 Physiological properties ofNR2B-containing receptors 
As discussed previously, subunit composition plays a critical role in receptor 
function and activity. NMDA receptors containing NR2B subunits therefore display 
distinctive properties such as a high sensitivity to magnesium blockade and increased 
sensitivity to glutamate (Fuller et a/, 2006; Cull-Candy et al., 2001). 
Electrophysiological measurements investigating channel kinetics showed that 
NR2B-containing receptors desensitise more slowly and take longer to recover than 
NR2A-containing receptors, thereby increasing the duration of channel opening 
(Vicini et al., 1998; Chen et al., 1999; Loft:is and Janowsky, 2003; Fuller et al., 
2006) and hence receptor activation. 
During synaptic development two populations of NMDA receptor develop, those 
which cluster at synapses and those which remain extrasynaptic (Cottrell et al., 2000; 
Thomas et al., 2006), though recent research suggests a more fluid movement of 
receptors between synaptic and extrasynaptic sites along the postsynaptic membrane 
(Choquet and Triller, 2003; Zhao et al., 2008). It is thought that these populations of 
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receptors may have different intracellular interactions with trafficking proteins and 
signalling cascades and therefore may have distinct roles in synaptic plasticity 
(Massey et al., 2004) and neuronal cell death (Hardingham et al., 2000) with 
extrasynaptic receptors potentially shutting down survival promoting pathways in the 
cell (Hardingham et al., 2000). It has been shown that extrasynaptic NMDA 
receptors promote neuronal plasticity via a key contribution to the calcium signal 
necessary to induce these changes (Harris and Pettit, 2007). 
Previous research has shown that NR2B-containing receptors occur both synaptically 
and extrasynaptically providing the potential for increased NMDA receptor activity 
via glutamate release both within and external to the synapse (Tovar and Westbrook, 
1999; Liu et al., 2004; Thomas et al., 2006). 
Via their key involvement in long-term potentiation (LTP) (Bliss and L0mo, 1973) 
and long-term depression (L TD), persistent activity-dependent increases and 
decreases in synaptic strength, NR2B-containing receptors are vital for information 
storage and synaptic plasticity in the brain (Y ang et al., 2005). The NR2B subunit 
has been associated with vital behavioural and physiological functions such as 
feeding, learning and memory (Bliss and Collingridge, 1993; Stanley et al., 1996, 
Kahn et al., 1999; Chazot, 2004). For example, NR2B-defective mice lack the 
suckling response and die shortly after birth (Kutsuwada et al., 1996) and over-
expression results in mice that exhibit superior ability in learning and memory tasks 
when compared to controls (Loftis and Janowsky, 2003). 
The NR2B subunit is important for localisation of the receptor, anchoring it to the 
membrane and connecting the receptor with specific intracellular signalling 
mechanisms that modulate receptor functions (Loftis and Janowsky, 2003). The last 
five residues of the C-terminal domain of the NR2B complex are thought to be 
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important for binding to the PDZ domain of PSD-95/SAP102 (Neithammer et al., 
1996; Lim et al., 2002) and are therefore critical for formation of multi-protein 
signalling complexes. Via PSD-95, NR2B is linked to many enzymes responsible 
for signal transduction within the cell, such as those essential for phosphorylation. 
NR2B is the most prominently tyrosine phosphorylated protein in the PSD fraction 
(Chazot 2004; Gardoni and DiLuca, 2006) which can contribute to potentiation and 
enhancement of receptor responses and alter intracellular signalling events (Lee, 
2006). An internalisation motif (YEKL) is located on the C-terminal of the NR2B 
subunit close to the binding site for PSD-95. Prybylowski et al., (2005) propose that 
phosphorylation of the tyrosine on this motif may inhibit internalisation of the 
receptor complex, thereby potentiating receptor localisation at the cell membrane 
and enhancing signal transmissions. 
NR2B also interacts with growth factors and hormones such as brain-derived 
neurotrophic factor (BDNF) via post-synaptic trkB receptors and tyrosine 
phosphorylation of the subunit (Levine and Kolb, 2000; Lin et al., 1999). It is 
reported that exposure to BDNF via these receptors increases single channel open 
probability, potentiating receptor activity. 
NR2B-containing receptors are also proposed to stabilise and maintain the 
intracellular enzyme serine/threonine kinase CaMKII in an active conformation 
(Bayer et al., 2001). lbis enzyme is activated by NMDA receptor mediated Ca2+ 
influx and by increasing phosphorylation of NMDA subunits and reducing 
desensitisation of NR2B-containing receptors it is thought to contribute to long-term 
potentiation (L TP) (Bayer et al., 2001; Lisman et al., 2002; Colbran et al., 2004.). 
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1.6.2 Physiological properties of NR3-containing receptors 
The modulatory properties of the NR3A or NR3B subunits are the most poorly 
characterised of all the NMDA receptor subunits, although initial studies show 
interesting differences between the NR2 and NR3 subunits. 
Critically, in the NR3 subunits, the asparagine residue at the QRN site of the second 
hydrophobic transmembrane domain is replaced with glycine followed by arginine at 
the N+ 1 site, properties which may be associated with reducing the Ca2+ 
permeability and altering the magnesium sensitivity ofthe receptor (Matsuda et'al., 
2002; Nishi et al., 2001). eo-expression of mouse NR3A with NR1 and NR2A in 
vitro reduced glutamate-induced whole cell current and single channel conductance 
(Ciabarra et al., 1995; Das et al., 1998; Sucher et al., 1995; Perez-Otano et al., 2001) 
and in NR3A-/- mice the amplitude of NMDA receptor currents was increased in 
comparison to wild type neurons (Das et al., 1998). It has also been proposed that 
the NR3A doesn't undergo extensive molecular rearrangement upon channel gating 
due to symmetrical alignment of the M3 segments of NR1 and NR3A. The M3 
segments of both subunits form a narrow constriction in the outer vestibule of the 
receptor channel modulating the passage of cations (Wada et al., 2006) and therefore 
possibly reducing calcium influx. 
Nishi et al., (2001) also describe suppressed glutamate-induced current when mouse 
NR3B was eo-expressed in HEK 293 cells with NR1/NR2A subunits, referring to 
NR3B as a dominant-negative subunit. In partial contrast to this study, research 
carried out by Matsuda et al., (2002) found no significant reduction in current 
amplitude in HEK 293 cells eo-expressing mouse NR3B with NRl and NR2A, 
although they did fmd reduced Ca2+ permeability of NMDA receptor channels in 
these cells. 
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Research to date has found that NR3A and NR3B eo-associate with NR1 and NR2A 
in heterologous cells and cultured neurons (Nishi et al., 2001; Matsuda et al., 2002, 
Das et al., 1998; Ciabarra et al., 1995; Sucher et al., 1995). Under native conditions 
the mechanisms behind NR3B trafficking and incorporation into the receptor 
complex remain unclear. It is known from recombinant work in mammalian cell 
models that expression of a functional receptor requires NR1 for formation of the 
channel pore and trafficking to the membrane. Co-transfection ofNR3B with NR2A 
or NR3B alone failed to produce functional receptors, however there remains some 
debate as to whether NRl and NR3 co-transfection results in functional glycine 
receptor formation (Chatterton et al., 2002). Evidence showing that NR3A has a 
soluble ligand binding domain with a high affinity for glycine (Kd 40nM) compared 
to a very low affinity for glutamate (Kd 9.6mM) (Yao and Mayer, 2006) fuels 
speculation for formation of such glycine channels in NR1/NR3 complexes. 
NR1/NR3B glycine-activated cation channels have been recorded in both oocytes 
(Chatterton et al., 2002) and mammalian cells (Pina-Crespo and Heinemann, 2004) 
though Perez-Otano et al., (2001) and Matsuda et al., (2002) found no such activity 
in their mammalian systems. Both NR3A (Perez-Otano et al., 2001) and NR3B 
(Matsuda et al., 2003) require association with NR1 in order to exit from the 
endoplasmic reticulum and express on the cellular surface. Within the C-terminal of 
the NR3B subunit, it is thought that amino acids 952-985 are important for receptor 
trafficking and may be able to mask the endoplasmic reticulum (ER) retention signal 
of the NR1 subunit (Matsuda et al., 2003). It is therefore possible that a receptor 
complex consisting of NR1/NR3B subunits may be actively transported to the 
membrane but full investigation of this controlled trafficking and specific subunit eo-
assembly has yet to be carried out. 
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The evidence currently available suggests important modulatory influences of the 
NR3 subunits on the NMDA receptor complex. Changes from NR3A to NR3B 
expression throughout development in the rodent may be important for regulation of 
calcium permeability throughout maturity and critical for maintaining control of 
intracellular calcium concentrations in NMDA receptors. 
1. 7 NMDA receptor signalling and trafficking 
The precise mechanisms governing NMDA receptor delivery to the synapse are 
complex and yet to be fully elucidated. However, their expression at the cell surface 
is known to be subject to plastic changes depending on the neuronal environment 
(Prybylowski and Wenthold, 2004). These alterations in NMDA receptor numbers 
and expression patterns are mediated via delivery, internalisation and translocation 
between synaptic and extrasynaptic sites (Prybylowski and Wenthold, 2004). 
In order to ensure that only functional NMDA receptors are delivered to the cell 
membrane, endoplasmic reticulum (ER) retention signals exist on the individual 
sub units. These retention motifs are masked upon formation of functional complexes 
and the receptor is able to exit the ER. Fukaya et al., 2003, showed that NRl was 
vital for the release of NR2 subunits from the ER in hippocampal pyramidal cells in 
vivo: in the absence of NRl, the NR2 subunits are retained and aggregated into 
intracisternal granules. 
NMDA subunits associate with members of the membrane-associated guanylate 
kinases (MAGUK.s) family, namely SAP102, (synapse associatea protein) afl'(i. 
PSD95 (post-synaptic density), which form scaffolding molecules linking the 
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receptor with intracellular enzymes and signalling molecules (Van Zundert et al., 
2004). Research suggests associations with protein complexes differ according to 
subunit composition of the receptor and its synaptic or extrasynaptic localisation, 
resulting in potentially different signalling cascades and functions (V an Zundert et 
al., 2004). PSD-95 binds directly to important signalling proteins such as GTPase-
activating protein, neuronal nitric oxide synthase (nNOS), Fyn and Ca2+ ATPases 
(Van Zundert et al., 2004). Associations of PSD-95 with kinesin motors KIF18 and 
KIF17 are important for NMDA receptor delivery to the synapse (Mok et al., 2002; 
Guillaud et al., 2003) and linkage of the protein huntingtin to PSD-95 provides some 
evidence for NMDA associated excitotoxicity in Huntington's disease models 
(Zeron et al., 2002; Prybylowski and Wenthold, 2004). Linkage with PSD-95 also 
enables phosphorylation of the subunits via enzymes such as tyrosine kinases and 
protein kinase C, important for movement of receptors from synaptic to 
extrasynaptic locations (Fong et al., 2002) and inhibiting internalisation of NR2B-
containing receptor complexes (Prybylowski et al., 2005). 
Recent data shows association of NR3A with microtubule-associated protein 1 S 
(MAPlS), which links this subunit with cytoskeletal proteins, possibly facilitating its 
anchoring and stabilization within the synapse and its potential for movement 
between synaptic and extra-synaptic sites (Eriksson et al., 2002). 
1.8 Pharmacological targeting of the NMDA receptor 
NMDA receptors play a vital role in excitatory transmissions within the central 
nervous system and therefore have long been implicated in disease pathogenesis. In 
the late 1980's Choi et al., 1988 noted toxic effects ofNMDA receptor activation in 
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primary cultured neurons which could be protected by NMDA antagonists. NMDA 
receptor mediated glutamate toxicity is now well documented with both in vitro and 
in vivo experiments. 
1.8.1 Non-selective NMDA antagonists 
The first generation ofNMDA antagonists were developed to treat stroke and trauma 
patients (Wang and Shuaib, 2005) and were either non-selective, non-competitive 
channel blockers such as phencyclidine (PCP), (+)-5-methyl-10,11-dihydro-5-H-
dibenzo[a,d]cyclohepten-5,10-imine (MK-801) (Kemp et al., 1987), memantine and 
ketamine, or competitive antagonists which act at the agonist glutamate or glycine 
binding domains. Some of the first compounds discovered such as (R)-2-amino-5-
phosphonopentanoate (R-AP5) (Paoletti and Neyton, 2006) and cis-4-
phosphonomethyl-2-piperidine carboxylic acid (CGS-19, 755) (Bennett et al., 1990; 
Murphy et al., 1988) are examples of competitive antagonists acting at the glutamate 
binding site on the NR2 subunits. They show good selectivity for NMDA receptors 
over other ionotropic glutamate channels but show modest selectivity variations 
between the NR2 subunits. Compounds acting at the eo-agonist glycine binding site 
such as 5-nitro-6, 7 -dichloro-1 ,4-dihydro-2,3-quinoxalinedione (ACEA-1 021 (Leeson 
and lversen, 1994) and 5, 7-dichlorokynurenic acid (5,7-DCKA) (Hess et al., 1998) 
also show minimal receptor subtype selectivity as they are targeting binding sites on 
the NR1 subunit. Animal studies using the channel blockers memantine and 
ketamine (Carlton and Hargett, 1995; Qian et al., 1996) have shown encouraging 
effects for treatment of neuropathic and inflammatory pain, which have also been 
seen in human studies (Mercadante et al., 1995; Eisenberg et al., 1998) and indeed, 
recently memantine and amantadine have been approved for treatment of late-stage 
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Alzheimer's and Parkinson's diseases (Roesler et a/, 2003). However, the non-
selective nature of these compounds and the resultant level of unacceptable side 
effects at analgesic doses such as psychomimetic effects, impaired learning, memory 
and motor function have limited their widespread use and resulted in largely 
unsuccessful clinical trials. 
Subunit specific, activity-dependent modulators are therefore greatly favoured, as 
they have potential for increased therapeutic indices based on selectivity for specific 
sub-populations such as NR2B-containing receptors. 
1.8.2 NR2B subunit selective antagonists 
The heterogeneous nature of the NMDA receptor complex and the pharmacological 
modulations and specific regional distribution provided by the various subunit eo-
assemblies has enabled more selective NMDA receptor targeting. 
Pharmacologically, the NR2B subunit has become important as a target for subunit 
specific antagonists, which can potentially block or reduce the excitatory effects of 
the receptors (Williams 2001, Zhuo 2002, Chazot et al., 2002). It is thought that the 
more restricted expression patterns and the particularly low expression levels in the 
cerebellum may enhance therapeutic action whilst limiting the risk of serious motor 
side effects (McCauley 2005). NR2B-containing NMDA receptors have been 
implicated in many CNS pathologies such as stroke, drug-induced dyskinesias, 
dementias and chronic pain (Chizh et al., 2001; Chazot, 2004) due to their specific 
distribution in affected brain areas and physiological properties. For example, high 
expression levels of NR2B-containing receptors in pain related structures such as the 
forebrain and dorsal horn of the spinal cord (Monyer et al., 1994; Boyce et al. 1999) 
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make it a therapeutic target. A large proportion of NR2B-containing receptors are 
located extrasynaptically, which is thought to be important as their excess 
stimulation by glutamate diffusing from the synaptic cleft can result in glutamate-
induced toxicity. Toxicity as a result of Ca2+ influx leads to loss of mitochondrial 
membrane potential, free radical production and hyper-excitation (Sattler and 
Tymianski, 2000; Chazot 2004). It has been shown that over-expression ofNR2B in 
the anterior cingulate and insular cortices of mice results in selective enhancement of 
persistent pain (Wei et a/, 2001) and that gene knockdown of NR2B reduces 
formalin induced nociception (Tan et al., 2005), implying that NR2B-containing 
receptors in the forebrain play an important role in chronic pain (Chizh et al., 2001; 
Wei et al., 2001; Petrenko et al., 2003; Chazot 2004). 
In the 1980s, it was discovered that ifenprodil (a phenylethanolamine originally 
developed as a vasodilating agent) (Williams, 2001) acted as an NMDA receptor 
antagonist, displaying neuroprotective effects but without the serious side-effect 
profile of other antagonists (Carter et al., 1988; Williams et al., 1993). lfenprodil is 
a non-competitive, voltage independent, activity-dependent antagonist (Williams, 
1993; Kew et a/, 1996; Chenard and Menniti, 1999), which is highly sensitive to 
extracellular pH and displays a high level of NR2B selectivity (Williams et al., 
1993), having a 400-fold higher affinity for NR1/NR2B than for NR1/NR2A 
receptors (Williams 1993; Kew et al., 1996). Inhibition with ifenprodil is activity 
dependent with a 40-fold higher affinity for the agonist-bound activated state 
(possibly present in excitotoxic conditions) than the inactivated state thereby 
increasing its side effect profile in comparsion to the channel blockers (Williams et 
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al. , 1993; Kew et al. , 1996). However, side effects such as hyperventilation, motor 
impairment and ptosis were seen (Boyce et al., 1999) partly as it has a high affinity 
for a1 -adrenergic, sigma and serotonin receptors (Williarns, 1993; Chenard et al. , 
1995) and is therefore not exclusively NMDA specific. 
The binding site of the ifenprodil molecule is distinct from the channel pore, the 
glutamate, glycine or the polyamine site (Grimwood et al. , 2000). It is located 
within the N-terminalleucine/isoleucine/valine binding protein-like domain (LIVBP-
like domain) (Perin-Dureau et al. , 2002). 3D mapping of this domain showed a cleft 
with a 'venus fly trap' mode of action (Perin-Dureau et al., 2002; Chazot, 2004). 
The presence of an aspartate and two phenylalanine residues within the lobes of the 
cleft appear to be essential for high affinity ifenprodil binding (Chazot, 2004). 
Figure 1.4 Schematic representation of the bi-lobular LIVBP ifenprodil binding site on the 
NR2B subunit showing the significant amino acids (Chazot, 2004). 
lfenprodil and its early analogues haloperidol and eliprodil still had problems with 
non-specific targeting and side-effects preventing their use clinically, though they 
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became very useful tools along with channel blockers like MK-801 to investigate 
receptor pharmacology and allosteric properties of binding sites. 
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Figure 1.5 Chemical structures of early NR2B-selective antagonists (Williams, 2001) and 
the channel blocker MK-801 (Nikam and Meltzer, 2002). 
The ifenprodil molecule subsequently became the congener for second generation 
NR2B antagonist development with a number of analogues such as Ro-256981, Ro-
04-5595 (Roche) and CP-101,606 (Pfizer) (Chazot, 2004). These compounds have 
been developed to display a higher affinity for NR2B-containing receptors with a 
reduced affinity for at-adrenergic receptors (Chenard et al., 1995). They work to 
enhance inhibition of the NMDA receptor (Lynch and Guttman, 2001) by increasing 
the effects of extracellular protons and possibly by decreasing the affinity of the 
receptor for eo-agonist glycine binding (Williams, 2001 ). 
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Figure 1.6 Chemical structures of second generation NR2B-selective antagonists (Nikam 
and Meltzer, 2002). 
Both CP-101 ,606 (Menniti et al. , 1997) and Ro-256981 (Fischer et al., 1997) are 
piperidine-containing compounds (B-linker analogues with hydroxyl functionality) 
and display structural similarity to ifenprodil, binding to the ifenprodil site on rat 
forebrain membranes with high affinities (Ko) of 9.4nM and (Kd) of 10nM for Ro-
256981 and CP-101,606 respectively (Chazot et al., 2002). 
Further work to identify the binding characteristics and subtype selectivity of these 
two compounds discovered two separate classes of antagonists. Ro-256981 binds to 
NR2B-containing receptors irrespective of the presence of another NR2 subunit, 
whereas CP-101,606 binding is highly affected by the presence of alternative NR2 
subunits within the receptor complex (Chazot et al., 2002). The heterogeneity of the 
receptor complex is therefore very important in defining antagonist affinities (Chazot 
and Stephenson, 1997). 
Both Ro-256981 and CP-101,606 have shown potent neuroprotective activity against 
glutamate-induced NMDA receptor-mediated toxicity in vitro and in vivo (Fischer et 
al., 1997; Tsuchida et al. , 1997; Boyce et al., 1999; Chizh and Headley, 2005). In 
vivo studies by Boyce et al., 1999 showed potent anti-nociceptive activity upon 
mechanical allodynia following nerve injury in rats with neither compound inducing 
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motor impairment at analgesic doses (3-1 Omg/kg), however some impairment of 
rotarod performance at high doses of Ro-256981 (up to lOOmg/kg) were noted and 
they concluded that CP-101,606 had the best therapeutic window (Boyce et al., 
1999; Boyce and Rupniak, 2002). 
Other studies showing CP-1 01,606 induced neuroprotection in primary neuronal 
cultures (Menniti et al., 1997) and in in vivo animal models of ischaemic brain injury 
(Diet al., 1997; Tsuchida et al., 1997; Wang and Shuaib, 2005) and chronic pain 
displayed reversal of mechanical hyperalgesia and reduced excitation of dorsal horn 
neurons following windup (Taniguchi et al., 1997; Boyce et al., 1999) with an 
improved side-effect profile in comparison to ifenprodil. The encouraging profile of 
CP-1 01,606 in animals led to clinical trials in humans for the treatment of traumatic 
brain injury and haemorrhagic stroke (Menniti et al., 1998). Phase I tolerability 
studies in healthy volunteers showed no adverse effects at therapeutic doses 
(200ng/ml) with the maximum tolerated plasma concentration of 4200ng/ml after 
which adverse effects included amnesia, dizziness and confusion (Menniti et al., 
1998; Boyce and Rupniak, 2002) were reported. An open-label phase I study in 
subjects with severe traumatic brain injury or intracerebral haemorrhage showed 
good penetration to the CSF and that CP-101,606 infusion for 24 or 72 hours was 
well tolerated with improvements on the Glasgow outcome score (Bullock et al., 
1999) and a double blind, placebo-controlled study of 53 subjects with traumatic 
head injuries showed good tolerability of the drug with no significant cardiovascular 
abnormalities reported (Merchant et al., 1999). 
To date, despite the improved safety profiles of these ifenprodil-like NR2B-selective 
compounds and promising data from clinical trials, they have not yet been approved 
for human use due to potential potassium channel mediated cardiotoxicity, poor oral 
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bioavailability (Kew and Kemp, 2005) and heterogeneity in the patient populations 
tested and therefore novel compounds structurally unrelated to ifenprodil are being 
developed (Claiborne et al., 2003). 
There are many other NR2B selective compounds in development and recently 
Merck and Co have disclosed a class of hydroxybenzimidazoles (McCauley et al., 
2004) and Gideon and Richter have a compound RGH-896, of undisclosed structure, 
entering phase Ha clinical trials for neuropathic pain (Parkas et al., 2003). 
1.9 NMDA receptor associations with pathology 
Tightly regulated control of NMDA receptor expression and function is required for 
normal physiological processing within the central nervous system. Their essential 
role and widespread distribution means disruption of NMDA receptor physiology is 
often evident in neuronal pathologies. Specific patterns of receptor heterogeneity 
may therefore provide therapeutic targets for many chronic conditions. 
1.9.1 Calcium-dependent excitotoxicity 
Excessive glutamate-mediated calcium entry into cells can lead to excitotoxicity and 
neuronal cell death. It is a mechanism of neuronal loss implicated in both acute 
disease such as ischaemia and chronic neurodegenerative diseases such as 
amyotrophic lateral sclerosis (Arundine and Tymianski, 2003). 
Within a cell calcium ions are vital for normal physiological processes such as 
signalling and synaptic activity, and therefore under normal conditions, homeostatic 
regulation of cytosolic Ca2+ is tightly controlled (Arundine and Tymianski, 2003). 
Excessive glutamate release from synapses triggers NMDA, AMP A and Kaimite 
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receptor channel opening and Ca2+ and Na + influx. Increased internal Ca2+ 
concentrations from excessive influx and release from intracellular stores overcome 
the regulatory mechanisms, the metabolic processes within the cell begin to fail and 
the cell dies (Choi, 1988; Sattler and Tymianski, 2000). The source-specificity 
hypothesis for Ca2+ toxicity was proposed by Tymianski et al., 1993 and states that 
neurotoxicity in cells requires specific signalling pathways triggered by Ca2+ entry at 
specific receptors to be activated. Their experiments showed high levels of toxicity 
when Ca2+ entered via NMDA receptors, whereas Ca2+ entry via voltage-sensitive 
channels was tolerated (Tymianski et al., 1993; Arundine and Tymianski, 2003). It 
is thought that this specific toxicity via NMDA receptors results from the formation 
of a ternary complex between NMDA receptors, PSD-95/SAP90 (post-synaptic 
density-95/synapse associated protein 90) and nNOS (nitric oxide synthase) (Sattler 
et al., 1999) increasing nNOS activity and thereby toxicity. The evidence from these 
studies therefore supports the potential beneficial effects of NMDA receptor 
therapeutic targeting. 
1.9.2 Huntington's Disease 
NMDA-mediated excitotoxicity and specific associations with the mutated 
huntingtin protein have been investigated as possible links with disease aetiology. 
Huntington's disease manifests as a hyperkinetic movement disorder with cognitive 
and psychiatric dysfunction and affects 5-10/1 00,000 population worldwide (Li et 
al., 2003). An autosomal dominantly inherited condition, it is caused by expanded 
CAG repeats in the first exon of the Huntington's disease gene (Li et al., 2003). eo-
expression of the mutant gene huntingtin with NR1/NR2B receptors increases 
current amplitudes and may increase the number of receptors expressed at the cell 
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surface (Chen et al., 1999b) potentiating NMDA activation and potential for toxic 
calcium accumulation within the cell. Cytotoxicity studies have also shown 
increased levels of cytotoxicity when NR1/NR2A and more so NR1/NR2B were eo-
expressed with the full length mutant huntingtin-138Q (Zeron et al., 2001) providing 
evidence for NMDA involvement in potential neuropathologies associated with the 
disease. Interestingly, NR2A and NR2B gene variations have recently been linked to 
modification of age onset in Huntington's disease accounting for 7.2% additional 
variance in the age of onset in patients (Arning et al., 2007). 
1.9.3 Schizophrenia 
Glutamatergic transmission via NMDA receptors has been implicated in some of the 
pathogenic mechanisms behind schizophrenia (Stefani and Moghaddam, 2004; 
Heresco-Levy and Javitt, 1998; Gao et al., 2000) based on observations that 
hypofunction of receptors as a result of NMDA antagonist treatment causes some 
transient psychotic states in healthy individuals (Du Bois and Huang, 2007; Loftis 
and Janowsky, 2003). Studies investigating the potential mechanisms of NMDA 
involvement have found abnormal glutamate receptor expression (Beneyto et al., 
2007). Grimwood et al., 1999 discovered up-regulation of NR2B-containing 
receptors in the superior temporal cortex using radioligand binding with eHJ 
ifenprodil. Gao et al., 2000 showed a 40% increase in NR2B mRNA in the CA2 
hippocampal region of schizophrenic post-mortem tissue in comparison to controls 
and elevated levels of NR3A were shown in the dorsolateral prefrontal cortex and 
inferior temporal neocortex in schizophrenic tissue in comparison to controls 
(Mueller et al., 2004). It has also been shown that inhibition of NMDA receptor 
activity during cortical development produces cognitive deficits phenotypically 
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relevant to schizophrenia in the adult (Stefani and Moghaddam, 2004) providing 
evidence for NMDA involvement in cognitive disorders and showing their 
importance for normal physiological development. 
1.9.4 Parkinson's Disease 
Parkinson's disease is a progressive neurodegenerative condition manifesting in 
dyskinetic effects with tremor, rigidity and cognitive dysfunction. Affecting 
millions of people world-wide, parkinsonian diseases arise due to dopamine-
glutamate imbalances within the striatothalamocortical loop, reducing stimulation of 
the motor cortex (Ulas et al., 1994). Reduced formation of dopamine in the 
substantia nigra causes increased activity of the striatal pathway to the external 
pallidum, lack of regulated inhibition of the subthalamic nucleus and glutamatergic 
hyperactivity in the basal ganglia (Albin et al., 1989; Loschmann et al., 2004). It has 
been proposed that this over-excitation at glutamatergic synapses may be NMDA 
receptor mediated as it is known that these receptors are vital in both the basal 
ganglia and striatum for normal physiological processes (Hallett and Standaert, 
2004). In addition it has been shown that receptor structure, function and abundance 
in the striatum of Parkinson's disease patients is altered by dopamine depletion 
(Hallett and Standaert, 2004) with selective increases in NMDA-sensitive glutamate 
binding (Ulas et al., 1994). Attempts to combat this up-regulation of NMDA 
receptors in diseased patients with selective antagonists has been a major focus for 
many studies with some success in animal models, where, for example, the NR2B-
selective compounds Ro-256981 (Loschmann et al., 2004) and CP-101,606 (Wessell 
et al., 2004) showed anti-parkinsonian activities. Development of NMDA 
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antagonists with increased selectivity and reduced side-effect profiles may therefore 
provide real potential for future treatments. 
1.9.5 Alzheimer's Disease 
Alzheimer's disease is the most prevalent neurodegenerative condition affecting 
millions worldwide. Few cases of familial early onset disease have been 
documented, however the majority of cases are sporadic with later-stage onset 
generally in the 6th decade of life. Manifesting as progressive cognitive decline with 
neuropsychiatric symptoms, amyloid plaques and neurofibrillary tangles in the brain 
remain indicative of this dementia. The aetiology behind disease onset is still not 
fully understood with many approaches such as pathophysiological mechanisms 
behind the misfolding of amyloid-beta and genetic mutations being explored 
(Albensi et al., 2004). Pharmacological therapies have mainly relied upon 
cholinergic inhibitors which partially enhanced patient cognitive states 
(Doraiswamy, 2003; Lipton, 2007) though recently therapeutic focus has shifted to 
NMDA receptor antagonism to combat the glutamatergic excitotoxicity and 
subsequent neuronal death seen in dementia (Albensi et al., 2004; Lipton, 2007). 
Memantine is a non-competitive, low-affmity NMDA receptor open channel blocker 
which has been clinically approved in Europe and the USA for the treatment of 
moderate-severe Alzheimer's disease (Doraiswamy, 2003; Albensi et al., 2004). The 
preferential binding of memantine to excessively activated NMDA receptors seems 
to reduce the adverse side-effect profile seen with other antagonists because normal 
physiological activity isn't disrupted to a high degree (Lipton, 2007) and there is 
some evidence to suggest memantine up-regulates production of BDNF, promoting 
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neuronal survival (Albensi et al., 2004). Second generation memantine derivatives 
are currently in development and it is hoped their safety profile and neuroprotective 
efficacy will be improved for more wide-spread use in neurodegenerative conditions. 
1.9.6 Amyotrophic lateral sclerosis (Motor neuron disease) 
Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disease 
characterised by the selective loss of somatic motor neurons in the spinal cord, 
brainstem and motor cortex (Samarasinghe et al., 1996; Shaw et al., 1994). The 
pathophysiology behind the disease and its rapid progression to paralysis and death 
remain largely unknown though advances, particularly in genetic techniques have 
increased knowledge and stimulated further research. 
90% of cases develop sporadically generally in older patients, though 1 0% of cases 
are familial with some genetic mutations in the Cu/Zn superoxide dismutase 1 
enzyme (SOD1). This SOD1 enzyme is a homodimeric cytosolic protein (Gorman et 
al., 1996) which breaks down highly toxic superanion radicals into harmless 
products making it very important for the cell's defence against free radical damage 
and excitotoxicity. 
Glutamate-mediated excitotoxicity via AMP A and NMDA (Samarasinghe et al., 
1996; Shaw et al., 1994) receptors as well as deficiencies in astrocytic glutamate 
uptake (Rao and Weiss, 2004) and damage to glutamate transporters (Rodriguez et 
al., 1997) have all been proposed as potential pathological mechanisms in both 
sporadic and familial diseases. All of these factors could lead to neuronal cell death 
via Ca2+ toxicity disrupting metabolic processes, inducing proteolysis, stimulating 
free radical production and damaging mitochondrial membranes (Rodriguez et al., 
1997). Motor neurons are also particularly susceptible to Ca2+ overload as they 
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naturally have reduced levels of calcium binding proteins and AMP A GluR2 
receptors which can flux Ca2+ so the effect is exacerbated in these cells. 
Research into NMDA receptor expression levels found reduced density of NMDA 
receptor expression, up to 50% reduction in NR1 mRNA expression in the ventral 
horn (Virgo and De Belleroche, 1995) in motor neuron disease patients in 
comparison to control tissue (Shaw et al., 1994; Samarasinghe et al., 1996). These 
data are likely to reflect the overall loss of motor neurons from the spinal cord of 
diseased patients, however they confirm the presence of NMDA receptors on motor 
neurons and a study by Samarasinghe et al., 1996 highlights the possibility of 
modification in the composition of receptor subunits with widespread loss of the 
NR2A subunit in both dorsal and ventral horns of diseased patients in comparison to 
controls. 
A mouse model carrying the SOD1 mutation has been developed which displays 
similar disease pathology and clinical symptoms to MND patients. Wang and 
Zhang, (2005) have found that treatment of these mutant mice with the NMDA 
antagonist memantine significantly delayed disease progression and increased the 
lifespan of the mice in comparison to controls, indicating that NMDA mediated 
excitotoxicity may be involved in MND pathogenesis and may therefore be a target 
for future therapies. 
1.9. 7 Chronic Pain 
Chronic pain is a serious debilitating condition resulting from prolonged tissue injury 
or more commonly from prolonged hypersensitisation of nociceptive neurons. It is 
estimated that over 20% of the world's adult population are affected by persistent 
pain resulting in healthcare costs of €200 billion per annum. 
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At present, despite advances in the understanding of the pathophysiological 
mechanisms of chronic pain, the underlying neuronal and neurochemical 
mechanisms involved in inducing, maintaining and processing nociceptive 
information are complex and still not fully understood. 
It is known that upon activation of peripheral nociceptors, pain transduction is 
conducted through myelinated AB and unmyelinated C fibres to the dorsal root 
ganglion in the spinal cord (see figure 1.7). Signals are then transmitted via the 
spinothalamic tract to the thalamus and cortex for modulation of sensory input 
(Markenson, 1996) and motor responses. However, prolonged activation of 
nociceptors and a reduction in transduction threshold can lead to chronic stimulation. 
Since the late 1980s the major research focus has been on the identification of 
molecules involved in pain perception in order to develop analgesic treatments. 
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Figure 1.7 Schematic diagram representing afferent A6 and C-fibre input to the dorsal 
root ganglion, through the cord and into the spinothalamic tracts (Anaesthesia UK, 
www.frca.co.uk). 
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1.9.8 NMDA receptor and central sensitisation 
Glutamate is known to be a major excitatory neurotransmitter in the central nervous 
system (Petrenko et al., 2003; Chizh, 2002; Kemp and McKeman, 2002) and plays a 
major role in excitatory synaptic transmission and sensitisation. Glutamatergic 
synapses therefore play important roles in both acute and chronic nociceptive 
processing at both normal and pathophysiological levels. Upon acute noxious 
stimulation primary afferent terminals in the spinal cord release glutamate which 
primarily activates AMP A receptors on second order neurons (Chizh, 2002). 
However, prolongued activation of nociceptors stimulates continuous release of 
glutamate and neuropeptides, causing long-lasting membrane depolarisation, 
removal of the voltage-dependent magnesium block on the NMDA receptor and thus 
sustained receptor activation and persistent pain response (Chizh, 2002; Haley et al., 
1990; Ma and Woolf, 2002). 
Tissue injury or inflammation generating pain hypersensitivity can often have a 
protective effect, reducing the pain threshold to prevent further injury; however in 
some circumstances this hypersensitivity can become pathological. An example is 
neuropathic pain associated with damage to the nervous system (Ma and Woolf, 
2002), which can arise secondarily from conditions such as viral infections, 
chemotherapy or traumatic injuries (Boyce et al., 1999). This hypersensitivity 
mechanistically can result from two sources, peripheral or central sensitisation (Ma 
and Woolf, 2002). Peripheral sensitisation restricts increases in pain sensitivity to 
the site of injury (Ji et al., 2003) increasing sensitivity of primary afferent 
nociceptors (Zhuo, 2002; Ma and Woolf, 2002). There is some evidence that the 
numbers of NMDA receptors are thought to increase upon peripheral sensitization, 
enhancing transmissions (Petrenko et al. 2003). Central sensitisation involves the 
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hyper-excitation of nociceptive neurons within the central nervous system, 
particularly in the dorsal horn ofthe spinal cord (Ma and Woolf, 2002; Woolf, 1983; 
Cook et al., 1987) where the receptive field and responsiveness of the dorsal horn 
neurons are increased and their activation threshold is reduced (Cook et a/, 1987; Ji 
et al., 2003). 
Biochemical, electrophysiological and behavioural data (Medvedev et al., 2004) 
indicate that the NMDA receptor can mediate long-term synaptic plastic changes 
lasting from hours to days (Zhuo, 2002), phenomena termed long-term potentiation 
(Bliss and L0mo, 1973) and long-term depression, and the NMDA receptor is 
therefore essential for the development of central sensitisation (Ultenius et al., 2006) 
and thus chronic pain. 
It is thought that NMDA receptors play a major role in central sensitisation due to 
their ability to alter neuronal membrane excitability via activation of protein kinase 
C (Ma and Woolf, 2002). Upon membrane depolarization, Ca2+ influx allows the 
translocation of protein kinase C from the cytosol to the membrane. Protein kinase 
C is then able to phosphorylate receptors including the NMDA receptor and in turn 
potentiate their activation, amplifying the NMDA response in a positive feedback 
manner greatly contributing to central sensitization (Zhen et al. 1997). 
In the 1980's two groups Davies et al., 1987 and Dickenson et al., 1987 first provided 
evidence for the role of NMDA receptors in nociception and their potential as 
analgesic targets observing that 'spinal delivery of NMDA receptor antagonists 
inhibited the hyper-excitability of the spinal cord nociceptive neurons induced by C-
fibre stimulation'. Many animal pain models have subsequently provided evidence 
for NMDA mediated nociceptive responses (Medvedev et al., 2004; Ultenius et al., 
2006; Boyce et al., 1999; Massey et al., 2004) which have initiated the current level 
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of biomedical and pharmacological interest in NMDA receptors driven by the 
potential therapeutic possibilities ofNMDA receptor antagonists. 
1.9.9 NR2B as an analgesic target 
NR2B-containing NMDA receptors have been a target for analgesic compounds 
since the requirement for subunit selective compounds with higher binding affinities 
and improved safety profiles became crucial. Studies have shown selective NR2B 
antagonist induction of anti-nociception without motor dysfunction demonstrating 
the improved safety profile and effectiveness of these compounds (Boyce et al., 
1999). 
Also, as knowledge of the physiological properties of NR2B-containing receptors 
has improved, evidence of their potential role in hyper-excitation and central 
sensitisation has increased. 
Expression studies using anti-NR2B antibodies, in situ hybridisation techniques and 
radiolabelled binding assays (Nagy et al., 2004; Tolle et al., 1993; O'Donnell et al., 
2004; Mutel et al., 1998; Chazot and Sheahan unpublished) have demonstrated the 
localisation of NR2B-containing receptor expression in pain-related structures such 
as the dorsal horn of the spinal cord, particularly in the outer laminae I-ll (Nagy et 
al, 2004), primary sensory fibres (Ma and Hargreaves, 2000), and forebrain 
structures such as the anterior cingulate cortex (Wei et al., 2001), cortex and 
thalamus (Sheahan and Chazot, unpublished). Research carried out by Wei et al., 
(200 1) demonstrated that over-expression of NR2B in mice can lead to enhanced 
pain behaviour in comparison with control animals, possibly caused by the slow 
receptor desensitisation and increased affinity for glutamate of NR2B-containing 
receptors, enhancing channel opening time and hence increasing activity. 
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The extra-synaptic localisation of NR2B-containing receptors also contributes to the 
potential for enhancing NMDA receptor activation as excessive glutamate release 
within the synaptic cleft could lead to glutamate spillover, which preferentially 
activates high-affinity NMDA receptors, enhancing responsiveness of the network 
(Momiyama 2000; Van Zundert et al., 2004; Lambe and Aghajanian 2006). A recent 
study by Liu et al., (2007) suggests that activation of synaptic or extrasynaptic 
NR1/NR2B receptors increases NMDA activity and potentially initiates apoptotic 
signalling cascades promoting neuronal cell death. 
Increased tyrosine phosphorylation of the NR2B subunit, which potentiates activity, 
has also been recorded following induction of long-term potentiation, providing 
evidence for this subunits involvement in synaptic plasticity and potential 
hyperexcitation (Rosenblum et al., 1996; Rostas et al., 1996; Lee, 2006). Also an 
important study by Abe et al., (2005) shows evidence suggesting Fyn kinase-
mediated phosphorylation of Tyr 14 72 on the NR2B subunit is essential for 
maintenance of neuropathic pain via post-translational modifications up-regulating 
receptor activity, (Chazot, 2004) by blocking endocytosis, again providing evidence 
for the suitability of targeting NR2B-containing receptors. 
It has also been proposed that NR2B interaction with BDNF enhances channel open 
probability (discussed in section 1.6.3), increasing evidence for potential over-
activation of NR2B-containing receptors (Levine and Kolb, 2000; Loftis and 
Janowsky, 2003) and increasing their association with diseases such as chronic pain. 
This thesis discusses the potential importance and clinical effectiveness of targeting 
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NMDA receptors, the difficulties in drug development arising from the heteromeric 
nature of the receptor and the inferred functional and pharmacological implications. 
1.10 Hypotheses, Aims and Objectives 
To investigate the physiological and pharmacological characterisation of NR2B and 
NR3B-containing NMDA receptors and evaluate the influence of receptor 
heterogeneity on NMDA antagonist development, the following hypotheses were 
addressed in this study; 
• NR2B-selective antagonists display differential pharmacological properties 
and are influenced by NMDA receptor heterogeneity. 
• The NR3B subunit influences the physiological function and pharmacology 
ofNMDA receptor complexes. 
• Chronic pain states elicit alterations of NMDA receptor physiology through 
changes in subtype expression and/or protein post-translational modification. 
To address these hypotheses, this study aimed to; 
• Investigate two novel NR2B subunit-selective antagonists developed by 
GlaxoSrnithKline (COMPOUND A and COMPOUND B), characterising 
their binding properties and using them as tools to explore the 
pharmacological influences ofNMDA receptor subunit heterogeneity. 
• Generate rodent and human anti-NR3B polyclonal antibodies and utilise 
them with a panel of selective NMDA antibodies to determine the 
distribution and complex associations of NMDA receptors, particularly 
NR3B-containing receptors in adttlt rat and human spinal cord. 
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• Investigate the functional implications of NR3 subunit inclusion in the 
NMDA receptor complex upon cytotoxicity, physiology and pharmacology. 
• Investigate the distribution, expression and phosphorylation of NMDA 
receptor subunits in rodent spinal cord and whole brain from a chronic pain 
model and compare with controls. 
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Chapter 2 
Materials and Methods 
2.0 Materials 
All chemicals and solutions were supplied by Sigma-Aldrich Company, UK and Gibco 
Ltd, UK except where specified. 
2.1 Preparation of standard solutions 
2.1.1 Acrylamide gels 
Reagent 6% 7.5% 10% 
Running Gel Buffer 3ml 3ml 3ml 
Stock Acrylamide 2.4ml 3ml 4ml 
dH20 6.6ml 6ml 5ml 
TEMED 6Jl) 6Jll 6Jll 
APS 60Jll 60Jll 60Jl) 
2.1.2 APS (Ammonium Persulphate) 
0.228g in 1ml deionised H20 (dH20). 
2.1.3 Coumeric Acid 
11mg coumeric acid in 1ml dimethyl sulphoxide (DMSO). 
2.1.4 DMEM F12 Media 
DMEM F12 Ham's F-12 (1:1 MIX), 2x50ml foetal calf serum (FCS), 300Jll 
gentomycin (5mg/ml), 40ml sodium bicarbonate (pH 7.6). 
2.1.5 DTT 
200mM DTT in 1ml dH20. 
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2.1.6 Electrode Buffer 
6g tris-HCI, 28.8g glycine, 0.67g EDTA, I g SDS in I L dH20.(pH 8.8) 
2.1.7 Extracellular solution for patch-clamping 
I 30mM NaCI, 5mM KC I, 2mM CaCb, 30mM glucose, 25mM HEPES 
(pH 7.3, osmolarity 330). 
2.1.8 Extracellular solution for Ca2+ permeability experiments 
0.3mM Ca2+ solution: 1 OOmM NaCI, 1 OmM HEPES, 1 OmM glucose, 
80mM sucrose, 0.3mM CaCb. (pH 7.3 osmolarity ~310). 
30mM Ca2+ solution: 100mM NaCI, 10mM HEPES, 10mM glucose, 
30mM CaCb (pH 7.3 osmolarity ~310). 
2.1.9 Homogenisation buffer 
2.1.10 
2.1.11 
2.1.12 
50mM tris-HCI, 5mM EDTA, 5mM EGTA, 320nM sucrose in 200ml 
dH20 (pH 7.4 ). 
Intracellular solution for patch-clamping 
140mM CsCI, 4mM MgCh, 10mM EGTA, 10mM HEPES (pH 7.3 with 
CsOH (pH 7.3 osmolarity 312). 
Intracellular solution for Ca2+ permeability experiments 
140mM NaCI, IOmM HEPES, l.lmM EGTA (pH 7.3 osmolarity ~290). 
Lowry assay reagents: 
Reagent A: 2% Na2C03, O.IM NaOH, 0.5% SDS in dH20. 
Reagent 8: 2% Sodium potassium tartrate in dH20. 
Reagent C: 1% CuS04 in dH20. 
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2.1.13 Luminol 
2.1.14 
2.1.15 
2.1.16 
2.1.17 
2.1.18 
2.1.19 
2.1.20 
1 OOmM tris-HCI, 22mg luminol in 1 OOml dH20 (pH 8.5). 
Lysis Buffer 
TBS, 2mM EDT A (pH 8), 1 : 100 protease inhibitor cocktail set III 
Phosphate buffered saline (PBS) 
8g NaCI, 0.2g KCI, 1.44g Na2HP04, 0.24g KH2P04 in 1L dH20 (pH 7.4). 
Radioligand Binding Assay buffer 
50mM tris-HCI, 5mM EDTA, 5mM EGTA in 500ml dH20 (pH 7.1). 
Radioligand Binding Wash buffer 
40mM NaH2P04-NaOH in 1L dH20 (pH 7.4). 
Running gel buffer 
1.5M tris, 8mM EDTA, 0.4% SDS (pH 8.8). 
Sample buffer 
30mM sodium hydrogen phosphate, 30% (v/v) glycerol. 0.05% (v/v) 
bromophenol blue, 7.5% (w/v) SDS in dH20 (pH 7.0). 
Solubilisation buffer 1% sodium deoxycholate 
50mM tris, 1% (w/v) deoxycholic acid, 0.15M NaCI, 5mM EDTA. 5mM 
EGTA, 1mM phenylmethylsu1phonyl fluoride, 1:100 Protease Inhibitor 
Cocktail Ill in dH20. 
2.1.21 Solubilisation buffer using sodium dodecyl sulphate 
50mM tris, various [SDS], 0.15M NaCl, 5mM EDTA, 5mM EGTA, 
1mM phenylmethylsulphonyl fluoride, I: I 00 protease inhibitor cocktail 
Ill. 
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2.1.22 
2.1.23 
2.1.24 
2.1.25 
2.1.26 
2.1.27 
Heather Chaffey 
Stacking gel buffer 
0.5M tris, 8mM EDT A, 0.4% SDS in I OOml dH20 (pH 6.8) 
Stacking gel 
2.3ml dH20, 0.65ml acrylamide, lml stacking gel buffer, 5fll TEMED, 
80fll ammonium persulphate (APS) (IO%). 
Tris/EDTA (TE) buffer 
lOmM tris, lmM EDTA (pH 8.0) in dH20. 
Transfer buffer 
25mM tris, 192mM glycine, 20% (v/v) methanol in 1LdH20. 
Tris buffered saline (TBS) 
50mM tris-HCI, NaCI 0.9% in IOOOml dH20 (pH 7.4). 
Tyrodes Buffer for FLIPR 
145mM NaCI, 2.5mM KCI, I OmM HEPES, 1 OmM glucose, I.5mM 
CaCh (pH 7.3 Osmolarity ~320). 
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2.2 Methods 
2.2.1 Glutaraldehyde method for conjugating peptides to carrier proteins. 
Method as previously described by Stephenson and Duggan, 1991. 
This procedure was used to conjugate the following rodent NR3B peptide (ISL, 
Paignton, UK) to thyroglobulin (carrier protein) through its amino terminal (N) residue. 
NR3B Rodent Peptide T G P P E G Q Q E RA E Q E C -amide 
Equal amounts (4mg) of peptide and carrier protein were dissolved in 2ml 0.1M 
NaHC03 buffer containing 0.5% (v/v) glutaraldehyde (freshly thawed). The peptide 
protein mixture was incubated in a glass tube for 16hrs at RT with vigorous mixing. 
200fll of 1 M glycine ethyl ester (pH 8) terminated the reaction. The peptide-protein 
conjugate was separated from the uncoupled peptide by dialysis against PBS for 4hrs at 
4°C (4x500ml), diluted to a final concentration of 1mg/ml and stored in lOOfll aliquots 
at -20°C. 
2.2.2 The 3-Maleimimdobenzoic acid N-hydroxysuccinimide (MBS) method of 
conjugating peptides to carrier proteins (cysteine coupling). 
Method as previously described by Stephenson and Duggan, 1991. 
This procedure was used to conjugate the following human NR3B peptide (ISL, 
Paignton, UK) to thyroglobulin through its amino-terminal cysteine residue. 
NR3B Human C T G P P E G S K E E TA E A E-amide 
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4mg of thyroglobulin were dissolved in KH2P04 buffer (pH 7 .2) containing 1 OmM 
Na2HP04 to a final concentration of 20mg/ml and the solution dialyzed overnight 
against 500ml 10mM KH2P04 buffer containing 10mM Na2HP04 (pH 7.2) at 4°C. 50J.1l 
of 1 OmM KH2P04 buffer (pH 7 .2) containing 1 OmM Na2HP04 was added to 4mg 
(200J.1l) of dialysed carrier protein, which was then activated by addition of 85J.1l stock 
MBS (3mg/ml of diamethylformanide). This mixture was then incubated at RT for 
30mins on an orbital shaker. 
The activated carrier protein was separated from free MBS by dialysis against 50mM 
KH2P04 buffer (pH6), containing 50mM Na2HP04 for 2hrs at RT (2x 1litre changes). 
1ml of 4mg/ml peptide, dissolved in lOmM KH2P04, pH 7.2, containing lOmM 
Na2HP04 was added to the dialysed activated carrier protein and incubated overnight at 
RT with gentle mixing. The peptide conjugate was separated from the uncoupled 
peptide by dialysis against PBS for a total of 4hrs at 4°C (4x500ml changes). 
The dialysed peptide-protein conjugate was diluted with PBS to a final concentration of 
1 mg/ml and stored in 1 OOJ.ll aliquots at -20°C. 
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2.2.3 Inoculation procedure. 
200111 of sterile PBS was mixed with lOOflg (I OOfll) of freshly thawed peptide-
conjugated carrier protein. This mixture was then emulsified with an equal volume 
(300fll) of Freunds complete adjuvant. This was mixed thoroughly using a wide bore 
syringe, until a viscous emulsion was obtained. 
The preparation was then injected intramuscularly into both hind legs of a New Zealand 
rabbit. Primary immunization was performed with Freunds complete adjuvant, whereas 
subsequent immunizations, at 1 month intervals, were performed with incomplete 
Freunds adjuvant. 
Rabbits were bled from the marginal ear vein 7-10 days post-booster injections, where 
1 0-15ml of blood was collected. The blood was allowed to stand at RT for 2hrs 
followed by clot contraction for 16hrs at 4°C. The cellular material was removed by 
centrifugation at 12000xg for lOmins at 4°C and the serum stored in 1ml aliquots at -
20°C. 
2.2.4 Generation of an NRJB peptide affinity column. 
The use of a peptide-carrier protein conjugate necessitates the affinity purification of the 
anti-peptide antibodies from the antiserum in order to remove non-specific binding from 
the anti-carrier protein antibodies. 
The synthesis of the peptide affinity columns is described by Stephenson and Duggen 
( 1991) and was carried out using an Immunopure rProtein A IgG Orientation Kit 
(Pierce, UK). 
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0.3g of activated CH-sepharose was incubated in 100ml water at RT for 15minutes to 
swell, before being applied to a 25ml column and washed under gravity with 1 OOml HCI 
(I mM) at 4°C. The sepharose was then equilibrated with 25ml O.IM NaHC03 (pH 8.0) 
containing 0.3M NaCI and transferred to a capped tube in 1 ml of equilibration buffer. 
1 ml of 5mg/ml of the respective peptide was dissolved in equilibration buffer and 
incubated with the sepharose beads for 1hr at RT with gentle mixing. 
25ml wash with equilibration buffer terminated the reaction and all the remaining active 
sites were blocked by incubation with 3ml 0.1M Tris-HCI (pH 8.0) containing 0.5M 
NaCI for 1 hr at RT with gentle mixing. The sepharose beads were then washed 
alternately with 4x O.lM CH3COOH (acetic acid pH 4.0), containing 0.5M NaCI and 
0.1M Tris-HCI (pH 8.0) containing 0.5M NaCI. 
The column was then equilibrated and washed with 20ml PBS and stored in 1 Oml PBS 
containing 0.02% NaN3 at 4°C until use. 
2.2.5 Immunopurification of anti-NRJB using an NRJB peptide affinity column 
The NR3B peptide column was washed with 1 OOml TBS before application of 5ml of 
serum. The column was batch mixed for 2 hrs at room temperature and then the 
unbound serum was collected and retained. The column was then washed under gravity 
with 1 OOml of TBS. The anti-NR3B antibody was then eluted in 1 ml fractions using 
50mM glycine pH 2.3 and immediately neutralized with15Jll of 2M Tris. Eight 
fractions in total were collected. 
The absorbance of each fraction was measured at 280nm using a Jenway Genova 
spectrophotometer and the peak fractions containing the antibody were pooled and 
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dialyzed overnight in 300ml TBS. The dialysate was collected and the optical density 
(OD) was measured at 280nm. The absorbance value was divided by 1.35, to give the 
concentration in mg/ml. 0.02% NaN3 was then added to the purified antibody as a 
preservative and stored in the fridge at 4°C. The column was then washed and stored in 
TBS containing 0.02% NaN3• 
)-
-< 
0 
NR38 peptide 
conjugated to sepharose 
beads via protein A 
Anti-NR38 
immunoglobulin 
Non-spedfic anti-carrier 
immunoglobulins 
Figure 2.1 Schematic diagram showing anti-NR3B purification via specific NR3B peptide-
affinity. The specific anti-NR3B antibodies bind to the peptide conjugated to the column and 
are eluted. The non-peptide specific antibodies are washed away. 
2.2.6 Homogenised membrane preparation 
All animal studies were performed with full ethical and Home Office approval (Project 
licence PPL-6003437). 
Adult male Sprague-Dawley Rat forebrains (whole brain minus the cerebellum) or 
spinal cords (cervical, thoracic and/or lumbar regions) were homogenized. 
2ml of cold homogenization buffer (solutions 2.1.9) was used to homogenize each brain 
or spinal cord using a Dounce glass homogenizer. All the homogenized tissue was 
placed into JA20 centrifuge tubes and centrifuged at 2200rpm, 4°C for I 0 minutes. 
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Following removal of the supernatant, the pellet was re-suspended in homogenization 
buffer, and the previous two steps repeated. The supernatant was removed and pooled 
together in a clean JA20 centrifuge tube. The supernatants were centrifuged at 
15000rpm at 4°C for 30 minutes. 
The supernatant was then discarded and the pellet re-suspended in homogenization 
buffer. 
The amount of buffer in which to re-suspend the pellet was calculated as follows: 
The initial weight of the tissue x 5ml = 11.6g x 5ml buffer = 58ml. 
The re-suspended pellet was gently homogenized to a smooth mixture, aliquoted and 
frozen at -20°C. 
2.2.7 Lowry Assay to determine protein concentration 
The reagents A, B, C and D (solutions 2.2.12) required for the assay were prepared, with 
a l mg/ml stock ofbovine serum albumin (BSA). 
A series of standard solutions were prepared as follows: 
0 
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Table 2.1 Preparation of standard solutions for Lowry assay. 
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Each concentration of BSA and a series of test protein (5 Jll protein +95J.!I dH20) were 
made up in triplicate and vortexed. 
0.5ml of reagent D was added to each tube, vortexed and left to stand at RT for lOmins. 
50J.!I ofFolin:dH20 was then added to each tube, vortexed and left to stand at RT for 30 
minutes. Addition of 0.5ml dH20 terminated the reaction. The absorbance at 750nm 
was then measured and analysed. A standard curve of absorbance against concentration 
was plotted and the concentrations of the samples being assayed calculated. 
2.2.8 SDS-PAGE and Western blotting 
2.2.8.1 Preparation of the samples: 
5-l OJ.!l of rat forebrain or spinal cord preparation, 5J.!l of sample buffer (3x), 2J.d DTT 
(3mg/ml) (1 Ox) and 8J.!I dH20. 
The samples were then pulsed at 6000rpm and placed in a 95°C heat block for 5 minutes 
to denature the proteins. They were then pulsed again at 6000rpm, vortexed, and loaded 
into the wells using a Hamilton page loader. 
2.2.8.2 SDS-PAGE: · 
The stacking gel was prepared (solutions 2.1.22), excess water drained and the stacking 
gel quickly poured, with the comb set in place. I 0-15 minutes was allowed for the 
stacking gel to set, before rinsing again with water. The tank was then filled with 
electrode buffer (solutions 2.1.6) and the samples loaded. The gel was then run at IOmA, 
180V for 30 minutes before increasing the current to 15mA for 1.5-2hrs. 
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2.2.8.3 Western blotting-Transfer: 
Hybond nitrocellulose membrane (Amersham International, Buckinghamshire, UK) 
was soaked in transfer buffer for 10 minutes prior to the transfer. The transfer system 
was built up on the white side of the cassette as follows; sponge, 2 pieces of blotting 
paper (Amersham International, Buckinghamshire, UK), nitrocellulose (Amersham 
International, Buckinghamshire, UK), gel, 2 pieces of blotting paper, sponge. The 
cassette was placed into transfer buffer (solutions 2.1.25) and transfer started at SOV, 
220mA for 2.5 hours. 
2.2.8.4 Incubating the nitrocellulose: 
The nitrocellulose was removed from the transfer tank and blocked to inhibit any 
endogenous reactive sites with 5% marvel (w/w), 0.2% Tween 20 (w/v) in TBS and 
SO!J.l 2M NaOH, for I hr at RT. 
The nitrocellulose was incubated in primary antibody against the protein of interest at 
varying concentrations. 2.5% (w/w) marvel in TBS buffer + 1°Ab (0.5-2!J.g/ml) 
overnight at 4°C. 
Unbound primary antibody was washed (4x10 min) with 2.5% marvel (w/w), 0.2% 
Tween 20 (w/v) in TBS. The nitrocellulose was then incubated in secondary (2°) anti-
rabbit horseradish-peroxidase linked antibody (Amersham International, 
Buckinghamshire, UK) (1 :2000 dilution) for 1hr at RT. 
The 2 °antibody was washed (4x10 min) with 2.5% marvel (w/w), 0.2% Tween 20 (w/v) 
in TBS, followed by rinsing in TBS. 
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2.2.8.5 Developing the nitrocellulose: 
In order to visualize the proteins on the blot the nitrocellulose was exposed to 6J.tl H20 2, 
1 Oml luminol (solutions 2.1.13) and 1 OOJ.tl coumaric acid (solutions 2.1.3) in order to 
complete the enzyme (2° antibody) -substrate (H20 2) reaction at RT for 1 minute. The 
blot was covered with clingfilm, taped inside the cassette and then exposed to the film. 
Following 1-5 minutes of exposure (antibody dependent) the film was removed and 
placed in Polymax RT developer and replenisher and Polymax RT fixer and replenisher 
(Kodak Professional, UK) and water. 
2.2.9 Cryostat sectioning of rat spinal cord and whole brain. 
2.2.9.1 Frozen preparations 
Whole spinal cords and brains were dissected from adult male Sprague-Dawley rats 
weighing approximately 270g and immediately frozen on dry ice and stored at -20°C 
until sectioning. 
The frozen tissue was orientated and mounted onto a specimen block at -20°C using 
Tissue-TeeM adhesive and Cryofreeze aerosol (Agar Scientific). The cryostat was 
adjusted and maintained at -20°C, with 20J.tm sections mounted directly onto poly-D-
lysine coated microscope slides. 
2.2.9.2 Formaldehyde fixed preparations 
Whole spinal cords dissected from adult male Sprague-Dawley rats weighing 
approximately 270g, were fixed using 4% paraformaldehyde and stored at 4°C. Three 
days prior to sectioning, the tissue was placed in 10% sucrose solution for 
cryoprotection. 
55 
Chapter 2 Heather Chaffey 
Immediately prior to sectioning, the fixed tissue was frozen in liquid nitrogen -70°C for 
1 minute in isopentane before being orientated and mounted onto a specimen block with 
Tissue-Tek™ adhesive and Cryofreeze aerosol (Agar Scientific). Transverse sections of 
the spinal cord were sliced at 20J.1m and stored in I ml PBS in 24-well plates or mounted 
directly onto poly-D-Iysine coated microscope slides. 
2.2.10 Immunohistochemistry on adult rat and human spinal cord. 
Tissue sections were either processed in 24-well plates (Iwaki, Japan) (with 0.5ml 
solution/well) or directly on the slides post-mounting (in coplin jars). The procedure 
was carried out at room temperature except where stated. 
The procedure was carried out on approximately 20 spinal cord sections (20J.1m) each 
run, with variation of the primary antibody at concentrations ranging from O.OI-2J.1g/ml. 
The sections were incubated in 10% methanol, 3% hydrogen peroxide in lOml TBS 
buffer for 10 minutes with shaking. 0.2% glycine, 0.2% Tween 20 in 50ml TBS buffer 
was then added to the wells for 15 minutes with shaking, followed by 0.2% Triton-X-
I 00 in TBS for a further 15 minutes. 
50mM sodium citrate pH8.4 was added to each well and incubated for 30 minutes at 
room temperature before being replaced by 50mM sodium citrate pH8.4 at 80°C for 30 
minutes. A wash step in 0.2% Triton-X-100 in TBS followed for 15 minutes before a 
blocking step using 2% serum, 0.2% Tween 20 in TBS for 60 minutes incubation. 
Primary antibody (0.01-2J.1g/ml) in 1% serum in TBS was then added to the tissue for an 
overnight incubation at 4°C. 
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The tissue sections were then washed in 1% serum in TBS (3x0.5ml) followed by 
addition of secondary biotinylated antibody (0.1%) in 1% serum in TBS. The sections 
were washed in 1% serum in TBS (3x0.5ml). The vector ABC solution (made up 10 
minutes prior to use) was then applied for 5 minutes with shaking before washing steps 
in TBS (5x0.5ml). Diaminobenzidine (DAB) developing solution (1 DAB tablet per 
10ml TBS and 6J.1l hydrogen peroxide) was added to the wells for 10 minutes incubation 
in the dark. DAB was removed and the sections washed in dH20 before mounting onto 
plain microscope slides (0.8x1.0mm) for drying. Once the tissue was dry the coverslips 
were applied using DPX histological mountant. 
2.2.11 Optimised method for immunohistochemistry on adult rat spinal cord tissue. 
Tissue sections were either processed in 24-well plates (Iwaki, Japan) (with 0.5ml 
solution/well) or directly on the slides post mounting (in coplin jars). The procedure 
was carried out at room temperature except where stated. 
Tissue was incubated with 10% methanol in PBS, with 3% H20 2 for 30 minutes before 
washing (3x 5minutes) with PBS-Triton-X-100 (PBS-T, 0.2%, v/v) pH 7.4. The tissue 
sections were then inbubated in PBS-glycine (0.2% w/v) pH 7.4 for 30 minutes to 
quench excess fixative before 1 hour incubation with blocking buffer (PBS-Triton plus 
10% goat serum). The sections were then incubated in primary antibody (diluted in 
PBS+ 1% goat serum) overnight (concentrations ranging from 0.5-2J.lg/ml, depending 
on the antibody). The tissue sections were then thoroughly washed (3x5 minutes with 
PBS-triton X 100, before incubation for 2 hours with the appropriate biotinylated 
secondary antibody from the vecta-stain ABC kit (1 drop in 1 Oml PBS/1% serum). 30 
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minutes before the end of this incubation, the ABC solution was prepared (I OOfll 
solution A and I OOfll solution B in 5ml PBS) and then applied to the tissue for an hour 
incubation. The tissue was then washed with PBS-TritonXIOO (3x5minutes) and then 
with PBS (2x5minutes) before the developing steps using DAB developing kit for 
approximately I 0 minutes or until staining occurs. 
2.2.12 Solubilisation and immunopurification ofNMDA receptors 
2.2.12.1 Solubilisation using 1% sodium deoxycholate (DOC) 
Male Sprague-Dawley adult rat forebrain preparation (3mg/ml) or spinal cord 
(1.5mg/ml) was used for this assay. 
6 x Iml aliquots of homogenized membranes (3mg/ml) were centrifuged at 13000rpm 
for 3 minutes, the supematant removed and discarded. The pellet was re-suspended in 
solubilisation buffer (solutions 2.1.20) to obtain a final concentration of 1.5mg of 
protein/m]. The samples were pooled together and the re-suspended mixture stirred 
batch wise at either 4 or 37°C for Ihour. Following this incubation, the samples were 
centrifuged at IOOOOg for 30minutes at 4°C. The supematant containing the solubilised 
membranes was collected, and the pellet re-suspended in solubilisation buffer 
(detergent-treated membranes)- a sample of each was retained for blotting. 
The solubilised membranes were then dialyzed against 2 x 1 L of dialysis buffer for 1.5 
hours each at 4°C. This dialyzed material then became the source of the NMDA 
receptors. The same procedure was also carried out at 37°C in order to investigate 
optimal solubilisation conditions. 
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2.2.12.2 Solubilisation using sodium dodecyl sulphate (SDS) 
Male Sprague-Dawley adult rat forebrain preparation (3mg/ml) or spinal cord 
(1.5mg/ml) was used for this assay. 
2xlml (1.5mg/ml) aliquots of homogenized membranes were centrifuged at 13000rpm 
for 3 minutes and the supematant discarded. The pellet was re-suspended in 
solubilisation buffer (solutions 2.1.21) to obtain a final concentration of 1.5mg 
protein/m!. This solubilisation/protein mixture was incubated at RT, 4 or 37°C for 3 
minutes with shaking. 5 volumes of ice-cold Triton-x-1 00 were used to dilute the [SOS] 
and the mixture was centrifuged at 13000rpm for 10 minutes. The supematant 
containing the solubilised receptors was removed and dialysed against 2xlL of dialysis 
buffer for 3hrs at 4°C. The unsolubilised fraction remaining in the pellet was 
resuspended in solubilisation buffer. 
Following dialysis, the solubilised membranes were purified via an immunoaffinity 
column or via immunoprecipitation with anti-NR3B antibodies. 
2.2.12.3 Immunopurification 
The dialyzed solubilised material was then purified via an anti-NRI immunoaffinity 
column. Purification is achieved as NR !-containing receptors covalently couple to the 
anti-NRI column, which is then washed and the receptors eluted. The solubilised 
receptors were incubated on the column for 20 hours at 4°C, using a peristaltic pump for 
constant circulation at a rate of 1 Oml/hr. Following incubation, any unbound receptors 
were drained from the column and retained to calculate uptake efficiency and the 
column washed with 50ml wash buffer. 
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The NMDA receptors were eluted using glycine pH 2.3. 8xlml fractions were collected 
and neutralized with 2M tris to a final pH 7.4. In order to identify the receptor-
containing fractions, immunoblotting was carried out using anti-NRl, anti-NR2A, anti-
NR2B and anti-NR3B antibodies. 
The same procedure was also carried out using an anti-NR2A column in order to isolate 
NR2A-containing receptors. 
• 
• 
I 
Anti-NRl 
NRl subunit 
NR1/NR2A 
NR1/NR28 
NR1/NR2A/NR28 
Figure 2.2 Schematic diagram showing immunopurification of NR1-containing receptors 
from detergent-solubilised material. Only those receptor complexes containing NR1 
subunits will bind to the specific anti-NR1 antibodies and be purified. The monomeric non-
functional NR2A and NR2B subunits are washed away. 
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2.2.12.4 Immunoprecipitation using Seize X Protein A Immunoprecipitation Kit 
(Pierce, Rockford, IL 61105). 
Following the manufacturers instructions, 200flg of rat anti-NR3B antibody was cross-
linked with DSS (disuccinimidyl suberate) to Immunopure® Immobilized Protein A 
before antigen precipitation. 
Adult male Sprague-Dawley rat spinal cord homogenate (1.5mg/ml) was solubilised 
with 0.5% sodium deoxycholate (see 2.2.12.1) before solubilised membranes were 
applied to the immobilized antibody for either 4 hours or 16 hours incubation at 4°C. 
Immunoprecipitated receptors were then eluted from the column using ImmunoPure® 
Elution Buffer and the fractions analyzed using SDS-PAGE. 
2.2.13 Chloroform/Methanol Procedure for protein precipitation 
50fll of sample were made up to IOOfll with dH20, to which 4xvolume (4x100fll) 
methanol was added. The samples were vortexed and pulsed up to 13000rpm. I OOfll of 
chloroform was added, after which the samples were again pulsed at I3000rpm. 300fll 
dHzO was added and the samples centrifuged for I minute at 13000rpm. 
The top layer of the sample was removed ensuring no disturbance to the intermediate 
phase (containing the protein). 
I OOf..Ll of methanol was again added, and the samples vortexed and centrifuged for 4 
minutes at 13000rpm. The supematant was removed and the pellet allowed to air dry 
for 30 minutes at RT before dissolving in sample buffer and loading for SDS-PAGE 
analysis. 
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2.2.14 Radioligand Binding 
2.2.14.1 Competition Binding 
Heather Chaffey 
Competitive binding experiments measure the binding of a single concentration of 
radioligand in the presence of various concentrations of unlabelled ligand (Motulsky 
1995) to determine the affinity of unlabelled ligands for receptors. 
During the experiment, both radiolabelled and unlabelled compounds compete for the 
available receptor binding sites providing a measurement of compound affinities. Once 
an equilibrated state of reaction has been attained, the amount of radiolabelled ligand 
bound to the receptor was measured following separation from the free, unbound 
radiolabelled ligand via filtration. The affinity of the unlabelled compound was then 
measured indirectly via its ability to compete with and displace the radio1abelled ligand. 
The parameters obtained are the concentration of unlabelled compound that inhibits the 
binding of the radiolabelled ligand by 50% (IC50) and subsequently the dissociation 
constant for the unlabelled compound (Ki). 
During binding experiments it is possible for the compounds to bind to non-specific 
sites distinct from the site of interest. It is therefore important to measure non-specific 
binding in the presence of a high concentration of unlabelled compound, that binds to all 
receptor sites of interest and subtract this value from the total binding to give specific 
binding. 
1mM ifenprodil was used to define non-specific binding for eH] CP-101,606 and eH] 
Ro-256981 assays and 1mM ketamine defined non-specific binding in eH] MK-801 
assays. All assays were also carried out in the presence of DTG (1 OJ.1M), a sigma-site 
antagonist to avoid non-specific binding, particularly in rat forebrain tissue. 
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A series of dilutions (10-3 -10-10 M) of the compound to be analyzed was prepared from a 
1 OmM (10-2 M) stock solution of compound dissolved in either 50mM Tris-HCL, 5mM 
EDTA and 5mM EGTA (pH 7.1) or DMSO depending on the compound. 
Adult male Sprague-Dawley rat homogenized forebrain was used as the source of 
NMDA receptors at a concentration of 1 mg/ml. (For recombinant receptors the forebrain 
is replaced with harvested recombinant NMDA receptors expressed in HEK293 cells). 
eH] Ro-256981 , eH] CP-101606 and eH] MK-801 were utilized as radioligands in 
order to compare the pharmacology of both compounds COMPOUND A and 
COMPOUND B (GlaxoSmithKline, Harlow, UK). Addition of I mM DTG (a sigma site 
antagonist) to the assay prevented non-specific binding to sigma sites. 
The scintillation tubes were set up as follows with a total of200j.ll/tube. 
Protl'in Compound J{:ulioli:,.:and \''"~ lrJ (; 
(lm:,.:/ml) (1W1 to tu- '' ) huiTtT (I m\)) 
Total l OOJ.ll 
Compound l OOj.ll 
Non-Specific l OOJ.ll 
Table 2.2 Preparation of scintillation tubes for competition radioligand binding assays. 
Following incubation on ice for 2hrs, the reaction was terminated and bound radio ligand 
washed with ice-cold 1 OmM sodium phosphate buffer and collected by rapid filtration 
through Whatman GF/B filters (Semat International , UK) using a Brandle Harvester. 
The filters were then collected and immersed in Ecoscint A liquid scintillation fluid 
(National Diagnostics, UK) overnight at RT before quantification using Packard tri-Carb 
1600TR spectrophotometer. The data was analyzed using GraphPad Prism version 4.0 
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to plot competition experiments as a one-site or two-site sigmoidal dose response curve 
with a variable slope. 
From these experiments the concentration of unlabelled ligand that inhibits the binding 
of the radioactive compound by 50% is the IC50 value, calculated as follows: 
For a one-site binding competition model: 
(Total-Nons~ecific) 
y = Nonspecific + I+ I o<log [DJ- og (ICSO) 
For a two-site binding competition model: 
Total-Nonspecific 
y = Nonspecific + 
[ 
Fraction I J l+ I 0 (x-log IC 
50 
I) 
y = the specific binding at a fixed concentration of displacing drug 
x = log10 concentration of the displacer 
log[D] =logarithm of concentration of unlabelled drug on x- axis 
Fraction I = The fraction of binding to the first type of receptor 
From the IC50 values, the inhibition constants (Ki) for the unlabelled ligand were 
calculated using the Cheng and Prusoff equation (Cheng and Prusoff, I973; Deupree 
and Bylund). 
ICso 
Ki = I+ [radio ligand] 
I«J 
Bmax can be calculated by the law of mass action 
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where: Bmax = Bo ~ + [L] )/ [L] 
IC50 = concentration of unlabelled ligand that inhibits 50% binding of radiolabeled 
ligand 
KI =the affinity of the radiolabelled ligand for the receptor 
Bo =the specific binding of the radioligand. 
2.2.14.2 Saturation Binding 
Saturation binding experiments were performed to determine the affmity ~) of a 
specific radioligand for a receptor and the density of receptor sites in a preparation 
(Bmax) (Deupree and Bylund). 
Adult male Sprague-Dawley rat forebrain homogenate (1mg/ml) was again used as the 
source ofNMDA receptors. A concentration range (0-30nM) of eH] Ro-256981 or eH] 
CP-1 01,606 was prepared with 1 OmM sodium phosphate buffer and incubated with 
1 OOfll forebrain homogenate (200fll total) for 2 hours on ice. Bound radio ligand was 
then washed and collected via rapid filtration and quantified (see 2.2.14.1 ). 
Saturation binding experiments were also analyzed using GraphPad Prism version 4. 
The affinity (K!) of the radiolabelled compound for the receptor was calculated as 
follows: 
y = l!max..:! 
Kl+x 
Where: 
y = specifically bound radiolabelled compound 
x = concentration of radio labelled compound 
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Bmax = density of receptor sites 
2.2.15 Plasmid DNA preparation 
2.2.15.1 Transformation of HB101 competent E.coli cells 
This method is essentially as previously described by Dagert and Ehrlich (1979). 
A 1 OOf.ll aliquot of frozen HB 101 competent cells (Promega Ltd, UK) was thawed on ice 
for 5 minutes. 20ng/f.1l of plasmid DNA to amplify was added to the competent cells 
and mixed gently. This cell mixture was then incubated on ice for 30 minutes before 
heat shocking the cells at 42°C for 1 min. The cells were incubated on ice for a further 2 
minutes, followed by addition of 900f.ll LB broth (47g broth in 1L dH20) to the 
transformed cells. This mixture was then incubated for an hour on a shaker at 37°C. 
1 OOf.ll of the cell suspension was spread onto previously prepared culture plates 
containing 1.5% (w/v) agar in LB broth containing ampicillin (50f.1g/ml). The culture 
plates were then incubated at 37°C for 18-20 hrs in an inverted position to prevent the 
build-up of condensation. 
2.2.15.2 Preparing glycerol stocks of transformed competent E. Coli cells 
500f.ll of terrific broth supplemented with 50% (v/v) sterile glycerol and 50f.1g/ml 
ampicillin to 500f.ll of the small overnight culture. Aliquots were then stored at -80°C in 
cryogenic vials until use. 
2.2.15.3 Amplification and preparation of plasmid DNA 
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Preparation of small-scale culture of plasmid DNA. 
I Oml of terrific broth containing ampicillin (50j.tg/ml) was inoculated with one isolated 
colony from the culture plates using a sterile loop and incubated for 18-20hrs on a 
shaker at 37°C. 
Preparation of large-scale culture of plasmid DNA. 
3mls of the small overnight culture were used to inoculate 500ml of terrific broth 
containing ampicillin (50j.tg/ml). This large culture was then incubated for 18-20hrs on 
a shaker at 37°C. 
2.2.15.4 Harvesting the large-scale culture and purification of plasmid DNA using 
the Qiagen plasmid maxi-kit (Qiagen, Crawley, West Sussex, UK). 
To harvest the transformed E.coli cells, the large-scale overnight culture was transferred 
into two ice-cold centrifuge tubes, and spun at 6500xg for I 0 minutes at 4°C. The 
supernatant was discarded, and the remaining pellet re-suspended in ice-cold Pl buffer 
(IOml). 
In order to lyse the bacteria containing the plasmid, 1 Oml of P2 buffer was added and 
mixed by gentle inversion, before incubation at RT for 5minutes. The mixture was 
neutralized with chilled P3 buffer (1 Oml) and mixed with gentle inversion before 
incubating on ice for 20 minutes. This solution was centrifuged at 14000xg for 30 
minutes at 4°C, before the clear lysate was transferred to a clean tube. 
During centrifugation, a Qiagen 500 tip was equilibrated with QBT buffer (lOml). The 
cell lysate was poured into the column and allowed to pass through under gravity flow. 
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The column was washed twice with QC buffer (30ml) and the plasmid DNA eluted 
using 15ml QF buffer. 10.5ml of ice-cold isopropanol (0.7 vol) was used to elute the 
DNA, and the solution centrifuged again at 14000g for 30 minutes at 4°C. The 
remaining pellet was washed carefully with ice-cold ethanol (1ml) and allowed to air 
dry for approximately 30 minutes. The purified DNA was dissolved in 5001J.l TE buffer 
(solutions 2.1.24) and stored at 4°C until the purity ofthe DNA was calculated. 
2.2.15.5 Quantification and determination of purity of the DNA yield 
The purity and the concentration of the plasmid DNA was determined by measuring the 
optical density at A 260nm and A 280nm. The ratio of the optical densities at these two 
wavelengths was determined. (OD~., 260 nm I OD~., 280 nm) should be within the range 
1.8-2.0. 
The plasmid DNA concentration is at A 260 nm. Therefore this absorbance relating to 
plasmid DNA concentration was multiplied by 50 as an OD of 1 corresponds to 
approximately 501J.g/ml for dsDNA. After calculating the plasmid DNA concentration 
in !J.g/!J.l, the final concentration was diluted to 11J.g/!J.l in TE buffer. The plasmid DNA 
was then stored in 1 OO!J.l aliquots at -20°C until use. 
Once thawed, the DNA was stored at 4°C to prevent freeze/thaw denaturation. 
2.2.16 Preparation of tissue culture medium 
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The tissue culture medium was prepared using 500ml Gibco DMEM F12 (1:1) 
(Cambrex Bio Science Verviers, Belgium) plus glutamate, 20ml sodium bicarbonate, 
50ml foetal calf serum and 1 Oml penicillin/streptomycin solution. The pH was adjusted 
to pH 7.6 before being filter sterilized (Nalgene™ 500ml filter unit). 
2.2.17 Sub-culturing HEK293 cells. 
The culture media was aspirated and the cells washed with 10ml PBS. 2ml 
trypsin/EDT A was added, the flask tapped and replaced in the incubator for 
approximately 30 seconds to remove cells. 1 Oml of pre-warmed new media was then 
added to the cells and the suspension titrated thoroughly to prevent aggregation. 2ml of 
this suspension was then seeded into each new flask or culture dish. 
For cell counting, the cell suspension was first centrifuged at 200g/5 min and the cell 
pellet resuspended in 10ml pre-warmed media. 1ml ofthe resuspended cell mixture was 
then used to count number of cells/ml. 
2.2.18 Transfection of HEK293 cells using lipofectamine reagent 
Transfections were carried out in 35mm culture dishes for western blotting, cytotoxicity 
assay and in 25cm2 culture flasks for radioligand binding. 
cDNA mixtures were prepared in ratios of 1:3 e.g, NR1:NRI/2B or 1:3:3 
NR1/NR1/2B:NRI/2B/3B. 
The transfection reagents were prepared as follows. 
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r 11 hl· 1 ., 11 hl' 2 
' Culture dishes 6~1 PLUS reagent 
I ~g Plasmid cDNA 
150~1 Optimem-1 media 
Culture Flasks 30~1 PLUS reagent 
5~g Plasmid cDNA 
750~1 Optimem-I media 
Table 2.3 Preparation of transfection reagents 
5~1 Lipofectamine 
150~1 Optimem-1 media 
25~1 Lipofectamine 
750~1 Optimem-I media 
Following al5minutes incubation at RT, the contents of the lipofectamine tube 2, were 
transferred into tube 1 and incubated for a further 15 minutes at RT. 
During the second 15 minute incubation, the HEK293 cells were washed (3x 2ml for 
dishes) (3xl0ml for flasks) with Optimem-1 medium. The contents of the remaining 
tubes were diluted with 2ml (35mm dishes) or IOml (25cm2 flasks) with Optimem-I 
medium, and added gently to the washed HEK293 cells. The cells were incubated in the 
transfection medium for 5 hrs (5% C02, 37°C). Following this incubation, the optimem-
I medium containing the plasmid DNA was replaced with the usual tissue culture 
growth medium (sections 2.2.16) and incubated for 48 hrs (5% C02, 37°C) before 
harvesting. l mM ketamine was added as an NMDA antagonist to those transfection 
mixtures which would be used in functional studies, to prevent cytotoxicity. 
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The above method was adapted for transfections for electrophysiology and FLIPR 
assays as follows: cells were seeded onto poly-D-lysine coated coverslips in 35mm 
culture dishes to be transfected for electrophysiology and in T175 culture flasks for 
FLIPR assays. Lipofectamine 2000 reagent replaced Lipofectamine PLUS reagent and 
incubation times were adjusted according to the manufacturer's instructions. 
2.2.18.1 Harvesting transfected HEK293 cells 
Each culture dish/flask was drained and the cells re-suspended in cold homogenization 
buffer (solutions 2.1.9) containing protease inhibitor cocktail Ill (Calbiochem) (1:100). 
The cells were scraped off the culture dish/flask and transferred to a glass-dounce 
homogenizer and homogenized for 30 strokes. The cell homogenate was then 
centrifuged at 13000 rpm for 5 minutes at 4°C. The supernatant was removed and the 
pellet re-suspended in homogenization buffer (lml per dish, 5ml per flask) and 
homogenized again. The transfected cells were stored in I OOfll aliquots at -20°C. 
2.2.19 CytoTox 96 Non-radioactive Assay (Promega Ltd, UK). 
1.5ml of media was removed from the cells and centrifuged for 2minutes at 13000rpm 
and the supematant retained. This supematant contains lactate dehydrogenase (LDH) 
released from the lysed cells. The pellet was re-suspended in 1 ml PBS and placed on 
the cells in the culture dish. The dish was then frozen for 2hrs at -20°C. The cells were 
thawed, centrifuged again (2minutes, 13000rpm) and the supematant retained, the 
contents of which was the total LDH. 
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A 1:10 and a 1:20 dilution of each of the supematants were prepared for the assay. 
Tissue culture medium DMEM:F12 was used as calibrator for the assay, with each 
dilution measured in triplicate (undiluted supematant, 1:10 and 1 :20). 50J.1l of substrate 
mix (Cytotox96 Promega) was added to each dilution before incubation for 30 minutes at 
RT in the dark. LDH was then quantified with absorbency readings at 490nm. 
2.2.20 Whole-cell patch-clamp electrophysiology on recombinant NMDA receptors 
expressed in HEK293 cells. 
HEK293 cells were passaged approximately every 3 days when cells were ~80% 
confluent. HEK293 cells were seeded onto poly-D-lysine coated coverslips in 35mm 
culture dishes 24hrs prior to transfection and incubated under normal conditions. 
Recombinant NMDA receptors (NR1, NR1/NR2B and NR1/NR2B/NR3B) labelled with 
GFP (green fluorescent protein), were transiently expressed in WT HEK293 cells using 
an optimized Lipofectamine™ protocol as described previously (section 2.2.18). 
Following 24hr incubation in the presence of the NMDA antagonist ketamine (1mM), 
successfully transfected (GFP-positive) cells were chosen for electrophysiology. 
Patch microelectrodes (GC120F-10 resistance 2-5MQ) were fabricated on a Sutter 
instruments P-87 electrode puller (Sutter Instruments Company, Novato, CA) whilst 
extracellular (solutions 2.1.8) and intracellular (solutions 2.1.11) solutions were warmed 
toRT (20-24°C) in a water bath. Solutions were set up to provide continual perfusion of 
the recording chamber with extracellular solution and alternating perfusion with the co-
agonists (IOOJ.1M Glutamate and lOJ.lM Glycine) and antagonists (CP-101606 and Ro-
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256981 1 OfJM and 300nM) through a multi-channel automated fast-switching solution 
exchange system (SF-77B; Warner Instrument, Hamden, CT). All experiments were 
conducted in the absence of extracellular magnesium to avoid voltage blockade of the 
receptor channel. 
HEK293 cells successfully transfected with NMDA receptor subunit combinations were 
identified using GFP and manipulated in the recording chamber into position beneath 
the perfusion barrels. The microelectrode was filled with intracellular solution and 
placed onto the head stage before being positioned onto the cell to make a seal. Whole-
cell patch clamp recordings were carried out at RT in voltage-clamp mode using an 
Axopatch 200B amplifier, controlled via the pClamp8/pClamp9 software suite (Axon 
Instruments Inc., Union City, CA). 
2.2.21 eH] Ro-256981 Autoradiography on rat spinal cord and whole brain 
Essentially as described previously by Mute! et a/, 1998. 
Selected slides were removed from the freezer and allowed to equilibrate to room 
temperature. The slides were incubated 2x I 0 minutes in Tris buffer (solutions 2.1.24) 
at RT followed by 1.5hr incubation in eH] Ro-256981 in Tris buffer (20nM). Slides 
were then washed in tris buffer (2x5minutes, 1xl5 minutes) on ice. In order to define 
non-specific binding, two slides were incubated in eH] Ro-256981 (20nM) containing 
ifenprodil (10-3M) for 1.5hrs on ice before repeating the washing steps detailed above. 
Following the washing steps, the slides were briefly dipped in ice-cold dH20 (IL) 
before air drying on the bench overnight. 
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The slides were then taped into a Kodak developing cassette with Amersham tritium 
hypersensitive film and stored for 5 weeks at RT, before fixing (Kodak GBX fixer and 
replenisher) and developing (Kodak GBX developer and replenisher) (Kodak 
Professional, UK). 
The autoradiograms were analysed 'blind' using the ImageJ program, where eH] Ro-
256981 binding density was measured and calculated from a tritium standard mini-scale 
(Amersham, UK), developed along-side the samples. 
2.2.22 Fluorescence imaging plate reader (FLIPR). 
The FLIPR assay enables measurement of changes m the concentration of free 
intracellular calcium using fluorophores which bind and react to calcium, emitting 
fluorescence in a concentration-dependent manner, when excited by an argon laser. 
This assay was used to measure the concentration of intracellular calcium in HEK293 
cells expressing recombinant NMDA receptors. 
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Figure 2.3 Schematic diagram representing the induction of fluorescence when Fluo-4 reacts 
with calcium in cells. The influx of calcium via NMDA receptors and calcium released from 
intracellular stores contribute to the fluorescent signal detected by the FLIPR machine. 
48hrs prior to FLIPR assay, HEK293 cells were transfected as described previously 
(section 2.2.18) with NRl , 38, NRl/28 and NRl/28/38 subunits. 24hrs post-
transfection, cells were removed from the culture flasks with trypsin!EDT A, centrifuged 
(200g/5minutes), re-suspended in pre-warmed fresh culture medium and counted. 
Approx 40000 cells/well were seeded onto Cornell™ black walled, clear bottomed poly-
D-lysine coated 96-well plates as shown below and returned to the incubator for a 
further 24hrs. 
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1 2 3 4 5 6 7 8 9 10 11 12 
WT 
NR1 
NR1/2B ~40,000 cells/well 
NR1/2B 
NR112B 
NR112B/3B 
NR112B/3B 
NR1/2B/3B 
Prior to the assay the FLIPR system (Molcular Devices, UK) was switched on and 
allowed to equilibrate for 30minutes. The water system, CCD camera and the computer 
were initiated followed by the laser according to manufacturer' s instructions and a 
yellow test plate signal generated and stored. 
Dye loading of the cells: 
An aliquot of Fluo 4 was thawed slowly and protected from direct light. The Fluo 4 was 
diluted to a final concentration of I mM (equated to 60J.1lll Oml) in Tyrode' s buffer 
(solutions 2.1.27) (without magnesium) and 50J.1llwell applied to the cell plate using a 
multi-channel pipette. Cells were then incubated at RT in the dark for I-2hrs. 
Following the dye loading, the cells were washed 4x150J.1l rinses with Tyrodes buffer 
using a Denley Cell washer system which leaves the cells in 125JJ.l of fresh buffer after 
washing. 
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For agonist studies, 50~1 of each agonist was added to the respective wells of the cell 
plate within the FLIPR system. Each agonist dose-response curve is made up of 12 half-
log concentrations. Prior to agonist addition a single image of the cell plate is taken as a 
signal test. During the run 60 images were taken at I second intervals followed by a 
further 24 images at 5 second intervals with agonist addition being made 20 seconds 
after the first image was taken. Agonist induced receptor activation was therefore 
detected as an increase in fluorescence. 
For antagonist studies, following the washing step, 25~1 of antagonist was added to the 
respective wells of the cell plate and incubated for 20minutes at R T in the dark. As 
above, addition of the agonist was carried out in the FLIPR system and signals recorded 
with multiple time resolved images as previously described. Functional antagonism was 
indicated by a suppression of agonist induced increases in fluorescence. 
The fluorescence measurements were extracted and tabulated using an ASCII text file 
and analysed using Microsoft Excel. 
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Chapter 3 
Pharmacological characterisation of two novel NR2B-selective 
antagonists COMPOUND A aBld COMPOUND B 
3.1 Introduction 
NMDA receptors have been a potential therapeutic target for the treatment of 
neuropathologies since the 1980's when it was noted that application of NMDA 
antagonists attenuated glutamate induced toxicity in primary neurons (Choi et al., 1988). 
Their widespread distribution, expression in disease related areas of the nervous system 
and potential for mediating toxic effects via over-activation, has led to focused research 
and interest in pharmaceutical intervention into NMDA receptor function. 
Initially developed as universal non-selective channel-binding antagonists, compounds 
such as MK-801, Phencyclidine (PCP) and AP-5 showed an unacceptably high side-
effect profile rendering them inappropriate for clinical use. Therefore the focus of 
research shifted to increasing the specificity and selectivity of receptor targeting, 
utilising the heterogeneous nature of the receptor. 
Modulation of the receptor complex by the inclusion of the NR2B subunit has been 
specifically implicated in many disease pathologies including chronic pain, dementia, 
schizophrenia, stroke and neurodegenerative conditions (Chazot and Hawkins, 1999; 
Chazot, 2004). NR2B-containing receptors potentiate NMDA receptor activation and 
therefore antagonising them specifically may be therapeutically beneficial, whilst 
limiting the adverse side-effect profile. 
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The development of NR2B subunit selective compounds such as ifenprodil and its 
analogues eliprodil, CP-101606 and Ro-256981 have provided important research tools 
for the pharmacological characterisation of the NMDA receptor complex, which 
enhance the potential for increasing specificity of pharmaceutical intervention. 
In 2005, McCauley reviewed the new patents and patent applications put forward in 
2001-2004 for novel compounds developed as a result of new structural diversities in 
small molecule NR2B antagonists. Currently Gideon Richter have promising preclinical 
data for the novel compound RGH-96 (Bradford and Chazot, unpublished), which is 
entering phase Ila clinical trials for the treatment of neuropathic pain. Merck & Co and 
Pfizer have also disclosed new compounds showing that despite problematic side-
effects, the targeting of NR2B-containing NMDA receptors remains a pharmaceutical 
focus. 
This chapter will review and characterise the pharmacological profile of two novel 
NR2B-selective antagonists developed by GlaxoSmithKline; COMPOUND A and 
COMPOUND B. Radioligand binding assays (2.2.14) will be used to investigate the 
binding affinity of these compounds and propose potential binding sites of the Iigands in 
native adult rat fore brain (2.2.6, 2.2. 7) and recombinant receptor populations (2.2.15-
18). The ifenprodil analogues CP-101606 and Ro-256981 and the channel blocker MK-
801 will be utilised as radioligands for displacement assays and to compare the 
selectivity and binding kinetics of the novel drugs. 
79 
Chapter 3 Heather Chaffey 
3.2 Results 
3.2.1 Competition binding to investigate the displacement of eHJ Ro-256981 by 
ifenprodil in adult Sprague-Dawley rat forebrain membranes. 
Adult rat forebrain membranes (IOOJ.Lg protein/tube) were used as the source of native 
NMDA receptors in this experiment where ifenprodil displacement of eH] Ro-256981 
was fitted to a 1-site sigmoidal variable slope model. This experiment acted as a control 
to demonstrate the effective displacement of the eH] Ro-256981 ligand by the batch of 
ifenprodil which would be used in subsequent experiments. A steep hills lope ( -0.9) 
and sigmoidal curve with Ki = 52 ± l.OnM demonstrates high affinity displacement of 
eH] Ro-256981 by ifenprodil and therefore high affinity binding towards receptor sites. 
The data shown is the average ± SD of three individual experiments, each performed in 
triplicate. 
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Figure 3.1 Competition binding experiment showing ifenprodil displacement of (3H] Ro-
256981 in adult rat forebrain membranes, best fit to a one-site binding model. Non-specific 
binding was defined with ifenprodil (lmM). 
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3.2.2 Competition binding to investigate displacement of (la] Ro-256981 with 
COMPOUND A in adult Sprague-Dawley rat forebrain. 
Adult rat forebrain membranes (100J.1.g protein/tube) were used as the source of native 
NMDA receptors in this competition assay with COMPOUND A [1 o-3M-10-10M]. 
Displacement of eH] Ro-256981 by COMPOUND A (10-3-10- 1~ was fitted to a 1-site 
sigmoidal variable slope showing one low affinity binding site piC50 4 ± 0.4 with a Ki = 
158 ± 14J.1.M. The hill slope ( -0.8) and low affinity binding may indicate heterogeneous 
receptor populations containing alternative NR2 subunits, to which COMPOUND A 
doesn't readily bind. Despite the presence of DTG, a sigma site antagonist, 
approximately 20% non-specific binding is evident. 
The data shown are an average ± SD of three individual experiments each carried out in 
triplicate. 
-CO en 
CD 
110 
N 
Hillslope = -0.8 ± 0.1 
piCso = 4.0 ± 0.4 
& 101~--~~--~~~~~ Ki = 158 ± l41J.M 
-10 ~ ~ q ~ ~ 4 
log [Compound A] (M) 
-3 
Figure 3.2 Competition binding experiment showing one-site displacement of PH] Ro-
256981 binding by COMPOUND A in adult rat forebrain membranes. Non-specific binding 
was defined with ifenprodil (lmM). 
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3.2.3 Competition binding to investigate the displacement of [~ Ro-256981 with 
COMPOUND B, in adult Sprague-Dawley rat forebrain. 
Adult male Sprague-Dawley rat forebrain membranes (IOOJlg protein/tube) were used as 
the source of NMDA receptors in this competition assay with COMPOUND B [1 o·3M-
10"10M]. The COMPOUND B displacement curve of eH] Ro-256981 binding was best 
fitted to a one-site binding model with low affinity binding (Ki = 180 ± 7JlM). Again 
this low affinity binding may indicate that eH] Ro-256981 is binding to alternative sites 
within the native tissue, to which COMPOUND B is largely insensitive. The data 
presented are an average ± SD of three individual experiments, each performed in 
triplicate. Again, despite the presence of DTG, a sigma site antagonist, approximately 
20% insensitive binding is evident. These experiments were performed with three 
different batches ofradioligand (from different sources) and produced consistent results 
(not shown). 
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Figure 3.3 Competition binding experiment showing one-site displacement of (3H] Ro-
256981 binding by COMPOUND Bin adult rat forebrain membranes. Non-spedfic binding 
was defined with ifenprodil (lmM). 
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3.2.4 Competition assay investigating the displacement of [Ja] CP-101606 binding 
by COMPOUND A in adult rat forebrain membranes. 
Adult male Sprague-Dawley rat fore brain membranes (1 OOJ.lg protein/tube) were the 
source ofNMDA receptors in this competition assay investigating COMPOUND A [1 o-
3M-10-IOM]. 
The high affinity (Ki = 6 ± 2nM) displacement of eH] CP-1 01606 binding by 
COMPOUND A was fitted to a one-site variable sigmoidal curve model and shows that 
this novel compound displays high affinity binding towards NMDA receptors composed 
of only NR1/NR2B subunits. There is some evidence for low affinity binding to a 
second site at high concentrations of COMPOUND A, which may be other NMDA 
receptor populations, or alternative, non-sigma receptor sites present in the native tissue. 
The data shown are an average ± SO of two individual experiments each carried out in 
triplicate. 
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Figure 3.4 Competition binding experiment showing COMPOUND A displacement of (3H] CP-
101,606 in adult rat forebrain membranes, best fit to a one-site binding model. Non-specific 
binding was defined usin~ ~f~~pr~C!it£1011\f). 
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3.2.5 Competition assay investigating the displacement of [3H] CP-101606 binding 
with COMPOUND B in adult rat forebrain tissue. 
Adult Sprague-Dawley rat forebrain membranes were used as the source of NMDA 
receptors in this competition study investigating COMPOUND B [I o-3M- I o-10M]. 
COMPOUND B bound with a high affinity (Ki :::;: 8 ± 9nM) to native NR2B-containing 
NMDA receptors displacing eH] CP-101606 in a model best fitted to a sigmoidal 
variable slope, one-site model. This data suggests similarity between the novel 
compounds and CP-101606 with a seemingly high affinity for only NRIINR2B 
receptors and the same site of action. Complete displacement of eH] CP-1 01606 was 
not achieved at milimolar concentrations of COMPOUND B, indicating that this 
compound maybe more highly selective for NMDA receptors than CP-101606. This 
data may indicate that COMPOUND B and COMPOUND A differ in pharmacological 
interaction with the receptor complex in the brain. The data shown are an average ± SD 
oftwo experiments, each carried out in triplicate. 
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Figure 3.5 Competition binding experiment showing COMPOUND B displacement of (3H] CP-
1Ql,6()6 in a~ult rat forebrain.tissue,fittedto a one-site,binding mode); Non-specific binding 
was defined with ifenprodil (lmM). 
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In order to further characterise the binding affinity and selectivity of COMPOUND A 
and COMPOUND B, competition binding assays were carried out using recombinant 
rNR1/NR2B receptors, in order to compare binding pharmacological properties with 
native tissue. 
Before binding assays were undertaken, the expression of NRIINR2B receptors was 
confirmed. 
3.2.6 Confirmation of recombinant NMDA receptor subunit expression 
The recombinant NRIINR2B NMDA receptors were expressed in HEK293 cells, 
following transient transfection using Lipofectamine reagent (2.2.15-18), and harvested 
48 hours post-transfection. 
To confirm NMDA receptor subunit expression, SDS-PAGE and immunoblotting was 
undertaken using cell homogenate. Immunoreactivity at - 120 and 170KDa shows 
successful eo-expression of both NRI and NR2B subunits, respectively. 
1 2 3 4 
+- 170KDa 
120KDa __. 
Figure 3.6 Immunoblot confirming the expression of NR1 and NR2B subunits in HEK293 cells 
for use in radioligand binding experiments. Lanes 1+2 HEK 293 cells expressing NR1/NR2B 
receptors and probed with anti-NR1 (2pgfml). Lanes 3+4 HEK 293 cells expressing 
NR1/NR2B receptors probed with anti-NR2B (2~g/ml). Representative blot from n=3 
experiments. 
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3.2.7 Competition binding assay to investigate the displacement of eH] Ro-256981 
by COMPOUND A in recombinant NR1/NR2B receptor complexes. 
NR 1/NR2B receptors were transiently expressed in HEK 293 cells and harvested 48 
hours post-transfection for use in radioligand binding studies. 
This competition assay shows two-site displacement of eH] Ro-256981 binding by 
COMPOUND A [10-3M-10-10M] and therefore affinity for two receptor populations. A 
small proportion (24%) of binding to a high affinity site (Ki = 10 ± lOnM) was evident, 
but the largest proportion (76%) of binding was to a second lower affinity site (Ki = 26 ± 
3J.lM). The high affinity binding is likely to be towards the recombinant NRl/NR2B 
receptors, whereas the lower affinity site may be another non-specific site endogenously 
expressed in HEK 293 cells. 
The data analysed are an average ± SD of three individual experiments, each performed 
in triplicate. 
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Figure 3.7 Competition binding showing two-site displacement of (3H) Ro-256981 by 
COMPOUND A in recombinant NMDA NR1/NR2B receptors expressed in HEK293 cells. Non-
specific binding was defined with ifenprodil (lmM). 
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3.2.8 Competition assay investigating the displacement of eH] Ro-256981 by 
COMPOUND B in recombinant NR1/NR2B receptors. 
NR1/NR2B receptor subunits were transiently expressed in HEK 293 cells and used as 
the source ofNMDA receptors for this competition assay. 
Displacement of eH] Ro-256981 binding by COMPOUND B [10-3-10- 1~] was fitted to 
a two-site model showing binding affinity to potentially two populations of receptors 
(binding ratio 33:67%). COMPOUND B displays high affinity binding (Ki = 5 ± 3nM) 
probably to NR1/NR2B receptors, with lower affinity (Ki = 19 ± 12J.1M) binding 
towards another population of receptors present in the HEK 293 cells. The data shown 
are an average ± SD of four individual experiments, each performed in triplicate. 
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Figure 3.8 Competition binding experiment showing two-site displacement of (3H] Ro-
256981 by COMPOUND Bin recombinant NR1/NR2B receptors expressed in HEK293 cells. 
Non-specific binding was defined with ifenprodil (tmM). 
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3.2.9 Competition binding assay to investigate the influence of COMPOUND A 
upon the binding of[~] CP-101606 in recombinant NR1/NR2B receptors. 
NR l/NR2B recombinant receptors were transiently expressed in HEK 293 cells and 
used as the source ofNMDA receptors in this assay. 
COMPOUND A displayed two-site displacement of eH] CP-101,606 showing high 
affinity binding (Ki = 5 ± 6nM) to NRIINR2B populations (binding ratio 82:18%). A 
small proportion of binding to a low affinity site at higher concentrations of 
COMPOUND A possibly results from non-specific binding to other receptor sites 
present endogenously in HEK 293 cells. 
The data plotted are an average± SD of three individual experiments, each carried out in 
triplicate. 
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Figure 3.9 Competition binding showing the two-site displacement of (3H] CP-101,606 by 
COMPOUND A in recombinant NR1/NR2B receptors expressed in HEK 293 cells. Non-specific 
binding was defined with ifenprodil (1mM). 
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3.2.10 Competition assay to show the influence of COMPOUND B upon the 
binding of eH] CP-101606 towards recombinant NR1/NR2B receptors. 
NR1/NR2B recombinant receptors were transiently expressed in HEK 293 cells and 
harvested 48 hours post-transfection for use as the source of NMDA receptors in this 
assay. 
COMPOUND B displayed high affinity one-site displacement of eH] CP-101606. A 
steep hill slope and high affinity binding (Ki = 9 ± 1 OnM) of COMPOUND B towards 
NR1/NR2B containing receptors is evident. COMPOUND B completely displaces the 
CP-1 01606 radio ligand, showing that the two compounds display equivalent 
pharmacology in HEK293 cells, and also highlighting potentially different binding 
interactions between COMPOUND B and COMPOUND A. 
The data presented are an average ± SD of three individual experiments, each performed 
in triplicate. 
Hillslope = -0.8 ± 0.3 
piCso 1 = 8.0 ± 1.0 
Ki= 9 ± 10nM 
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Figure 3.10 Competition binding experiment showing one-site high affinity displacement of 
(3H] CP-101,606 by COMPOUND Bin recombinant NR1/NR2B receptors expressed in HEK293 
cells. Non-specific binding was defined using ifenprodil (lmM) . 
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To further characterise the binding site of the two novel compounds COMPOUND A 
and COMPOUND Band investigate their interactions, competition binding was carried 
out with eH] MK-801. MK-801 is a non-selective NMDA channel antagonist and 
enabled any allosteric interactions of the novel compounds with the channel pore to be 
investigated. 
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3.2.11 Competition curve to investigate the competitive binding between eHJ MK-
801 and ifenprodil in adult rat forebrain tissue. 
Following a 90 minute incubation period ifenprodil (1 o-3 -10-9M) displacement of eH] 
MK-801 binding was fitted to a one-site competition model in this assay using adult rat 
forebrain membranes as the source of NMDA receptors with a Ki = 120 ± I OJJM. 
Reducing the incubation times to sub-equilibrium (30 and 60 minutes) shifted the 
binding curve to the left indicating a reduction in open channel probability reducing the 
ability of eH] MK-801 binding and/or an allosteric linkage with the channel pore 
binding site, consistent with previous findings (data provided by Chazot, unpublished). 
The data presented for 90minute incubation are an average ± SD for three individual 
experiments carried out in triplicate. 
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Figure 3.11 Competition binding experiment showing low affinity ifenprodil displacement of 
(3H] MK-801 binding in adult rat forebrain membranes. Non-specific binding was defined 
with ketamine (1mM) and the reaction terminated after 30, 60 and 90 minutes. 
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3.2.12 Competition assay to investigate the influence of COMPOUND A upon the 
binding of eH] MK-801 to adult rat forebrain tissue. 
Adult Sprague-Dawley rat forebrain membranes (IOOJ..Lg protein/tube) were used as the 
source of NMDA receptors in this assay. The experiment was carried out on ice and 
terminated after either 30, 60 or 90 minutes to investigate time-dependent binding 
affinities. The data was fitted to a one-site competition model with similar low affinity 
binding of COMPOUND A at all three time-points (Ki = 14 ± OJ..LM, 18 ± 9J..LM, 15 ± 
lOJ..LM, respectively. This evidence suggests that binding of COMPOUND A has 
minimal allosteric linkage with the receptor channel and therefore MK-801 binding 
remains unaffected until high concentrations. 
The data shown are an average ± SD of two individual experiments, each carried out in 
triplicate. 
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Figure 3.12 Competition binding experiments showing the COMPOUND A displacement of 
(3H] MK-801 binding in adult rat forebrain, terminating the reaction after 30, 60 and 
90minutes. Non-specific binding was defined with ketamine (1mM). 
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3.2.13 Competition binding assay investigating the influence of COMPOUND B on 
the specific binding of eH] MK-801 in adult rat forebrain tissue. 
Adult Sprague-Dawley rat forebrain membranes (1 OO~g protein/tube) were utilised as 
the source of NMDA receptors for this assay. Again, the reaction was terminated after 
30, 60 and 90 minutes before and after equilibrium was achieved to assess time-
dependent responses. Following 90 minute incubation period COMPOUND B 
displacement of eHJ MK-801 was best fitted to a one-site model with a Ki = 13 ± 
15~M. A shift to the left of the curves sub-equilibrium at 30 and 60 minutes showed 
two-site binding with a high affinity piC50 = 8 and Ki = 4nM after 30 minutes. These 
results may be indicative of potential differences in the binding interactions and kinetics 
of the two compounds, as COMPOUND B shows greater allosteric interaction with the 
MK-801 binding site particularly sub-equilibrium than COMPOUND A. Data shown 
are an average± SO of between one-five experiments, each carried out in triplicate. 
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Figure 3.13 Competition binding experiments showing the COMPOUND B displacement of (lH] MK-
801 binding in adult rat forebrain, terminating the reaction after 30, 60 and 90minutes. Non-
specific binding was defined with ketamine (1mM). 
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_______ Rect'pt·ors---Gompet-it-in·-displaet·ment-witlnlm el--
com po1mds 
COMPOUND A COMPOUNDB 
Native Low affinity Low affinity 
eH] Ro- Ki = 158J.1M Ki= 180J.1M 
256981 Recombinant Proportion of high Proportion ofhigh 
Affinity (24%) affinity 
Ki= 10nM (33%) 
Ki=5nM 
Native High affinity High affinity 
[~CP- Ki=6nM Ki=8nM 
101606 Recombinant High affinity High affrnity 
Ki=5nM Ki =9nM 
[~ MK-801 Native Low affrnity Proportion ofhigh 
Ki = 14, 18, 15J.1M affinity 
sub-equilibrium 
Ki = 4, 57nM, l3J.1M 
Comment High affinity antagonism High affinity 
NR1/NR2B populations antagonism 
Minimal influence on NR1/NR2B populations 
channel Potentially some inter-
pore binding sites. action with channel 
pore. 
Table 3.1 Summary of the competitive binding data obtained for the novel compounds 
COMPOUND A and COMPOUND B. 
94 
Chapter 3 Heather Chaffey 
3.3 Discussion 
NR2B subunit-selective NMDA antagonists are some of the most clinically advanced 
compounds targeting this excitatory receptor family, with the potential clinical benefits 
of pharmaceutical intervention evident from animal models and in vitro systems. 
Continuing the generation and development of high-affinity, subunit-selective 
compounds is therefore very important to ensure specific, effective targeting with 
minimal adverse side-effects. 
This study focuses on the characterisation of two novel anti-NR2B antagonists 
developed by GlaxoSmithKiine COMPOUND A and COMPOUND B, using 
competitive radioligand binding experiments. 
The NR2B selective antagonist ifenprodil and its analogues Ro-256981 and CP-101606, 
and the channel blocker MK-801, were utilised in this series of experiments to 
characterise the binding properties and kinetics of the two novel compounds. 
To confirm assay protocol and validate the action of the test compounds, initial 
competition experiments were carried out with ifenprodil (I0-4-I0-9M) and tritiated Ro-
256981. Ifenprodil displayed high affinity binding towards NR2B-containing receptors 
in native tissue, with a Ki of 52nM, similar to previous findings of 37nM (Bradford and 
Chazot, unpublished), 20nM (Mute! et al., 1998) and 33nM (Grimwood et al., 2000). 
lfenprodil has been the prototypical NR2B-selective antagonist since it was shown to 
have a significantly higher affinity for NR2B-containing NMDA receptors than those 
containing alternative NR2 subunits (Williams, 1993; Williams, 2001) in both native 
(Tovar et al., 2000) and recombinant receptors (Williams, 1993). Originally developed 
as a vasodilating agent, as it binds to adrenergic-a I receptors, it was found to have 
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selectivity for NR2B-containing NMDA receptors, providing neuroprotection with more 
limited side-effects than the broad spectrum, non-selective channel blockers. 
Effective, high affinity displacement of fH] Ro-256981 binding by ifenprodil shows 
both compounds are actively competing for the same receptor binding sites. 
Ifenprodil and its analogues bind to a distinct site (LIVBP-like domain) on the NR2B 
subunit (see section 1.7.3) and act via increasing proton inhibiton at these receptors 
(Perin-Dureau et al., 2002). Sequence variation of the LIVBP-like domain between 
NR2 subunit family members enables the selective targeting of the NR2B subunit 
(Malherbe et al., 2003). 
The NR2B-selectivity of ifenprodil and its analogues therefore arises from specific 
modulation and interaction with this binding domain. Chemically, ifenprodil-like 
compounds contain a common motif thought to be important for NR2B selectivity, 
where a tertiary basic amine is attached via tinkers to an aryl ring (Nikam and Meltzer, 
2002) in an optimum spatial orientation (Williams, 2002). 
The number of bonds between the acidic groups appears to be important for subunit 
selectivity with Feng et al., (2005) showing that longer chain antagonists (containing 
seven instead of five bond lengths) displayed greater subunit selectivity aiding the 
design of new analogues. Of these analogues, Ro-256981 developed by Roche (Fischer 
et al., 1997) and CP-1 01606 developed by Pfizer (Menniti et al., 1997) showed 
advanced affinity and selectivity for NR2B-containing receptors via addition of a tinker 
bearing a hydroxyl group and a hydroxyl group in the aryl-ring, which reduced 
compound non-specific affinity for adrenergic, sodium and potassium channels 
(Williams, 2002). 
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In animal models Ro-256981 has been shown to effectively attenuate glutamate induced 
NMDA currents (Malherbe et al., 2003) showing success in disease models (Loschmann 
et al., 2004). Ro-256981 binds to NR2B-containing receptors with high affinity despite 
the presence of alternative NR2 subunits (Chazot et al., 2002) highlighting the different 
populations of receptors which would be targeted by this compound. 
Like ifenprodil and Ro-256981, CP-101606 acts to inhibit NMDA receptor channel 
activity by potentiating proton inhibition (Chazot, 2000) and is able to distinguish 
between sub-populations of receptor, binding with significantly greater potency to 
NR1/NR2B populations (Chazot et al., 2002). 
Competition binding using these NR2B-selective tools was performed to characterise 
and assess the binding properties and affinities of the two novel compounds. 
Competition binding assays using unlabelled COMPOUND A and COMPOUND B(l o-
3-10-1~) and eH] Ro-256981 showed low affinity binding to NMDA receptors within 
the native adult rat forebrain tissue, with inhibition of eH] Ro-256981 binding at 
relatively high concentrations only (Ki = 158 ± 14 and 180 ± 7J.1M, respectively). This 
low affinity binding may result from the presence of heterogeneous NMDA receptor 
populations within the forebrain to which Ro-256981 binds but COMPOUND A and 
COMPOUND B do not, preventing high affinity binding. It could also be an indication 
that COMPOUND A and COMPOUND B bind to distinct sites or interact differently 
with the Ro-256981 binding pocket on the receptor complex. It is also possible that 
assay conditions were unfavourable for effective compound binding, for example if high 
concentrations of magnesium were present blocking receptor activity, or if rec~l'!?r 
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expression levels were different between tissue homogenates, however parallel 
experiments with the control compound ifenprodil showed competitive displacement. 
The lack of apparent effect by COMPOUND A and minimal high affinity displacement 
by COMPOUND B of eHJ Ro-256981 binding in the brain is surprising, yet consistent 
(observed with three separate batches of radio ligand which were all displaced as 
expected with the control compound ifenprodil). These data are in contrast to previous 
data, where this low affinity inhibition of eH] Ro-256981 is not seen with other NR2B 
antagonists such as ifenprodil, CP-101606 and RGH-896 (Chazot et a/, 2002 and 
Bradford, unpublished) (data not shown), which support confidence in the assay. 
In the second set of competition experiments, eH] CP-1 01606, a compound which binds 
primarily to NR1/NR2B receptors, was used to assess the binding properties of the two 
novel compounds in adult rat forebrain. Experiments with unlabelled COMPOUND A 
(I 0"3 -J 0"1<M) showed a steep, sigmoidal displacement curve indicative of high affinity 
competitive binding (Ki = 6 ± 2nM) to populations of receptor containing only 
NRIINR2B subunits. Under the same assay conditions, COMPOUND B (10-3-10-1<M) 
again displayed high affinity binding (Ki = 8 ± 9nM), with a single-site displacement of 
eH] CP-101606. COMPOUND A and COMPOUND B (Ki = 6 and 8nM, respectively) 
therefore show a greater binding affinity than ifenprodil (20nM), haloperidol (600nM) 
and eliprodil (200nM) (Mutel et al., 1998) and display comparable selectivity and 
potency with other NR2B antagonists such as Ro-256981 and CP-101606. The 
competitive antagonism of eH] CP-1 01606 binding in particular is comparable with 
published Ki values for unlabelled CP-1 01606 (8nM) (Mutel et al., 1998) and tritiated 
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CP-101606 (12nM) (Chazot et al., 2002), (13nM) (Menniti et al., 1997) showing that 
both COMPOUND A and COMPOUND B are potent NR2B-selective antagonists. 
Interestingly, even at high concentrations complete inhibition and displacement of eH] 
CP-101606 by COMPOUND B was not achieved. This provides evidence suggesting 
that CP-1 01,606 may bind to an alternative site/receptor population within the native 
tissue to which COMPOUND A but not COMPOUND B binds. 
To further assess the binding properties and selectivity of the novel compounds, the 
assays were repeated using recombinant NR1/NR2B receptors expressed in HEK 293 
cells. 
COMPOUND A (10-3-10-10M) displayed biphasic displacement of eH] Ro-256981, 
showing a site of high affinity binding, presumed to be NR1/NR2B receptors (Ki = 10 ± 
10nM) and a lower affinity site (Ki = 26 ± 3J.1M) possibly non-specific binding to other 
non-sigma receptor sites endogenously expressed in HEK 293 cells. The inhibition of 
eH] Ro-256981 binding by COMPOUND B (10-3-10-1<M) shows a comparable biphasic 
two-site binding curve with recombinant NR1/NR2B receptors as was seen with 
COMPOUND A, with a high affinity NR1/NR2B binding site (Ki = 5 ± 3nM) and a low 
affinity at the second binding site (Ki = 19 ± 12J.1M, ratio 33:67%). 
This low affinity site has previously been detected using other NR2B-ligands in HEK 
293 cells (Bradford and Chazot, unpublished) and reported in L (tk-) cells (Grimwood et 
al., 2000). To minimize the effects of this endogenous element in HEK293 cells and 
maximize NR1/NR2B receptor binding, immunopurification of the recombinant 
receptors could be carried out prior to the assay. It should also be noted that in vitro 
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modelling in HEK 293 cells also presents potential changes in the cell membrane, 
receptor trafficking and expression mechanisms in comparison to the host neurons in 
native tissue, which may affect pharmacology. 
Comparing this data with that obtained from adult rat forebrain tissue, the high affinity 
site seen in the recombinant NRI/NR2B receptors may be masked in the native tissue 
due to the presence of alternative receptor subunit combinations or receptor 
conformations. 
Competitive antagonism of COMPOUND A (10-3-10-10M) towards eH] CP-101,606 in 
recombinant NR1/NR2B receptors displayed a biphasic distribution with high affinity 
binding (Ki = 5 ± 6nM) to NRI/NR2B receptors comparable to that obtained in the 
native tissue (Ki = 6 ± 2nM). 
Displacement of eH] CP-101606 with COMPOUND B (10-3-10-10M) also showed 
comparable high affinity binding in recombinant NR1/NR2B receptors (Ki = 9 ± lOoM) 
and native tissue (Ki = 8 ± 9nM). Again these high affinity binding values are 
comparable with published values for eH] CP-101606 binding to NR1/NR2B 
recombinant receptors expressed in HEK 293 cells (Ko = 6nM) (Chazot et al., 2002) 
demonstrating high affinity novel compounds. The discrimination between two receptor 
populations shown by COMPOUND A in this assay provides further evidence for 
distinct binding interactions to receptor populations between the two novel compounds. 
In the recombinant NRIINR2B receptors, both COMPOUND A and COMPOUND B 
display high affinity inhibition of eH] Ro-256981 and eH] CP-10 1606 binding, which 
may indicate that HEK 293 cells lack components which prevent high affinity inhibition 
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of eH] Ro-256981 binding by COMPOUND A and COMPOUND B in the brain. Both 
COMPOUND A and COMPOUND B appear to have a high affinity for NRIINR2B 
receptors and are potentially more sensitive to receptors containing alternative NR2 
subunits as is evident from their competitive antagonism of eH] CP-1 01606 binding. 
The data may also suggest evidence for distinct, but possibly overlapping binding sites 
between the novel compounds and Ro-256981. 
To further investigate the binding site characteristics and any allosteric modulations of 
the receptor channel inferred by the two novel compounds, competition studies with 
eH] MK-801 were undertaken, terminating the reaction after 30 minutes, 60 minutes 
and 90 minutes to observe any time-dependent changes. Competitive binding with 
ifenprodil (1 o-3 -10-9M) and eH] MK -801 showed evidence for allosteric coupling 
between the ifenprodil binding site and the channel pore binding site. 
Displacement curves with both COMPOUND A and COMPOUND B were fitted to 
one-site binding models at equilibrium, with indication of differential allosteric coupling 
to the channel pore site using sub-equilibrium conditions. 
COMPOUND A displays very little competitive antagonism of eH] MK-801, with 
similar binding affinities at all three time-points (14, 18 and 15J.1M, respectively). 
In contrast, COMPOUND B shows increased binding affinity, with a curve shift to the 
left and shallowing of the curves following 60 and 30 minute incubation times, 
respectively. 
These apparent differences in the modulatory effects on the channel pore binding sites, 
shows that COMPOUND A and COMPOUND B may have overlapping bin~in~ sites or 
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distinctive interactions with their binding sites which mediate different open channel 
probabilities or different allosteric effects on the MK-801 binding site. 
From the evidence collected both COMPOUND A and COMPOUND B display high 
affinity antagonism towards NRIINR2B-containing receptors and could be classified 
along with CP-1 01606 in terms of NMDA receptor selectivity as both compounds 
appear to be sensitive to the presence of alternative NR2 or NR3 subunits in the receptor 
complex. 
Furthermore, the data indicates that COMPOUND B and COMPOUND A may have 
distinct pharmacological interactions with the receptor complex, which differentially 
effect channel open probability and allosteric coupling. 
In order to increase the efficacy and selectivity ofNR2B-selective antagonists as well as 
understand the implications of targeting this population, the heterogeneous nature of the 
NMDA receptor and the subunit eo-assemblies need to be considered. 
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Chapter 4 
Investigating NR3B eo-expression and eo-assembly in rat and 
hllDmalll spinal cord using subunit-selective antibodies 
4.0 Introduction 
Immunological probes are an essential, extremely useful tool within molecular biology. 
Since Paul Erhlich first proposed the antibody formation theory in 1900 huge advances 
in the field of immunology have led to the development of commercial antibodies which 
are utilised in research to provide an effective means of identifying, locating, targeting 
and characterising proteins both in vivo and in vitro. Antibody molecules are a large 
family of glycoproteins, produced by B-lymphocytes in response to the presence of 
foreign molecules in the body (Janeway et al., 2001). Structurally, immunoglobulins are 
composed of three protein domains, forming a bivalent Y -shaped molecule (Fig.4.1 ), 
composed of two heavy chain polypeptides (approximately 55KDa) and two light chain 
polypeptides (approximately 25kDa) held together by disulphide bonds. The amino 
terminals of the heavy and light chains associate to construct an Fab fragment with an 
antigen-binding domain specific to a particular epitope on an antigen molecule. The 
carboxy-terminals of the heavy chains associate to form the Fe fragment, which binds to 
specific proteins within the immune system. 
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~--- Antigen Binding Site -----... 
F(ab')2 Fragment 
F"r gmenl 
• Ughl Chains • Hea,vy Chains 
Figure 4.1 Schematic diagram of immunoglobulin structure 
Cloning ofNMDA receptor subunits has allowed the design and production of epitope-
specific antibodies, which have been used to study expression and to characterise the 
component parts of the receptor using immunohistochemistry and western blotting. The 
antibodies have also been used to affinity purify receptor complexes, allowing subunit 
compositions to be determined (e.g., Chazot and Stephenson, 1997; Blahos and 
Wenthold, 1996). The generation of polyclonal antibodies relies upon the humoral 
response of laboratory animals following immunisation with a specific peptide. In order 
to elicit a strong host response against the peptide molecule, the immunogenicity of the 
peptide may be increased via conjugation to a larger carrier protein such as 
thyroglobulin. Development of the immune response takes several weeks, after which 
blood samples are collected, from which the antibody may be purified. 
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In this study the heterogeneity of the NMDA receptor complex was investigated 
utilising a panel of previously validated subunit specific polyclonal antibodies; anti-
rNR1-1a (929-938) (Chazot et al., 1992), anti-rNR2A (1435-1445) (Cik et al., 1993) 
and anti-rNR2B (46-60) (Chazot and Stephenson, 1997). In addition, two further 
antibodies were generated, purified and characterised; anti-rodent NR3B (885-899) 
(Based on a sequence previously published by Matsuda et al., 2002 and a novel anti-
human NR3B (885-899) (sequence selected in house). This chapter presents novel data 
that collectively maps the protein expression of the NR1, NR2A, NR2B and particularly 
the NR3B subunit in rat spinal cord at the cervical, thoracic and lumbar level and human 
spinal cord at the cervical level using immunohistochemistry. Previously research has 
focussed on mRNA and/or protein expression of NR1, NR2A, NR2B, NR2C/D in the 
adult rat brain and lumbar cord regions (Nagy et al., 2004; Tolle et al., 1993) and adult 
human lumbar-sacral regions (Sundstrom et al., 1997), showing widespread NR1 
expression with more specific localisation of the NR2 subunits. One study mapped 
expression in a range of cord levels, investigating NMDA NRI and NR2 expression in 
cervical, thoracic and lumbar regions of the human spinal cord during first trimester 
development (Akesson et al., 2000). mRNA (Nishi et al., 2001; Fukaya et al., 2005) 
and protein (Matsuda et al., 2003) expression studies of the NR3B subunit in the adult 
mouse brain and spinal cord show motor neuron-specific expression, though a recent 
study provided evidence for a more widespread expression in the cortex, cerebellum, 
hippocampus and spinal cord of the adult rat (Wee et al., 2007). 
This chapter also describes the optimisation of NMDA receptor solubilisation and 
immunoaffmity purification to investigate the native eo-associations of the NR3B 
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subunit within the rat spinal cord. Immunopurification studies to date describe the eo-
associations ofNR1 and NR2 subunits in the adult rat brain (Dunah et al., 1998; Chazot 
and Stephenson, 1997) and human lumbar-sacral spinal cord (Sundstrom et al., 1997), 
though native spinal cord complexes containing NR3B remain unknown. 
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4.1 Results 
4.1.1 Rodent anti-NR3B characterization. 
4.1.2 Immunopurification of polyclonal rodent anti-NR3B 
The peptide corresponding to residues 885-899 in the C-terminus of the mouse NR3B 
subunit (ISL, Paignton, UK) was conjugated to thyroglobulin (section 2.2.1) and 
emulsified with Freund's adjuvant and injected into New Zealand rabbits (section 2.2.3). 
The induction of a secondary immune response in the rabbits generates polyclonal 
antibodies raised against both the peptide and its affiliated conjugated protein 
thyroglobulin. The production of non peptide-specific antibodies therefore necessitated 
purification of selective anti-NR3B antibodies via an NR3B peptide immunoaffinity 
column, which utilizes specific antigen-antibody interaction to pull down the peptide 
specific antibodies (see section 2.2.1 ). 
Following collection and preparation of the antiserum, immunoaffinity purification of 
5mls yielded the following concentrations of anti-mNR3B polyclonal antibody from 
each bleed, as determined by Lowry protein assays (section 2.2.7). 
-
Bll'l'd ant•i-r:odl'nt NR3B antihod~· ~ idd (.11:.!11111) 
1 57 
2 170 
3 190 
Table 4.1 Anti-rodent NR38 antibody yield (Jlgfml) from each collection of antisera. 
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4.1.3 Characterisation of anti-rodent NR3B antibody via western blotting with 
recombinant NMDA receptor subunits. 
To confirm the subunit specificity and characterization of the purified rodent anti-NR3B 
antibody previously published by Matsuda et al., 2002, western blotting was carried out 
on both native and recombinant receptors. 
HEK 293 cells recombinantly expressing the single subunits of rNR3B, rNR3A or 
rNRl-la were harvested 48hours post-transfection and utilized as the source of 
recombinant NMDA receptor subunits for this analysis. SDS-PAGE was followed by 
overnight incubation of the nitrocellulose with anti-rodent NR3B (2J.lg/ml) and resulted 
in evidence for selective NR3B recognition with an immunoreactive band at 
approximately lOOKDa. The lack of immunoreactivity with the NR3A subunit (which 
shares close sequence homology with NR3B) and NRI, shows no non-specific cross-
reactivity of the antibody, verifying the anti-rodent NR3B selectivity and displaying 
consistency with results published by Matsuda et al., 2002. 
The non-specific bands of approximately 90 and 80KDa are likely to be cross-reacting 
irrelevant proteins endogenously expressed in the HEK 293 cells. 
100KDa ___. 
38 3A NR1 
Figure 4.2 lmmunoblot showing recombinant NR38, NR3A and NRl subunits expressed in 
HEK 293 cells. Probed with anti-rodent NR3B (2JLg/ml). Representative from n=3 
experiments. 
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4.1.4 Characterisation of anti-rodent NR3B using western blotting with native and 
recombinant NMDA receptors. 
To analyse the binding selectivity of the anti-rodent NR3B antibody in native tissue, 
adult Sprague-Dawley rat forebrain and spinal cord membranes were prepared and 
utilized in immunoblotting experiments. 20J.1g/lane forebrain and spinal cord 
membranes were loaded for SDS-PAGE together with samples oftransiently transfected 
cells expressing NR3B as a positive control. The immunoblot was then probed 
overnight with anti-rNR3B, bleed 2 (2J.1g/ml). 
Immunoreactivity was detected in both the forebrain and spinal cord membranes 
showing the detection of NR3B in both tissues. In the forebrain homogenate, an 
immunoreactive band was detected at -llOKDa, a molecular weight similar to that 
detected in the HEK 293 cells expressing NR3B (I OOKDa) and consistent with 
previously published data (Nishi et al., 200 I; Matsuda et al., 2002), though interestingly 
in both forebrain and spinal cord homogenates an immunoreactive band -30KDa was 
also detected. This species may be due to NR3B subunit proteolysis and/or post-
translational modifications, but to ensure specificity a peptide block was performed. 
IIOKDa --+ 
IOOKDa --+ 
10KO:~--+ 
1 2 3 4 
Figure 4.3 lmmunoblot showing adult rat forebrain (1) and spinal cord (2) membranes 
(30~Jg) and recombinant NR38 expressed in HEK 293 cells (3+4), probed with anti-rodent 
NR3B (2~Jg/ml). Representative from n=3 experiments. 
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4.1.5 Characterisation of the specificity of the anti-rodent NR3B with antigenic 
peptide blockade. 
To confirm the selectivity of the anti-rodent NR3B antibody for the antigenic peptide 
and thus for the NR3B subunit, immunoblotting was carried out on both native and 
recombinant rNR3B sources using anti-rodent NR3B antibody which was pre-incubated 
with the peptide used to generate the antiserum. 
Pre-absorption of the anti-NR3B antibody with the respective antigenic peptide 
completely inhibited immunoreactive signaling confirming antibody selectivity for the 
peptide antigen. Detection of smaller molecular weight proteins may therefore be an 
indication of proteolysis of the NR3B subunit within native tissue which isn't replicated 
in recombinant models probably due to the absence of endogenous neuronal processing 
and transporting machinery. 
This antibody was utilized for immunohistochemical investigations detailed in chapter 
6. 
2 3 4 5 6 
IOOKDa 
30KDa 
Pre-incubation with antigenic peptide 
Figure 4.4 lmmunoblot showing adult rat forebrain (1+4) and spinal cord (2+5) (30Jlg, 
respectively), and recombinant NR3B (3+6) subunits expressed in HEK 293 cells probed 
overnight with anti-rodent NR3B (2Jtg/ml). Representative from n=2 experiments. 
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4.2 Anti-human NR3B characterization 
4.2.1 Immunoaffinity purification of polyclonal anti-human NR3B 
An anti-human NR3B antibody was generated from the antigenic peptide 
C T G P P E G S K E E T A E A E corresponding to amino acids 885-899 in the C-
terminal region of the NR3B protein. 
As previously stated, following the generation of an immune response in the host rabbit, 
resulting antisera was collected and purified using a newly generated human NR3B 
peptide immunoaffinity column (see section 2.2.2). 
Following the collection and preparation of antisera, 5mls from each bleed generated the 
following antibody yields. 
1 
2 
3 
323 
350 
439 
Table 4.2 Anti-human NR3B antibody yield (tJ.gfml) from each collection of antisera. 
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4.2.2 Characterisation of the anti-human NR3B antibody using western blotting on 
native NMDA receptors. 
To investigate the binding selectivity of the anti-human NR3B antibody, western 
blotting analyses were performed using adult human putamen membranes (50J.1g 
protein) (obtained as a gift from Dr Margaret Piggott, Newcastle University) and adult 
Sprague-Dawley rat forebrain membranes (30J.lg) to detect any cross-reactivity between 
species. Following SDS-PAGE, the nitrocellulose was probed overnight with anti-
hNR3B (2J.lg/ml, bleed 3), with resulting immunoreactivity in both species. A large 
molecular weight species (174KDa) was detected in the human putamen, together with 
smaller fractions around 11 OKDa (the expected molecular weight for NR3B) and 
~50KDa, similar to species detected by the anti-rodent NR3B antibody. Some cross-
reactivity is also evident from detection of NR3B at 11 OKDa and 50KDa in the rat 
forebrain. To confirm specificity, an antigenic peptide block was performed. 
2 
174KDa -----. 
11 OKDa _____. 
82KDa _____. 
57KDa _____. 
Figure 4.5 lmmunoblot showing post-mortem human putamen membranes (1) (SOJlg) 
and adult rat forebrain membranes (2) (30Jlg) probed with anti-human NR3B (2Jlg/ml). 
representative from n=3 experiments. 
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4.2.3 Characterisation of anti-human NR3B in both human and rat native tissue 
with antigenic peptide blockade. 
Immunoblotting was performed on adult Sprague-Dawley rat forebrain and spinal cord 
membranes (30J.1g, respectively) and human putamen membranes (50J.lg) and probed 
with either anti-hNR3B (2J.lg/ml, bleed 2) or anti-hNR3B which had been pre-incubated 
overnight with the antigenic peptide to which it was derived. 
Pre-absorption of the anti-hNR3B antibody with the antigenic peptide blocked specific 
antibody-protein interactions. The resulting blockade of all immunoreactive bands 
demonstrates the selectivity of the anti-hNR3B and shows that the high molecular 
weight species (174KDa) in the human tissue is NR3B, possibly in a dimeric form, and 
that this antibody cross-reacts with rat NR3B. 
A human NR3B recombinant clone was not available for further characterization. 
1 2 3 4 5 6 7 8 9 
174KDa---. 
50KDa___,. 
-
' . 
Pre-incubation with antigenic peptide 
Figure 4.6 Immunoblot (n=l) showing adult rat forebrain membranes (1+6), adult rat spinal 
cord membranes (2+7) (30Jtg) and human putamen membranes (4, 5, 8+9) (50Jtg) probed 
with anti-human NR3B (2J.lg/ml). Lane 3 was loaded with sample buffer. 
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4.3 Characterisation of the commercial anti-rat NR3B Upstate® 
A commercial anti-NR3B antibody generated against amino acids 916-928 in the C-
terminal domain, with a peptide sequence R R V R R A V V E R E R R was purchased 
for experimental use during generation and characterization of our antibodies. 
To characterize and verify the selectivity of this commercial antibody, immunoblotting 
was carried out with native NMDA receptors from rat forebrain and spinal cord 
membranes (301-!g/lane) and with recombinant NR3B expressed in HEK 293 cells, 
probing with commercial anti-NR3B (1: I 000). 
The commercial anti-NR3B displayed immunoreactivity in the native tissue, detecting 
species at ~ 11 OKDa in both rat forebrain and spinal cord, where expression of NR3B 
may be reduced. Other smaller species are detectable, including the species ~30KDa, 
which may be the result of post-translational modifications. No clear band of 
immunoreactivity can be detected in the recombinant NR3B, in contrast to the in house 
anti-rNR3B, which may be due to ineffective transfection and subunit expression, or due 
to a lack of specific reactivity in in vitro models. 
2 3 4 
IIOKD 
Figure 4.7Representative immunoblot (n=2) showing adult rat forebrain membranes (1) 
and adult rat spinal cord membranes (2) (30Jtg) and recomblnant NR3B expressed in HEK 
293 cells (3+4) probed with commercial anti-NR3B (1:1000). 
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4.4 eo-expression of the NMDA receptor subunits NRl, NR2A, NR2B and NR3B 
in the adult rat and adult human spinal cord. 
In order to map subunit expression within the rat and human spinal cord tissue, 
purification of anti-NR1, anti-NR2A and anti-NR2B antibodies was also carried out to 
produce a panel of subunit selective antibodies which were used for 
immunohistochemical and immunopurification investigations. 
4.4.1 Purification of subunit selective anti-NMDA antibodies 
New batches of anti-rNR1, anti-rNR2A and anti-rNR2B antisera (previously published 
Chazot et al., 1992; Cik et al., 1993; Chazot and Stephenson, 1997) were purified using 
selective peptide affinity columns to generate a panel of subunit selective antibodies to 
define NMDA receptor subunit localisation. Immunoblotting was performed with adult 
rat forebrain and spinal cord membranes (251J.g), and probed with the respective 
antibody overnight (21J.g/ml). 
The immunoblots show clear immunoreactivity towards each NMDA subunit species. 
Anti-rNR1, anti-rNR2A and anti-rNR2B display distinct immunoreactive bands at 
~120KDa, 180KDa and 180KDa, respectively, in both forebrain and spinal cord, 
concurring with previously published sizes for each subunit (Hawkins et al., 1999). 
115 
Chapter 4 Heather Chaffey 
A B c 
2 1 2 2 
ISOKDa _.. 
ISOKDa _.. 
120KDa 
' 
. 
Anti-NRl Anti-NR2A Anti-NR2B 
Figure 4.8 Representative immunoblots (n=3) showing adult rat forebrain membranes 
(25J1g) (Lane 1) and adult rat spinal cord membranes (25J~g) (Lane 2), probed overnight with 
anti-rNRl (2J1g/ml) (A), anti-rNRZA (2J1g/ml) and anti-rNRZB (2J1g/ml). 
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4.4.2 Immunohistochemical investigations of NMDA subunit eo-expression in the 
rat spinal cord. 
All animal and human studies were performed with full ethical and Home Office 
approval (Project licence PPL-6003437). 
Adult male Sprague-Dawley rat spinal cords were dissected and rapidly frozen , before 
cryostat sectioning (see 2.2.9). Immunohistochemical analysis (see 2.2.10) was then 
performed on the cervical, thoracic and lumbar regions of rat spinal cord using the panel 
of subunit selective antibodies previously generated. Controls were carried out in the 
absence of primary antibodies (see figure 4.1 0). Both the dorsal (sensory) and the 
ventral (motor) areas of the cord were investigated and NMDA subunit expression 
mapped for each antibody according to the immunoreactivity in the spinal laminae 
shown below. 
Dorsal Horn 
Ventral Horn 
Figure 4.9 Schematic diagram showing the laminae in the dorsal and ventral regions of the 
rodent lumbar spinal cord (Tolle et al., 1993). 
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A B 
\ 
c D 
.. ,. 
Figure 4.10 Control sections showing the immunoreactivity in tissue in the absence of 
primary antibodies in the cervical dorsal horn (A), the lumbar dorsal horn (B) and the 
thoracic ventral horn (C). Low resolution image of the cervical cord showing NR1 
iinmunostaining (Bigini et al., 2006) with red arrows highlighting the dorsal and ventral 
areas of the cord focused upon in this study. 
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41.4.2.1 Expression of NRl, NRJB, NR2A and NR2B in adult rat cervical spinal 
cord 
Immunohistochemical analysis in the cervical region of the adult rat spinal cord revealed 
differential expression of the four subunits between motor and sensory areas confirming 
distinct cellular localization and likely modulatory functioning of the subunits. 
NR I is ubiquitously expressed throughout the spinal cord layers, with its abundant 
expression confirming that previously published for mRNA {Tolle et al., 1993; 
Furuyama et al., 1993) and protein (Nagy et al., 2004) studies in the lumbar region. 
NR3B expression is predominantly confined to the motor neuron cell bodies and 
dendrites within the ventral horn, with modest immunoreactivity in the dorsal sensory 
regions consistent with previous mRNA expression studies (Nishi et al., 2001). 
Immunoreactivity to both NR2A and NR2B was detected in dorsal and ventral horns, 
particularly in motor neuron cell bodies and outer laminae I, 11 and Ill, concurring with 
previous studies in cervical (Watanabe et al., 1994) and lumbar (Nagy et al., 2004) 
tissue and suggesting a role in motor and sensory transmissions. 
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Dorsal Ventral 
A 
B 
r:. 
Ill 
MN 
.. 
Figure 4.11 Expression of NR1 (probed anti-rNR1 2Jtgjml) (A), NR3B (commercial anti-
rNR38 1:1000) (B) in the dorsal horns laminae I, 11, Ill and ventral horns showing the motor 
neurons (MN) ofthe cervical rat spinal cord (n=2). Scale bars represent 100J1D1. 
120 
... 
{ 
Chapter 4 Heather Chaffey 
c Dorsal Ventral 
D 
Figure 4.12 Expression ofNR2A (anti-rNR2A 2J,tg/ml) (C) and NR28 (anti-rNR2B 2J,tgfml) (D) 
in the dorsal horns laminae I, 11, Ill and ventral horns showing the motor neurons (MN) of the 
cervical rat spinal cord (n=2). Scale bars represent 100JU11. 
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4.4.2.2 Expression of NRl, NR2A, NR2B and NR3B in adult rat thoracic spinal 
cord. 
Immunohistochemical analysis was then performed using the same panel of subunit 
selective antibodies on adult rat thoracic spinal cord sections. The tissue was probed 
overnight with anti-rNRl (1 ~g/ml), anti-rNR2A (2J.lg/ml), anti-rNR2B (2~g/ml) and the 
commercial anti-rNR3B (1: 1 000) and analysed using a Nikon Eclipse E300 light 
microscope with a Coolpix MDC lens Nikon Camera (Japan) (x400 magnification). 
Distinct patterns of sub unit expression were detected in the thoracic region of the adult 
rat spinal cord, showing prominent changes and potential evidence for varying NMDA 
subunit modulation and function in different cord regions. 
NRI expression is again abundant with immunoreactivity evident in the ventral horn and 
the dorsal horn. A prominent band of immunoreactivity was detected in laminae II of 
the dorsal horn, possibly implying increased NMDA receptor presence in this puncta of 
sensory neurons. The concentration of anti-NR1 was reduced in order to reduce the 
high level ofbackground staining seen in the cervical region. 
NR3B expression remains comparatively low and concentrated mainly within the motor 
neuron cell bodies ofthe ventral horn. 
NR2A expression appears to have shifted predominantly from the dorsal to the ventral 
horn with concentrated immunoreactivity within the motor neuron cell bodies within 
laminae IX, consistent with previous mRNA studies on human spinal cord 
(Samarasinghe et al., 1996). The predominant immunoreactivity of the NR2B subunit 
appears to shift from more wide-spread expression to the dorsal horn and in particular 
laminae I and 11, consistent with published data (Nagy et al., 2004; Mutel et al., 199~). 
_, . . . . ~ .-• ... ~ _.;. 
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Dorsal Ventral 
A 
• 
MN 
MN 
11 
Ill 
B 
11 
MN 
Figure 4.13 Expression of NR1 (probed anti-rNR1 1J1g/ml) (A), NR3B (commercial anti-
rNR3B 1:1000) (B) in the dorsal horn laminae I, 11, Ill and ventral horns showing the motor 
neurons (MN) of the thoracic rat spinal cord (n=2). Scale bars represent 100J1m. 
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Dorsal Ventral 
c 
. ... 
11 
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D 
MN 
MN 
Figure 4.14 Expression of NR2A (anti-rNR2A 2J1g/ml) (C) and NR2B (anti-rNR2B 2J1g/ml) (D) 
in the dorsal horn laminae I, 11, Ill and ventral horns showing the motor neurons (MN) of the 
thoracic rat spinal cord (n=2). Scale bars represent 100J1m. 
124 
Chapter4 Heather Chaffey 
4.4.2.3 Expression of NRl, NR2A, NR2B and NR3B in the adult rat lumbar spinal 
cord 
Immunohistochemistry was carried out on adult rat lumbar spinal cord using the panel 
of subunit selective antibodies previously used. The tissue was probed overnight with 
anti-rNR1 {lJ..lg/ml), anti-rNR2A (2J.1g/ml), anti-rNR2B (2J.1g/ml) and the commercial 
anti-rNR3B ( 1: 1 000). 
The immunoreactivity of the four NMDA receptor subunits in lumbar tissue shows a 
similar pattern to expression in the thoracic tissue. NR 1 shows abundant expression in 
both the ventral horns and the dorsal horns, again with particularly concentrated 
immunoreactivity in laminae 11. 
NR3B immunoreactivity is concentrated within the cell bodies of the motor neurons 
with minimal expression in the sensory dorsal horn. 
NR2A immunoreactivity remains predominantly in the ventral regions, in the cell bodies 
of the motor neurons. 
The NR2B subunit remams predominantly located in the dorsal regions, again 
particularly in the outer laminae, with some immunoreactivity within the motor neurons 
of the ventral horn. 
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Dorsal Ventral 
A 
B 
MN 
Ill 
Figure 4.15 Expression of NR1 (probed anti-rNR1 1J1gfml) (A), NR38 (commercial anti-
rNR3B 1:1000) (B) in the dorsal horn laminae I, 11, Ill and ventral horns showing the motor 
neurons (MN) ofthe lumbar rat spinal cord (n=2). Scale bars represent 100J1m. 
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Figure 4.16 Expression of NR2A (anti-rNR2A 2J.Lgfml) (C) and NR2B (anti-rNR2B 2J.Lg/ml) (D) 
in the dorsal horn laminae I, 11, Ill and ventral horns showing the motor neurons (MN) of the 
lumbar rat spinal cord (n=2). Scale bars represent 100J.Lm. 
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4.4.2.4 Qualitative summary of NMDA subunit expression in the dorsal and ventral 
horns spanning the three different upper regions of the adult rat spinal cord. 
From the immunohistochemical investigations on rat spinal cord, the four NMDA 
subunits appear to be differentially expressed both between the sensory and motor areas 
of the cord and between the different regions of the cord. The NRl subunit is 
ubiquitous and essential for all functional NMDA receptors with expression 
subsequently prominent throughout all regions. The modulatory NR2 subunits appear to 
be differentially expressed, with NR2A immunoreactivity predominant in the motor 
neurons in the ventral horns of the cord, whereas the NR2B sub unit appears to be more 
concentrated in the dorsal sensory horns, particularly in the thoracic regions. The NR3B 
subunit shows modest expression in the sensory areas of the cord, but in all regions 
shows predominant expression within the ventral horns. This data provide the first 
comparative study of the major NMDA receptor subunits in the dorsal and ventral horns 
of the upper levels of the rat spinal cord. Generally NR2A appears to be the major 
subunit in the ventral horn, whereas NR2B appears to be the major subunit in the dorsal 
horn. 
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NRl NR2A NR2B NR3B 
Dorsal horn ++++ ++ +++ (+) 
Cervical Ventral horn +++ +++ ++ +++ 
Dorsal horn ++++ ++ +++ + 
Thoracic Ventral horn ++++ +++ + +++ 
Dorsal horn ++++ + ++ (+) 
Lumbar Ventral horn ++++ +++ ++ ++ 
Table 4.3 Qualitative summary of the average intensity of immunoreactivity for each subunit 
in the cervical, thoracic and lumbar regions of adult rat spinal cord. 
( +) = Very weak expression, + =Weak expression, ++ = Moderate expression, 
+++ = Strong expression, ++++ = Very strong expression. 
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4.4.3 NMDA subunit expression in human cervical spinal cord 
Expression profiles of the NMDA subunits NR1, NR2A, NR2B and NR3B were 
mapped in the adult male human cervical spinal cord (obtained ethically under project 
licence PPL-6003437) using immunohistochemistry (see 2.2.10). The anti-hNR3B 
antibody {2J.1g/ml) was utilized along with the anti-rNR1 (lJ.lg/ml), anti-rNR2A 
(2J.lg/ml) and anti-rNR2B {2J.1g/ml). 
As in the rat tissue, NR 1 expression is abundant throughout the dorsal and ventral 
regions of the human cervical spinal cord showing consistency with previous studies of 
mRNA expression (Samarasinghe et al., 1996) and protein expression in lumbar regions 
of human spinal cord (Sundstrom et al., 1997). 
The NR3B subunit displays discrete expression in the motor neuron cell bodies and 
dendrites of the ventral horn, displaying a similar distribution pattern to that in the rat 
and consistent with mRNA studies in the mouse (Fukaya et al., 2005; Nishi et al., 2001; 
Matsuda et al., 2002). 
Consistent with published literature, NR2A showed wide-spread distribution, similar to 
that of NR 1 (Samarasinghe et al., 1996) with expression in the dorsal laminae, 
particularly 11 and Ill and in the cell bodies of the motor neurons in the ventral horn. 
NR2B expression is predominantly concentrated in laminae I and 11 of the dorsal horn 
consistent with previous primate studies (Rigby et al., 2002) and immunoreactivity seen 
in the rat. Evidence for prominent expression in the motor neurons in the ventral horn 
sh<;>ws initial evidence for species difference in NR2B protein expression between the rat 
and human. 
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Figure 4.17 Expression of NR1 (probed anti-hNR1 1~g/ml) (A), NR3B (commercial anti-
rNR3B 1:1000) (B) in the dorsal horn laminae I, 11, Ill and ventral horns showing the motor 
neurons (MN) of the cervical human spinal cord (n=1). Scale bars represent 100~. 
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Figure 4.18 Expression ofNR2A (anti-rNR2A 2Jtg/ml) (C) and NR2B (anti-rNR2B 2Jtg/ml) (D) 
in the dorsal horn laminae I, 11, Ill and ventral horns showing the motor neurons (MN) of the 
cervical human spinal cord (n=l). Scale bars represent 100Jlm. 
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4.4.4 Qualitative summary of NMDA receptor subunit expression in the dorsal and 
ventral horns of the adult human cervical spinal cord 
Immunohistochemical investigations into the subunit expression in adult human cervical 
spinal cord have revealed some initial evidence for NMDA receptor subunit localization 
differences between the rat and human. 
Both species show abundant NR I expression throughout cervical regions in both the 
dorsal and ventral horns, consistent with previous findings (Samarasinghe et al., I996; 
Sundstrom et al., I997). 
In the human tissue, NR2A shows strong immunoreactivity in the dorsal and ventral 
horns, showing a similar distribution pattern to NR I, however in the rat spinal cord; 
more prominent expression was evident in the ventral horn, suggesting more widespread 
inclusion and prominent role for NR2A in receptor complexes in the human. 
NR2B showed prominent immunoreactivity specifically in the superficial laminae of the 
dorsal horn and in the ventral horn of the adult human cervical cord, whereas in the rat, 
NR2B was more prominent in the dorsal horn and showed more limited expression in 
the ventral areas. This evidence suggests that NR2B may have a greater role in motor 
neuronal transmissions in the human than in the rat. 
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Spinall·ord len•l Region lntcnsit~ of immu,norl·acti' ity 
NR1 NR2A NR2B NR3B 
Dorsal horn ++++ +++ ++ (+) 
Cervical Ventral horn ++++ +++ ++++ ++ 
Table 4.4 Qualitative summary of the average intensity of immunoreactivity for each subunit 
in the cervical region of adult human spinal cord. 
( +) = Very weak expression, + =Weak expression, ++ = Moderate expression, 
+++ = Strong expression, ++++ = Very strong expression. 
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4.5 eo-associations of NMDA sub units in the rat spinal cord 
eo-expression of specific NMDA subunits within particular cells and regions of the 
spinal cord has been established, however, the specific eo-associations, particularly of 
the NR3B subunit, which combine to form functional NMDA receptors within these 
neurons is a characterisation needed to further understand the pharmacology and 
function of these channels and for therapeutic receptor targeting. 
Optimisation of solubilisation conditions to isolate these membrane bound receptors was 
undertaken followed by generation of NRI, NR2A immunoaffinity columns to pull 
down and isolate specific NMDA receptor subunits and their eo-associations from 
native receptors in adult rat cervical spinal cord. 
4.5.1 Solubilisation and immunopurification of adult rat spinal cord receptors 
using 1% SDS. 
The cervical region of adult rat spinal cord (3-4mg/ml protein) was homogenized and 
solubilised using 1% SDS, a technique utilized by Lau et al., 1996 and Chung et al., 
2004 to purify NMDA receptors from adult rat forebrain. 
Immunoblotting was carried out following solubilisation with 1% SDS (2.2.12.2), 
loading the solubilised and unsolubilised fractions for analysis. The nitrocellulose was 
probed overnight with anti-rNRl (2~g/ml), anti-rNR2A (2~g/ml), anti-rNR2B (2~g/ml) 
and the commercial anti-rNR3B (1:1000), with the resulting detection of NRI 
(120KDa), NR2A (180KDa), NR2B (180KDa) and NR3B (IOOKDa) and therefore 
efficient solubilisation of all four subunits from the rat spinal cord. 
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This solubilised material was then applied to an anti-NRl immunoaffinity column to 
investigate the eo-associations of the NRI subunit within this tissue. 
A 
1 2 
120KDa 
NR1 
B 
... 
180KDa 
1 2 
NR2B 
c 
1 2 
NR2A 
D 
--. 
100KDa 
1 2 
NR3B 
Figure 4.19 Representative immunoblots (n=2) showing solubilised membranes (lane 1) 
and unsolubilised membranes (lane 2) probed overnight with anti-rNR1 (2~gjml) (A), 
anti-rNR2B (2~g/ml) (B), anti-rNR2A (2~/ml) (C) and anti-rNR3B (1:1000) (D). 
4.5.1.1 Immunopurification of 1% SDS solubilised adult rat spinal cord 
homogenate using an anti-NR1 immunoaffinity column 
Following the solubilisation of the cervical spinal cord homogenate in 1% SDS and 
dialysis of the solubilised material, the solubilised fraction was applied to an anti-NRI 
immunoaffinity column overnight at 4°C to investigate eo-associations with the NRI 
subunit. Following washing steps, the bound fraction was eluted with glycine pH 2.3, 
immediately neutralized with 2M Tris pH 7.4 and analysed using immunoblotting. 
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The NRl subunit has been successfully solubilised, purified and eluted in elutions 2-4, 
confirming the functioning of the column. Both the NR2A and the NR2B subunits have 
also been solubilised, though show no eo-associations with NR1 under these conditions 
as there is no evidence of these subunits in the column elutions implying disruption of 
the native receptor complex and protein instability. In these assays, NR3B solubilisation 
was inconsistent, likely to be due to such low expression levels in the spinal cord. 
To reduce the denaturing conditions of solubilising in 1% SOS, optimization of 
detergent concentrations was investigated. 
SC S DT UB E 1 E2 E3 E4 E5 
A Anti-NR1 
B Anti-NR2A 
C Anti-NR2B 
' D Anti-NR3B 
t 
Figure 4.20 Immunoblot showing adult rat spinal cord homogenate (25J1g/ml) (SC), 
solubilised membranes (S), unsolubilised membranes (DT), unbound material (UB) and 
elutions 1-5 (E1-5), probed overnight with anti-NR1 (2J.lg/ml), anti-NR2A (2J.lg/ml), anti-
NR2B (2J.lg/ml) and anti-NR3B (1:1000). Representative immunoblots from n=3 
experiments. 
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4.5.1.2 Optimisation of SDS solubilisation between 0.75 and 0.05%. 
To investigate the optimal SDS concentrations for effective solubilisation and eo-
association, the concentration of the detergent SDS was reduced in increments between 
0.75% and 0.05%. Following solubilisation, the material was analysed using 
immunoblotting, probing overnight with anti-rNR1 (2~-tg/ml), anti-rNR2A C2~-tg/ml) , 
anti-rNR2B (2~-tg/ml) and commercial anti-NR3B (2~-tg/ml). The first set of 
immunoblots showed that the abundant NRI subunit solubi lised effectively down to 
0.05% [SDS], possibly due to large intracellular pools which are easy to solubilise. 
Both NR2A and NR2B were solubilised at 0.5% [SDS], with lower concentrations 
seemingly unsuccessful at removing these subunits from the cell membrane. NR3B was 
solubilised effectively to 0.1% [SDS], suggesting it may be more readily removable 
from the cell membrane than the NR2 subunits. 
1 2 3 4 5 6 7 8 9 10 
A Anti-NRl 
B Anti-NR2A - - -
C Anti-NR2B 
D Anti-NR3B 
Figure 4.211mmunoblots (n=1) showing solubilised and unsolubilised membranes at 0.75% 
(SDS) (1+2), solubilised and unsolubilised membranes at 0.5% (SDS) (3+4), solubilised and 
unsolubilised membranes at 0.25% (SDS) (5+6), solubilised and unsolubilised membranes at 
0.1% (SDS) and solubilised and unsolubilised membranes at 0.05% [SDS). Probed with anti-
NR1 (2J1g/ml) (A), anti-NR2A (2J1gfml) (B), anti-NR2B (2J1g/ml) and anti-NR3B (1:1000). 
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4.5.1.3 Optimisation of SDS solubilisation between 0.5 and 0.2%. 
The variable extents to which the four subunits were solubilised between 0.5 and 0.1% 
required further optimization; therefore concentrations between 0.5 and 0.2% SDS were 
also investigated using the same immunoblotting procedure. 
Again, NRI was effectively solubilised down to 0.2% SDS. NR2A was effectively 
solubilised at concentrations down to 0.3% before the levels of NR2A in unsolubilised 
material were greater. NR2B and NR3B were also effectively solubilised at 0.2% SDS 
in a similar manner to NRI. From these concentration ranges of SDS, all four subunits 
were solubilised effectively at 0.3% SDS and therefore it was decided to proceed to 
immunopurification using this detergent concentration, applying the solubilised material 
firstly to an anti-NR 1 column and secondly to an anti-NR2A column. 
2 3 4 5 6 7 8 
A Anti-NRI 
B Anti-NR2A 
C Anti-NR2B 
D Anti-NR3B 
Figure 4.22 Immunoblots (n=1) showing solubilised and unsolubilised membranes at 0.5% 
[SDS) (1+2), solubilised and unsolubilised membranes at 0.4% [SDS] (3+4), solubilised and 
unsolubilised membranes at 0.3% (SDS) (5+6), solubilised and unsolubilised membranes at 
0.2% [SDS). Probed with anti-NR1 (2tJg/ml) (A), anti-NR2A (2J1gfml) (8), anti-NR28 
(2J1g/ml) and anti-NR38 (1:1000). 
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4.5.1.4 Immunopurification of 0.3% SDS solubilised material from adult rat 
cervical spinal cord using anti-NRl and anti-NR2A immunoaffinity columns 
Using the optimized concentration of 0.3% SOS to effectively solubilise the NMDA 
receptor subunits, immunopurification was carried out to determine whether the native 
receptor complex associations could be elucidated. 
Solubilised material was applied to either an anti-NRI immunoaffinity column or an 
anti-NR2A immunoaffinity column as described previously (2.2.12.3) and following 
overnight incubation, the bound fractions were eluted and analysed with 
immunoblotting. The nitrocellulose was probed with anti-rNRl (2J.lg/ml), anti-rNR2A 
(2J.lg/ml), anti-rNR2B (2J.lg/ml) and commercial anti-NR3B (2J.lg/ml). 
4.5.1.5 Immunopurification using an anti-N:Rl affinity column. 
NRl has been successfully solubilised, purified and eluted from the column. NR2A has 
also been effectively solubilised, bound to the column (demonstrated by lack of protein 
in the unbound lane) and possibly eluted in fractions 4 and 5. Faint immunoreactivity 
shows minimal solubilisation ofNR2B with an indication, but no clear elution. NR3B 
has also been solubilised, with seemingly specific immunoreactive bands in elutions 2 
and 3, which are of a higher molecular weight possibly due to dimerisation of associated 
subunits. This experiment gives potential evidence of NRl, NR2A and NR3B eo-
association from native adult rat spinal cord preparations. 
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SC S DT UB E 1 E2 E3 E4 E5 
A Anti-NRl 
B Anti-NR2A 
C Anti-NR2B 
D Anti-NR3B 
Figure 4.23 Representative immunoblots (n=2) showing purified fractions from an anti-NR1 
affinity column. Spinal cord homogenate (25J.Lg/ml) (SC), solubilised membranes (S), 
unsolubilised membranes (DT), unbound material (UB) and elutions 1-5 (E1-5). Probed with 
anti-NR1 (ZJ.Lg/ml) (A), anti-NR2A (ZJ.Lg/ml) (B), anti-NR28 (ZJ.Lg/ml) and anti-NR38 (1:1000). 
4.5.1.6 Immunopurification using an anti-NR2A affinity column 
Applying the 0.3% SDS solubilised material to an anti-NR2A immunoaffinity column 
resulted in NR2A uptake onto the column but minimal immunoreactivity in the elutions. 
NR 1 has been solubilised and purified in elutions 1 and 2 via eo-association with the 
NR2A subunit. Low level expression of NR3B in the cervical spinal cord is evident 
from weak immunoreactivity, though the subunit has been solubilised. The majority of 
the solubilised NR3B remains unbound to the column, though immunoreactivity in 
elution 2 may be evidence for eo-association of NR3B with NR2A. Therefore, again 
there is possible evidence for eo-association ofNRl , NR2A and NR3B in native adult 
rat cervical spinal cord. It has previously been suggested that NR3A has weak 
interactions with anchoring proteins and possibly other subunits (Perez-Otano et al., 
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2006) and therefore NR3B may behave simi larly, solubilising effectively but loosing 
interactions, reducing purification efficiencies. The difficulty in solubilising and eluting 
NR2B and in maintaining receptor complex eo-assembly is likely to be the result of low 
expression levels in the cervical cord and possibly protein instability and sensitivity 
towards the strongly ionic detergent SOS. 
SC S DT UB E 1 E2 E3 E4 E5 
A Anti-NR2A 
B Anti-NRl 
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C Anti-NR2B 
D Anti-NR3B 
Figure 4.24 Representative immunoblots (n=2) showing purified fractions from an anti-
NR2A affinity column. Spinal cord homogenate (25J,tg/ml) (SC), solubilised membranes (S), 
unsolubilised membranes (DT), unbound material (UB) and elutions 1-5 (E1-5). Probed with 
anti-NR1 (2J.Lgfml) (A), anti-NR2A (2J.Lgfml) (B), anti-NR2B (2J.Lgfml) and anti-NR3B (1:1000). 
142 
Chapter 4 Heather Chaffey 
4.6 NR2A, NR2B and NR3B protein expression levels in different spinal cord 
regions 
To further optimize the likelihood of effective solubilisations, different regions of the 
adult rat spinal cord were analysed using immunoblotting to investigate expression 
levels ofNR2A, NR2B and NR3B. 
SDS-PAGE was carried out with adult rat forebrain membranes (20J.lg), cervical spinal 
cord membranes (20J.lg) and thoracic/lumbar spinal cord membranes (20J.1g) and the 
nitrocellulose probed overnight with anti-rNR2A (2J.lg/ml), anti-rNR2B (2J.lg/ml) and 
commercial anti-rNR3B (2J.lg/ml). Re-probing the nitrocellulose with P-actin (an 
endogenous 'house-keeping' protein) enabled quantitative comparisons oflane loading. 
The imrnunoblot shows that NR2A appears to be the most prominent subunit expressed 
both in the forebrain and spinal cord across the regions. NR3B is particularly expressed 
within the lower regions of the spinal cord which are more associated with motor 
systems. The NR2B subunit is more prominently expressed in forebrain regions, with 
some expression mainly in the lower spinal cord regions. NR2A, NR2B and NR3B 
therefore have higher expression levels in the lower regions of the spinal cord and it 
may be important for future investigations to isolate receptors from this region of the 
cord, or for whole cord preparations to be used, as one of the main difficulties in 
successful purifications appears to be the low abundance of expression. 
143 
Chapter 4 Heather Chaffey 
2 3 
A Anti-NR2A 
B Anti-NR2B 
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Figure 4.25 Representative immunoblots (n=3) showing adult rat forebrain membranes 
(20J1g) (1), adult rat cervical cord membranes (20J1g) (2) and adult rat thoracic/lumbar cord 
membranes (20J1g) (3). Probed with anti-rNR2A (2Jigfml), anti-rNR2B (2J!g/ml) and anti-
rNR3B (1:1000). 
1 2 3 
A NR2A 
B NR2B 
C NR3B 
Figure 4.26 Re-probing the immunoblots in figure 4.22 with anti-mouse p-actio (1:1000). 
Immunoblot showing adult rat forebrain membranes (20J1g) (1), adult rat cervical cord 
membranes (20J1g) (2) and adult rat thoracic/lumbar cord membranes (20J1g) (3). 
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4. 7 Discussion 
The importance of unravelling the heterogeneity of the NMDA receptor complex and 
understanding the impact of different subunit combinations on receptor signaling is 
evident when considering pharmaceutical intervention. 
Antibodies remain one of the most useful, diverse molecular tools for investigating these 
factors and have been widely used for NMDA receptor characterization since the 
molecular cloning of the respective subunits. In this chapter a panel of subunit-selective 
polyclonal antibodies was used to investigate NMDA subunit expression in the adult rat 
and human spinal cord, and to decipher native NMDA receptor subunit eo-associations 
in the adult rat spinal cord. 
The panel of selective anti-NR1 (929-938), anti-NR2A (1435-1445) and anti-NR2B (46-
60) polyclonal antibodies utilized throughout this thesis for western blotting, 
immunohistochemsitry and immunopurification have previously been characterized and 
validated in our laboratory (Chazot et al., 1992; Cik et al., 1993; Chazot and 
Stephenson, 1997). In order to investigate the expression patterns and associations of 
the NR3B subunit, an anti-rodent NR3B (885-899) polyclonal C-terminal antibody 
previously published and characterized by Matsuda et al., 2002 was generated and 
affinity purified via coupling specifically to a newly generated antigenic peptide 
sepharose column. The synthetic peptide TGPPEGQQERAEQEC corresponding to 
amino acids 885-899 in the mouse NR3B C-terminal region is identical to the rat NR3B 
sequence except for one amino acid change substituting at the end of the sequence from 
cysteine to arginine. To confirm the characterisation and specificity noted by Matsuda 
and colleagues, the anti-NR3B (885-899) was tested against native adult rat forebrain 
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and spinal cord tissue and recombinant rat NR3B clones (pCISNR3B, pCISNR 1-1 a, 
pCISNR3A cDNA transfection into HEK 293cells) and the peptide specificity 
confirmed using peptide blockade. Immunoreactivity towards the recombinant NR3B 
cON A identifying a species approximately I OOKDa and a lack of cross-
immunoreactivity with the NR3A cDNA was in agreement with results published by 
Matsuda et al., who also confirmed specificity with recombinant NR3B expression in 
HEK293 cells (Matsuda et al., 2002). Immunoreactivity in the native tissue identified 
molecular weight species at approximately 1 OOKDa, but also a more prominent smaller 
molecular weight species at approximately 30KDa. This protein species was confirmed 
as antigenic peptide specific, upon pre-absorption of anti-NR3B with the antigenic 
peptide, therefore this smaller species is likely to be a proteolytic fragment or due to 
post-translational modifications of the subunit present in native neurons. 
During the development and characterization of the anti-NR3B (885-899) antibody, an 
Upstate® commercial polyclonal rat anti-NR3B antibody was purchased for expression 
studies. The commercial anti-rNR3B was raised in rabbits against the C-terminal amino 
acids 915-927 RRVRRA VVERERR and showed immunoreactivity towards a diffuse 
species of ~ 11 OKDa in adult rat forebrain and spinal cord homogenate and towards a 
smaller species ~30KDa likely to result from post-translational modifications, consistent 
with that of the in house anti-rodent NR3B (885-899). 
A novel anti-human NR3B (885-889) raised against the synthetic peptide sequence 
CTGPPEGSKEETAEAE in the C-terminal of the human NR3B sequence, was also 
generated and affinity purified via a novel antigenic peptide sepharose affinity column. 
The anti-hNR3B (885-899) antibody was characterized using western blotting with post-
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mortem human putamen homogenate (obtained as a gift from Dr Margaret Piggott, 
Newcastle University) where immunoreactivity identified a large peptide specific 
species ~ 174KDa which may be due to NR3B subunit dimerisation. A prominent 
doublet species evident at ~82KDa may be a proteolytic fragment of this larger NR3B 
species caused by postmortem delay. The human anti-NR3B (885-899) also showed 
immunoreactivity towards adult rat forebrain and spinal cord membranes, identifying 
the same small molecular weight species ~30KDa despite eight amino acid changes in 
the sequence. This evidence for cross-reactivity with the rat NR3B protein was also 
confirmed using ELISA data and was again shown to be specific with antigenic peptide 
blockade. ELISA assays (data not shown) were performed on each bleed of the anti-
human NR3B antibody and showed that it has a high titer (1 in 30000) and cross-reacts 
with the rat antigenic peptide due to sequence homology with the first 6 amino acids of 
the peptide, which may form the primary epitope. 
The expression pattern of the various NMDA receptor subunits has been the focus of 
many studies particularly within the rodent brain and spinal cord, though many focus on 
single subunit expression (e.g. Samarasinghe et al., 1996) or expression of multiple 
subunits in one particular region of tissue (e.g. Nagy et al., 2004). This study enhances 
current knowledge by directly analysing NRl, NR2A, NR2B and NR3B subunit 
expression in human cervical tissue and within rat cervical, thoracic and lumbar tissue, 
providing the first parallel data set on NR3B protein expression in different spinal 
levels. Immunohistochemical analysis probing adult rat tissue with anti-NRl (929-938) 
shows abundant expression throughout the cervical, thoracic and lumbar regions 
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confirming the presence of NMDA receptors on glutamatergic synapses (Nagy et al., 
2004) throughout the spinal cord adding to previously published mRNA (Tolle et al., 
1993; Furuyama et al., 1993; Goebel et al., 1999) and protein (Nagy et al., 2004) 
expression studies in rat lumbar cord. NRl protein expression was evident in both the 
dorsal and ventral horns, showing NMDA receptor involvement in both sensory and 
motor system transmissions. High levels of immunoreactivity may also result from the 
large intracellular pools of monomeric NR1 subunits, associated with endoplasmic 
reticulum, which may serve as a reserve for receptor up-regulation (Chazot and 
Stephenson, 1997). 
Expression of the NR2A subunit followed a similar abundant pattern to that of the NRl 
subunit showing that NMDA receptors in the spinal cord may be predominantly 
composed of receptors containing NR1/NR2A subtypes. This data is consistent with 
previous findings detailing prominent NR2A mRNA expression in adult rat (Nagy et al., 
2004) and human spinal cord (Samarasinghe et al., 1996), but in contrast to Tolle et al., 
1993 who report undetectable levels ofNR2A mRNA in rat lumbar spinal cord. 
Interestingly, Nagy et al., 2004 and Watanabe et al., 1994 report a distinctly increased 
level of NR2A mRNA expression in laminae Ill of the dorsal horn in comparison with 
laminae I and 11, thought to be particularly located within post-synaptic areas, however 
no such clear distinction in protein expression is apparent in this study which may be 
accounted for by post-translational protein transportation within the cell to processes 
located in other regions. The distribution of low-threshold cutaneous primary afferent 
terminals within laminae Ill and the presence of NR2A immunoreactivity on synapses 
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opposed to primary afferent terminals suggest a role for NR2A-containing receptors in 
low threshold sensory transmission (Nagy et al., 2004). 
In this study prominent expression of NR2A is apparent within the cell bodies of motor 
neurons consistent with previous results showing protein expression ofNR2A in lamina 
IX and NR2A presence on synapses in the ventral horn (Nagy et al., 2004) and 
suggesting a role for NR2A-containing receptors in motor systems. 
Expression patterns of the NR2B subunit show some distinction from the NR2A 
subunit, implying a different functional role within distinct loci. NR2B protein 
expression was concentrated in the superficial laminae I and predominantly 11 in the 
dorsal horn throughout each region of the spinal cord particularly evident in the thoracic 
and lumbar regions. These findings are consistent with previous research showing 
NR2B mRNA concentrated in lamina II (Watanabe et al., 1994) and NR2B protein 
expression in rat lumbar cord (Shibata et al., 1999; Nagy et al., 2004), though in contrast 
to a study showing undetectable levels ofNR2B mRNA in adult rat lumbar cord (Tolle 
et al., 1993). Implications of NR2B subunit involvement in nociceptive transmission 
resulted from the detection of prominent expression in the superficial laminae of the 
spinal cord where most nociceptive primary afferents terminate and has since been 
proven with many studies where NR2B gene knockdown attenuates formalin-induced 
nociception in the rat (Tan et al., 2005) and NR2B-selective antagonists induce 
antinociception (e.g., Boyce et al., 1999). Current data contributes to the evidence for 
NR2B involvement in windup of spinal neurons with both synaptic (Nagy et al., 2004) 
and extrasynaptic (Momiyama, 2000) NR2B-containing receptors in this region. It is 
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this combined evidence that is driving forward the search for effective NR2B 
antagonists. 
NR2B protein expression was also detected in the large cell bodies of motor neurons in 
the ventral horn, particularly within the cervical region, suggesting a role for the NR2B 
subunit in motor neurons as well as sensory neurons. These results confirm previous 
findings showing NR2B mRNA (Shibata et al., 1999) and protein (Nagy et al., 2004) 
expression in somatic motor neurons and therefore pharmaceutical targeting of NR2B-
containing receptors is likely to additionally affect motor systems. This modulation 
could therefore present adverse side effects, when targeting sensory areas; however it 
could potentially be advantageous and therapeutically useful for diseases such as motor 
neuron disease where antagonists may be able to reduce motor neuronal cell death due 
to glutamate toxicity, as well as targeting the sensory areas to combat conditions such as 
chronic pain. 
NR3B expression was predominantly located within the large cell bodies of motor 
neurons and their dendrites in all three regions of the rat spinal cord consistent with 
previous mouse mRNA data (Nishi et al., 2001; Matsuda et al., 2002; Fukaya et al., 
2005). The immunoreactivity of NR3B within the motor neuron cell bodies may result 
from the presence of large intracellular pools of monomeric subunit or extrasynaptic 
receptors (Matsuda et al., 2003), activated following synaptic stimulation (Clark and 
Cull-Candy, 2002). It is possible that NR3B is transported from internal stores and 
incorporated into the receptor complex upon up-regulation of synaptic input in order to 
regulate calcium entry into the cell. 
150 
Chapter4 Heather Chaffey 
There was also evidence for some minimal immunoreactivity ofNR3B within the dorsal 
horn particularly within the thoracic and lumbar regions suggesting that NR3B may 
additionally be involved in modulation of sensory pathways. A previous study 
identified rat NR3B mRNA in the hippocampus (Andersson et al., 2001) and recent 
research suggests more wide-spread localization with NR3B protein expression in the 
cortex, striatum and hippocampus (Wee et al., 2007), evidence to suggest NR3B-
containing NMDA receptor modulation of sensory signaling. 
In the human cervical spinal cord, NR1 protein was abundantly expressed in both dorsal 
and ventral horns and again predominantly in neuronal cell bodies, consistent with 
previous studies examining mRNA expression (Samarasinghe et al., 1996) and protein 
expression in lumbar regions of human spinal cord (Sundstrom et al., 1997). 
Expression of NR2A protein in the human cervical cord, showed a similar wide-spread 
distribution to that detected in the rat tissue, but with seemingly increased expression in 
the dorsal regions. Prominent immunoreactivity was evident in the superficial laminae 
I, II and Ill of the dorsal horn and in the motor neuronal cell bodies of the ventral horn 
consistent with mRNA studies in human spinal cord (Samarasinghe et al., 1996), 
lumbar-sacral (Sundstrom et al., 1997) and cervical regions (Luque et al., 1994). 
In the human cervical tissue, NR2B protein expression is predominantly located in the 
superficial laminae I and II contrasting with a previous study which showed 
undetectable levels of NR2B protein in human lumbar-sacral cord (Sundstrom et al., 
1997). The expression pattern of NR2B implies a similar involvement of NR2B-
containing receptors in nociceptive afferent signaling in the human and the rat. There is 
also prominent immunoreactivity of NR2B in the motor neurons of the ventral horn, 
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greater than that observed in the rat cervical tissue, possibly implying a greater role for 
NR2B in motor transmissions in the human. 
Interestingly, expression levels of the NMDA NR2 subunits between rodent species 
varies considerably. The immunoblot below carried out using adult mouse tissue, shows 
that the predominant subunit expressed in the forebrain and spinal cord is the NR2B 
subunit, however in adult rat tissue, the predominant NR2 subunit appears to be NR2A 
showing an expression pattern more closely related to the human. These important 
species differences have yet to be fully characterized but this initial evidence could have 
important implications for the design of subunit specific drugs and the use of animal 
models when relating data to human NMDA targets. 
NR2B » NR2D > NR2A 
FB se FB se FB se 
FB = Forebrain SC = Spinal cord 
Chazot, unpublished 
Expression of the NR3B protein in the human cervical tissue showed a similar 
distribution to that of the rat with predominant localization in the motor neurons of the 
ventral horn consistent with expression in rodent studies (Matsuda et a/, 2003; Fukaya et 
al. , 2005; Wee et al., 2007). Undetectable expression ofNR3B in the dorsal horn ofthe 
human cervical cord may be initial evidence for either a species difference or for 
expression changes between the cervical, thoracic and lumbar regions, as in the rat 
NR3B expression in the dorsal horn appeared to increase as the spinal cord was 
descended. 
152 
Chapter4 Heather Chaffey 
These data provide evidence for protein expression and eo-localisation ofNR1, NR2A, 
NR2B and NR3B in adult rat spinal cord in both dorsal and ventral horns and for the eo-
localisation of NR1/NR2AINR2B in human dorsal horn and NR11NR2AINR2B/NR3B 
eo-localisation in adult human ventral horn ofthe cervical spinal cord. 
eo-localisation ofNR1, NR2A, NR2B and NR3B within the same cell type (and even 
the same cell) does not necessarily translate into the eo-assembly of all four subunits to 
form functional NMDA receptors expressed on the cell surface. Therefore it was 
important to investigate the native spinal cord NR3B-containing receptor eo-assemblies, 
via immunopurification. 
In order to carry out immunopurification, the NMDA receptors present in the rat spinal 
cord homogenate must be available in a stable, detergent-solubilised preparation 
although previous research has found that the NMDA receptor is notoriously resistant to 
detergent extraction (Chazot and Stephenson, 1997). 
The detergent most widely used for extraction of NMDA receptors from rodent brain 
tissue is 1% (wt/vol) sodium deoxycholate (pH9.0) (Chazot and Stephenson, 1997; 
Blahos and Wenthold, 1996; Sundstrom et al., 1997) though inconsistent levels of 
subunit solubilisation were achieved from spinal cord preparations in this study (data not 
shown) possibly due to the lower expression levels of the subunits in the spinal cord. 
Temperature optimization was attempted to increase solubilisation efficiencies (Blahos 
and Wenthold, 1996) though immunoblotting analysis of the solubilised receptors 
showed minimal differences in the efficiency of solubilisation of the NR 1, NR2A, 
NR2B and NR3B subunits between 4 and 37°C. The inconsistencies in solubilisation 
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efficiency with 1% DOC between experiments may be due to reduced receptor 
abundance in the spinal cord or possible differences in the stability of the complexes 
between the forebrain and spinal cord. Blahos and Wenthold, 1996 stated that 'the 
NMDA receptor complex is dissociated more readily than it is solubilised' causing 
inherent problems when trying to extract in-tact native complexes for analysis. 
To achieve increased efficiency of solubilisation, particularly of the NR2 and NR3 
subunits, detergent extraction using SOS (pH7.4) was attempted, following a protocol 
published by Richard Huganir's group in 2004 (Chung et al., 2004). As expected, this 
strongly ionic detergent successfully solubilised high yields of all four subunits NR1, 
NR2A, NR2B and NR3B, though immunoaffinity purification demonstrated that the 
NMOA complex had been dissociated by the stringent conditions. The concentration of 
SOS required for effective solubilisation but maintenance of complex association was 
therefore optimized. 0.3% (wt/vol) SOS was the lowest concentration that successfully 
achieved good solubilisation and provided some limited initial purification data. 
Immunopurification using the anti-NR1 column showed potential evidence for eo-
association of NR1/NR2A/NR3B and possibly NR2B subunits, with a high molecular 
weight species in the elutions possibly suggesting subunit dimerisation of NR3B. 
lmmunopurification using an anti-NR2A column yielded clear association of 
NR1/NR2A, though solubilisation of NR2B remained problematic. The association 
between the NR 1 and NR2A subunit reflects the abundant expression of these two 
subunits in the spinal cord seen in the immunohistochemical analysis, and it may be the 
reduced expression of NR2B and NR3B in this region of the spinal cord which made 
effective solubilisation and detection very difficult. It is also possible that associations 
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between the NR1, NR2 and NR3 subunits differs in strength between the brain and the 
spinal cord, with weaker associations being disrupted in the spinal cord preventing 
successful purifications. 
The NR1/NR2A and possible NRIINR2B, NR1/NR2A/NR2B associations observed are 
consistent with previous co-immunoprecipitation data of NMDA subunits from adult rat 
forebrain (Blahos and Wenthold, 1996), immunopurification data from adult mouse 
fore brain using an anti-NR 1 column (Chazot and Stephenson, 1997) and 
immunoprecipitation from adult human lumbar-sacral cord (Sundstrom et al., 1997). 
Initial evidence for the eo-association ofNR3B with NRI or NRIINR2A and possibly 
NR1/NR2B or NRIINR2AINR2B from adult rat spinal cord supports previous data 
showing NR1/NR2A!NR3B association in recombinant HEK293 cell in vitro models 
(Nishi et al., 2001; Matsuda et al., 2003). It has also been shown that the NR3A subunit 
(shares 62% homology with NR3B) associates with NR1/NR2A/NR2B in adult rat brain 
preparations (Al-Hallaq et al., 2002) and adult human brain and spinal cord (Nilsson et 
al., 2007). 
In order to maximize the likelihood of effective solubilisation and purification ofNR3B-
containing NMDA receptors whole spinal cords, or preparations containing thoracic and 
lumbar sections should be used to ensure the greatest abundance of subunit expression, 
as it is evident from the immunoblotting studies that subunit expression is increased in 
lower regions of the cord. 
The data in this chapter provides novel evidence for eo-localisation of the NR3B protein 
and NRI, NR2A and NR2B throughout the cervical, thoracic and lumbar regions of rat 
spinal cord and human cervical cord. It also presents initial data to suggest variable 
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expression patterns of the NR3B sub unit between spinal cord regions and eo-association 
ofNR3B with NRI and NR2A in native receptors from adult rat cervical spinal cord. 
Further characterization of native NMDA receptor complexes within the spinal cord is 
required, particularly of the little known NR3B subunit to fully understand the 
mechanisms of NMDA receptor signalling and the consequences of pharmaceutical 
targeting. 
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Chapter 5 
The influence of NR3 sub units on NMDA receptor 
cytotoxicity, physiology and pharmacology 
5.1 Introduction 
5.1.1 Effect of NR3 subunits upon NMDA-mediated cytotoxicity 
Influx of calcium, mediated in part by NMDA receptors plays a vital role in normal 
neurological functions. However, over-activation of NMDA receptors leading to 
calcium toxicity has been implicated in various neuropathologies, for example 
dementias and neurodegenerative disorders such as motor neuron disease. 
NR2B-containing receptors in particular have been implicated in the aetiology of 
disease states due to hyperexcitability ofNMDA receptors (Fuller et al., 2006) and have 
therefore been a target for novel NMDA antagonists with selective subunit specificity. 
Interestingly, in contrast to the NRl and NR2 subunits, previous research suggests that 
NR3A and NR3B reduce Ca2+ permeability when part of the receptor complex (Nishi et 
al., 2001; Matsuda et al., 2002), potentially reducing intracellular calcium levels and 
reducing associated adverse effects. 
This chapter explores the possibility that this reduction in Ca2+ permeability induced by 
the NR3A and NR3B subunits would be reflected in vitro as reduced calcium toxicity 
and cytoprotection. 
The immunohistochemical data in the previous chapter provides initial evidence for 
NR3B eo-localisation with NRl, NR2A and NR2B in both rat and human spinal cords. 
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The cytotoxicity experiments therefore investigated the potential influences of the NR3 
subunits upon both NR2A and NR2B-containing receptors. 
5.1.2 Effect of NR3 upon the functional and biophysical characteristics of the 
NR1/NR2B receptor channel 
In addition to the cytotoxicity assay, whole-cell patch clamp electrophysiology (2.2.20) 
was used to investigate the influence of NR3B upon NR1/NR2B functional properties 
such as calcium permeability, current amplitude, magnesium blockade and reversal 
potential. 
Ionic flux across the cell membrane mediated by NMDA receptor activity was measured 
using intracellular voltage clamp recordings. Here the cell membrane potential is 
controlled at -60m V and the ionic current crossing the membrane is measured via an 
electronic feedback system. 
agonist 
control 
:::.C::::, 
Figure 5.1 Schematic diagram representing electrode position and cell placement in the 
microscope bath beneath the barrels used for rapid agonist and antagonist application 
(From Jon Spencer, GSK). 
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Previous research suggests that the NR3 subunits have a modulatory role within the 
receptor complex. Recombinant expression ofNR3A with NRIINR2A and NR1/NR2B 
(Al-Hallaq et al., 2002) and NR3B with NR1/NR2A (Nishi et al., 2001; Matsuda et al., 
2002) suggest reduced Ca2+ permeability of the receptor in addition to lowered 
magnesium sensitivity of the complex. This novel study reports the effect of NR3B 
upon NRIINR2B and NRIINR2A receptors and therefore provides important 
information regarding putative motor neuron NMDA receptor complexes. 
5.1.3 Pharmacological influences of the NR3B subunit upon NR1/NR2B receptors 
Some of the most promising NMDA antagonists generated to date are NR2B subunit 
selective compounds. In order to understand the pharmacological interactions between 
these compounds and to develop new higher affinity, potentially more selective 
antagonists, the associations of NR2B-containing receptors and the influence of the 
NR3B subunit upon compound pharmacology is vital. 
Research to date has shown evidence for two classes of NR2B subunit selective 
compounds, one which binds only to NR2B-containing receptors and one which binds to 
NR2B-containing receptors in the presence of other NR2 subunits (Chazot et al., 2002). 
There is currently no data regarding the influence of the NR3 subunits upon NR2B 
receptor pharmacology or NR2B-subunit selective compounds. Using the cytotoxicity 
assay (2.2.19), whole-cell patch clamp electrophysiology (2.2.20) and radioligand 
binding (2.2.14 ), this study therefore provides the first novel data investigating the effect 
of NR3B upon the NR2B-selective compounds Ro-256981, CP-1 01606, ifenprodil and 
the novel antagonists COMPOUND A and COMPOUND B. 
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5.2 Results 
5.2.1 Differential cytoprotective effects of NR3A and NR3B upon cell death 
mediated by NR1/NR2A and NR1/NR2B receptors expressed in HEK 293 cells. 
The Promega CytoTox 96™ cytotoxicity assay can be used as a measure of cell lysis in 
mammalian cells. The assay allows quantitative measurements of lactate dehydrogenase 
(LDH), a stable cytosolic enzyme which is released upon cell lysis. LDH from the 
cultured supematants is measured with a 30 minute coupled enzymatic reaction that 
results in conversion of a tetrazolium salt into a red formazan product which can be 
quantified through measuring absorbance at 490nm. 
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5.2.1.1 Differential cytotoxicity of various recombinant NMDA receptors. 
Recombinant NMDA receptor complexes; NR1/NR2A, NR1/NR2AINR3A, 
NR1/NR2AINR3B, NR1/NR2B, NR1/NR2B/NR3A and NR1/NR2B/NR3B were 
expressed in HEK 293 cells. Following 48hr incubation in the absence of an NMDA 
antagonist, the cytotoxicity assay was performed (n=6-10 individual experiments). 
eo-expression ofNR1/NR2B receptor subunits resulted in the highest incidence of cell 
mortality (50 ± 11 %), in comparison to no DNA and NR1 controls. eo-expression of 
NR1/NR2A receptor subunits resulted in a significantly lower level of cell death (19 ± 
2%). The inclusion of the NR3 subunits with NR1/NR2B receptors significantly 
reduced cell death in comparison to NR1/NR2B receptors alone; NR1/NR2B/NR3A and 
NR1/NR2BINR3B eo-assemblies showed 29 ± 3% and 23 ± 3% cell mortality, 
respectively, reflecting significant levels of cytoprotection (figure 5.2). However, eo-
expression of NR3 subunits with NR1/NR2A receptors showed no significant influence 
on cell mortality. NR1/NR2AINR3A and NR1/NR2AINR3B resulted in 17 ± 3% and 
23 ± 2% cytotoxicity with no significant cytoprotection (figure 5.2). These data provide 
evidence for a differential influence ofNR3A and NR3B upon cytotoxicity mediated by 
NR1/NR2B and NR1/NR2A receptors. 
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A 
*** 
** 
* ~ 
' Ren·ptor combination 'll·an ± SE'I 
No DNA 3±0.6 
NR1 9±1 
NR1/2B 50± 11 
NR1/2B/3A 29±3 
NR1/2B/3B 23±3 
NR1/2A 19±2 
NR1/2A/3A 17±3 
NR1/2A/3B 23±2 
Figure 5.2 The percentage cytotoxicity of HEK 293 cells expressing various combinations of 
NMDA receptor subunits *p<0.05, **p<O.Ol, ***p<O.OOl one way AN OVA. 
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5.2.2 Functional influence of NR3B upon NR1/NR2B receptor physiology 
In order to investigate the functional effects of the NR3B subunit on the NR1/NR2B 
receptor complex, patch clamp electrophysiology was carried out on recombinant 
receptors transiently expressed in HEK 293 cells. The parameters measured were 
current amplitude, reversal potential, calcium permeability and magnesium sensitivity. 
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5.2.2.1 Peak NMDA current amplitude of cells transfected with NR1/NR2B and 
NR1/NR2B/NR3B receptors. 
Whole-cell patch clamp recordings were made from cells transfected with NRl , 
NRIINR2B and NR1/NR2BINR3B receptors (n=25, respectively). GFP-positive cells 
were taken as a marker of successful transfection. The peak amplitude resulting from 
receptor channel activation with 10 second application of co-agonists glutamate 
(100!-lM) and glycine (IO!!M) was measured. Pooled data show minimal channel 
activity (18 ± 5pA) for control NRl expressed as a single subunit (C). Functional 
activity in cells expressing NR1/NR2B and NR11NR2BINR3B showed peak amplitudes 
averaging 675 ± 146pA and 592 ± 130pA, respectively; however, there was no 
statistically relevant reduction in peak amplitude in the presence ofNR3B (0 and E). 
A NR1/NR28 
Glutanate (100 ~M)+ Glydne (10 ~M) 
5sec 
< -2 
.eo 
J ~ -50 pA -m a. -750 
Peak amplitudes 
B NR1/NR2B/NR3B 
Glutamate (100uM) + Glydne (10uM) 
I I 
5 sec 
E_ 
··. 
·: 
. 
5 sec 
-1000-L---,.----.------r---
NR1 NR112B NR1128138 
IWOA receplor c001J0Sition 
n=25 P=>0.05 (NR1128 and NR1/28/38) 
. 
. 
Figure 5.3 Electrophysiological traces of peak amplitudes (pA) obtained from recombinant 
NR1/NR2B (A), NR1/NR2B/NR3B (B) and NRl (C) receptors. Histogram (D) and data range 
charts (El show the mean± SD for 25 individual exueriments. 
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5.2.2.2 Reversal potentials of cells transfected with NR1/NR2B and 
NR1/NR2B/NR3B receptors. 
The current/voltage (1/V) relationship was measured in cells transfected with 
NR1/NR2B (A) and NR1/NR2B/NR3B (B) receptors (n=21, n=15, respectively). 
Taking into account the junction potential (potential between two salt solutions, i.e. 
different concentrations of ions) the reversal potential (Erev) for NR1/NR2B was -3.9 ± 
1.6mV and for NRI/NR2B/NR3B -3.6 ± 1.6mV. Therefore the characteristics of each 
channel were very similar, again the presence of NR3B had no statistical effect on 
reversal potential. 
Reversal potentials (IV ramps) 
A NR1/2B 
IV IIR11211 
'L!. 
i 
ii Qf, 
~ 
& 
~ -SO -6) 40 6l !iO 
5 
.!)5 Erev =-3.9 ± 1.6mV (I'F21) () 
-1 RedlflcaUon ratio (1.7cuo"'IVI =1.1 
.;f, 
WIBge(mV) 
B 
IVHR112808 
NR1/2B/3B 15 
" = ;; 
E 
! i-ro 80 
il 
Erev= -3.58t1.6mV(n=16) 
-Hi 
1A>Itogo ln"l Rectification ratio (1.7cr_1gii1V) =1.03 
Figure 5.4 Current/voltage (IV) relationships for NR1/NR28 (A) and NR1/NR2B/NR38 (B) 
receptors expressed in HEK 293 cells, showi(lg g~ sta.ti~~l differ~nces J,J,etwee~ channel <C 
characteristics. 
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5.2.2.3 Calcium permeability experiments investigating the shift in reversal 
potentials of HEK 293 cells transfected with NR1/NR2B and NR1/NR2BINR3B 
receptors. 
The 1/V relationship for each receptor complex was used to investigate calcium 
permeability of the two receptor complexes. GFP-positive NR1/NR2B (n=lO) (A) and 
NRIINR2B/NR3B (n=9) (B) cells were exposed to 0.3mM and 30mM extracellular 
calcium concentrations in succession. The subsequent shift in reversal potentials 
between the two solutions was calculated for each receptor complex. Taking into 
account the junction potential the shift in reversal potential was measured (15.9 ± lOmV 
and 21 ± 9mV for NR1/NR2B and NR1/NR2B/NR3B, respectively), no statistical 
differences were detected, contrasting previous research (Matsuda et al., 2002) and 
showing no differences in calcium permeability in this assay. 
A 
2.5 
NR1/NR2B 
1.5 
0 .5 
-60 -60 
-0.5 20 40 60 60 
-1 
-1.5 
-2 Reversal potentia l = 15.9!10 
B 
NR1/NR2B/NR3B :DmM 
2.5 
-80 
Reversal potentia l = 21±9 
-1 .5 
-2 
Figure 5.5 Calcium permeability experiments, measuring the shift in reversal potential of 
the receptor channel between 0.3 and 30mM extracellular calcium. 
166 
Chapter 5 Heather Chaffey 
5.2.2.4 Sensitivity of NR1/NR2B and NR1/NR2B/NR3B receptor complexes to 
magnesium blockade using current/voltage (1/V) relationship. 
The IN relationship for each receptor complex was used to investigate the voltage-
dependency of the magnesium blockade at both I OOJ.LM and 20J.1.M concentrations. The 
magnesium blockade is almost maximal at hyperpolarised potentials ( -70m V) and is 
released when the membrane potential becomes more positive. I 00 and 20J.LM Mg2+ 
block of NRIINR2B receptors remains at almost 100% until the membrane potential 
reaches approximately -35mV, whereas both concentrations of Mg2+ blockade are 
relieved at membrane potentials of ~ -50-60mV in NR1/NR2B/NR3B receptors 
providing evidence for reduced sensitivity of NR3B-containing receptors towards 
magnesium. 
A Magnesium blockade 
NR1/2B 
0 .8 
0.0 
80 
-1.2 
B 
NR1/2B/38 
80 
·1.2 
Figure 5.6 Characterisation of magnesium sensitivity of recombinant NR1/NR2B (A) (n=8) 
and NR1/NR2B/NR3B (B) (n=6) receptors using current/voltage (1/V) relationships. 
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5.2.2.5 Investigating the sensitivity of NR1/NR2B and NR1/NR2BINR3B receptor 
complexes towards lOOflM magnesium blockade. 
GFP-positive NR1/NR2B (n=8) and NR1/NR2BINR3B (n=6) cells were selected for 
patching. I OOj.lM MgCh was applied for 1 0 seconds following activation of the 
receptors using 1 OOj.lM glutamate and 1 Oj.lM glycine. 83 ± 5% inhibition resulted from 
1 0011M MgCh application to NR1/NR2B receptors whereas 69 ± 3% (mean ± SD) 
inhibition of NR1/NR2BINR3B receptors showed a slightly reduced level of sensitivity 
towards the magnesium blockade (previously suggested in the literature to be due to 
amino acid alteration in TM2 region, Matsuda et al. , 2002). Kinetically 1 OOj.lM MgCh 
displayed both fast onset and rapid reversal of inhibition. 
100uMMQ2+ 
I I 100uM Glutamate +10uM glycine 
1 OOJJM Mg2+ blockade 
A 
NR1/2B 
C Inhib ition with 1 OOuM Mg 2 -
90 
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80 
70 B ----.---
NR1/2B/3B 
~+ 100uMGiutamale+10uMg¥ine 
I 
6 60 
"' 50 :n
t 40 
~ 30 
20 
10 
0 
_j1~ n=B n=6 
5 sec 
Figure 5.7 Electrophysiological traces depicting the sensitivity of NR1/NR28 (A) and 
NR1/NR2B/NR3B (B) receptors towards lOOuM concentrations of magnesium and a 
histogram (C) representing the mean ± SD of data from all experiments. 
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5.2.2.6 Investigation the sensitivity of NR1/NR2B and NR1/NR2BINR3B receptors 
towards 20p.M magnesium blockade. 
Again, GFP-positive NR1/2B (n=8) and NR1/2B/3B (n=6) cells were selected and 
exposed to 20J.1M MgCb following activation of the receptor channels with 1 OOJ.1M 
glutamate and lOJ.1M glycine. The application of20J.1M MgCh resulted in 49 ± 5% and 
44 ± 3% (mean ± SD) inhibition of both NRIINR2B and NRIINR2B/NR3B receptor 
combinations, respectively. Once again, there is a slightly lower sensitivity with the 
inclusion of the NR3B subunit; however, there is no significant difference between the 
data sets. 
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Figure 5.8 Electrohysiological traces representing the signals measured from NR1/NR2B (A) 
and NR1/NRZB/NR3B (B) receptor complexes when exposed to 20J1M magnesium chloride, 
and a histogram (C) showing the mean± SD of all data sets. 
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5.2.3 Pharmacological influence of NR3B upon NR2B subtype selective antagonists 
In order to investigate the pharmacological influences of NR3B, cytotoxicity assays, 
whole cell patch-clamp electrophysiology and radioligand binding were carried out 
using NR2B subunit-selective antagonists. 
5.2.3.1 Cytoprotective effect of NR2B-selective antagonists upon NR1/NR2B and 
NR1/NR2B/NR3B receptors expressed in HEK293 cells. 
Cytotoxicity assays were performed in parallel on recombinant NR1/NR2B and 
NR1/NR2B/NR3B receptors expressed in HEK 293 cells in the presence of the NR2B-
subunit selective antagonists ifenprodil (100nM, 1J.1M, 10J.1M), COMPOUND A (lOnM, 
lOOnM, 1J.1M) and COMPOUND B (lOnM, lOOnM, 1J.1M) (n=4 respectively) and with 
no antagonist as a control. The level of cell death with no antagonist present was 
significantly reduced from 41±4% to 23±5% in the presence ofNR3B. 
All three compounds effectively antagonized NR1/NR2B receptor activity in this 
functional assay, particularly 10J.1M ifenprodil and 1J.1M COMPOUND A which 
significantly reduced cytotoxicity to 17 ± 6 %and 16 ± 4% respectively. 
The presence ofNR3B appears to slightly increase the binding of ifenprodil towards the 
receptor complex, reducing cytotoxicity at 1 OOnM, 1 J!M and 1 OJ!M to 16 ± 6%, 18 ± 5% 
and 9 ± 5%, respectively. The binding affinity and effective cytoprotection of 
COMPOUND B is similar in the presence and absence of NR3B. Binding affinity of 
COMPOUND A appears to have been reduced by the presence of NR3B, with no 
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significant reduction in cytotoxicity, showing that inclusion of this subunit may modify 
the binding site or allosteric interactions of the two novel compounds. 
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NR1/NR2B 
c::l NR1/NR2B/NR3B 
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Figure 5.9 Differential cytoprotective effects ofthe NR2B-selective antagonists ifenprodil (A), 
COMPOUND B (B) and COMPOUND A (C) upon NR1/NR2B and NR1/NR2B/NR3B receptor 
complexes* p=<O.OS, **p=<O.Ol Two-tailed T-Tests. 
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5.2.3.2 Investigating the influence of the NR3B subunit upon the NR2B subtype-
selective antagonist CP-101,606 (10 J.LM) in recombinant NR1/NR2B and 
NR1/NR2BINR3B receptors. 
Cells transfected with NRIINR2B (n=9) and NRIINR2B/NR3B (n=ll) were exposed to 
co-agonists (glutamate (lOO!J.M) and glycine {lO!J.M)) and the NR2B-subtype selective 
antagonist CP-101606 for 10 seconds. A fast onset of blockade and minimal wash-out 
after several minutes demonstrated high affinity binding of the antagonist to the 
complex. Pooled data showed no significant effect of the NR3B subunit with 84 ± 2% 
and 83 ± 3% (mean ± SD) inhibition of NRIINR2B and NRIINR2B/NR3B receptor 
complexes, respectively. 
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Figure 5.10 Electropbysiological traces representing inhibition of signals from recombinant 
NR1/NR2B (A) and NR1/NR2B/NR3B (B) receptors. Figure C represents the mean± SD of 
percentage inhibition from all data sets. 
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5.2.3.3 Investigating the influence of the NR3B subunit upon the activity of the 
selective NR2B antagonist CP-101,606 (300nM, 10 seconds) in recombinant 
NR1/NR2B and NR1/NR2BINR3B receptors. 
Cells transfected with NRIINR2B (n= l2) and NR1/NR2B/NR3B (n= IO) receptors were 
exposed to co-agonists (glutamate (IOOJ..LM) and glycine (lOJ..LM)) and the NR2B subtype 
selective antagonist CP-1 01606 (300nM) for I 0 seconds. Inhibition was calculated to 
be 28 ± 6% and 20 ± 3% (mean ± SD) for NR1/NR2B and NR1/NR2BINR3B receptor 
complexes respectively, with no significant reduction in sensitivity of CP-1 01 ,606 in the 
presence of NR3B. In order to maximize inhibition and investigate time-dependent 
blockade at 300nM, application time ofCP-101606 was increased to 60seconds. 
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Figure 5.11 Electrophysiological traces representing the inhibition of NR1/NR28 (A) and 
NR1/NR2B/NR3B (B) receptor activity by 300nM CP-101606. Figure C shows the mean± SD 
of percenta2e inhibition from all data sets. 
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5.2.3.4 Investigating the influence of the NR3B subunit upon the activity of the 
selective NR2B antagonist CP-101,606 (300nM, 60 seconds) in recombinant 
NR1/NR2B and NR1/NR2B/NR3B receptors. 
300nM CP-101606 was applied to cells transfected with receptor complexes NR1/NR2B 
(n=4) and NR1/NR2B/NR3B (n=4) for 60 seconds. A slower, gradual onset of time-
dependent inhibition was observed, which was maintained after antagonist app lication, 
indicating potent high-affinity binding to both receptor complexes and no significant 
modulation induced by the NR3B subunit. 
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Figure 5.12 Electrophysiological traces representing the inhibition of NR1/NR2B (A) and 
NR1/NR2B/NR38 (B) receptor activity by 300nM CP-101606. Figure C shows the mean± SD 
of percentage inhibition from all data sets. 
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5.2.3.5 Investigating the influence of the NR3B subunit upon the activity of the 
selective NR2B antagonist CP-101,606 (30nM, 60 seconds) in recombinant 
NR1/NR2B and NR1/NR2B/NR3B receptors. 
Antagonism ofGFP-positive cells NR1/NR2B (n=5) and NR1/NR2BINR3B (n=5) using 
CP-101606 (30nM), applied for 60seconds was then investigated. No significant 
alterations in binding affinities were observed between the two receptor populations 
although inhibition of NR1/NR2B receptors was greater (40 ± 9%) than inhibition of 
NR1/NR2B/NR3B complexes (29 ± 14%), again suggesting possible reduced sensitivity 
of the compound in the presence ofNR3B. 
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Figure 5.13 Electrophysiological traces representing the inhibition of NR1/NR28 (A) and 
NR1/NR28/NR3B (B) receptor activity by 30nM CP-101606. Figure C shows tbe mean± SD of 
percentage Inhibition from all data sets. 
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5.2.3.6 Investigating the influence of the NR3B subunit upon the activity of the 
selective NR2B antagonist Ro-256981 (10J.1M, 10 seconds) in recombinant 
NR1/NR2B and NR1/NR2B/NR3B receptors. 
1 OJ.!M of the selective NR2B antagonist Ro-256981 was applied to GFP-positive cells 
NR1/NR2B (n=6) and NR1/NR2B/NR3B (n=6) for 10 seconds following activation of 
NMDA currents with co-agonists. Ro-256981 showed high-affinity interaction with 
percentage inhibition of 100 ± 14% and 93 ±2% (mean ± SD) for NR1/NR2B and 
NR1/NR2B/NR3B complexes respectively, with fast-onset of action and minimal wash-
out towards both receptor complexes. 
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Figure 5.14 Electrophysiological traces showing the inhibition of NR1/NR2B (A) and 
NR1/NR2B/NR3B (B) receptor activity by the NR2B-selective antagonist Ro 256981 (10~M 
10 seconds). Figure C shows the mean ± SD of percentage inhibition from all data sets. 
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5.2.3.7 Investigating the influence of the NR3B subunit upon the activity of the 
selective NR2B antagonist Ro-256981 (30nM, 60 seconds) in recombinant 
NR1/NR2B and NR1/NR2BINR3B receptors. 
Ro-256981 (30nM) was applied to GFP-positive NRIINR2B (n=5) and 
NRIINR2B!NR3B (n=4) cells for 60 seconds to investigate time-dependent inhibition. 
At 30nM, the presence of the NR3B subunit in the receptor complex significantly 
reduced the percentage inhibition from 41 ± 12% (NR1/NR2B) to 10 ± 7% 
(NR1/NR2BINR3B) implying potential alterations in binding affinity, the complexes 
reaching the cell surface or allosteric modulations of the antagonist binding site. 
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Figure 5.15 Electrophysiological traces showing the inhibition of NR1/NR2B (A) and 
NR1/NR2B/NR3B (B), by recombinant receptor activity by Ro·256981 (30nM, 
60seconds). Figure C, shows signal from NR1/NR2B receptors before antagonist 
application, Figure E, shows signal from NR1/NR2B/NR3B receptors before antagonist 
application. FigureD, shows the mean± SD of percentage inhibition from all data sets. 
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5.2.3.8 Competition binding to investigate the pharmacological influence of NR3B 
expression upon the displacement of eH] CP-101606 by COMPOUND A. 
Competition binding was carried out on recombinant NR1/NR2B and 
NR1/NR2B/NR3B receptors expressed in HEK 293 cells. The two-site displacement of 
eH] CP-101606 by COMPOUND A showed high affinity binding (82% in NR1/NR2B 
cells, 53% in NR1/NR2BINR3B cells). Therefore, NR3B reduced the number of high 
affinity sites (by 29%), and therefore appeared to reduce the affinity of COMPOUND A 
for the NR1/NR2B receptors (Ki = 14 ± 22nM in the presence ofNR3B). The increase 
in lower affinity sites (Ki = 12 ± 15J..LM in the presence ofNR3B) may be the result of 
reduced receptor numbers reaching the cell surface and/or modulation of the compound 
binding site by inclusion ofNR3B in the receptor complex. The data displayed are mean 
± SD taken from three individual experiments performed in triplicate. 
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Figure 5.16 Competition binding showing two-site displacement of (3H] CP-101606 by 
COMPOUND A in recombinant NR1/NR28 and NR1/NR2B/NR38 receptors. The results 
displayed are mean ± SD of three individual experiments and non-specific binding was 
defined using 1mM ifenprodil. 
179 
Chapter 5 Heather Chaffey 
5.2.3.9 Competition binding to investigate the pharmacological influence of NR3B 
upon the displacement of eH] CP-101606 by COMPOUND B. 
Competition binding was carried out to investigate the displacement of eHJ CP-1 01606 
by COMPOUND B in recombinant NRIINR2B and NR1/NR2B!NR3B receptors 
expressed in HEK 293 cells. In cells expressing NRIINR2B receptors, COMPOUND B 
displacement of eHJ CP-101606 was fitted to a one-site curve, showing high affinity 
binding (Ki=l4 ± llnM) to this receptor population. However, eo-expression ofNR3B 
with NR1/NR2B receptors results in the binding of COMPOUND B to two receptor 
populations, one with high affmity (Ki = 0.4nM, 54%), likely to be NRIINR2B 
receptors and one with a lower affinity (Ki = 11J.M, 46%). Therefore the presence of 
NR3B in the receptor complex introduces low affinity binding sites and thus appears to 
reduce the affmity of COMPOUND B for the NRIINR2B populations. The data 
displayed are mean ± SD taken from two individual experiments performed in triplicate. 
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Figure 5.17 Competition binding experiments showing the displacement of PH] CP-101606 
by COMPOUND Bin recombinant NR1/NR2B and NR1/NR2B/NR3B receptors. Data shown 
are mean ± SD for two individual experiments and non-specific binding was defined using 
1mM ifenprodil. 
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5.2.3.10 Radioligand binding assay investigating the specific binding of eH] Ro-
256981 in recombinant NR1/NR2B and NR1/NR2B/NR3B receptors. 
NR1/NR2B and NR1/NR2B/NR3B receptors were transiently expressed in HEK293 
cells and harvested for parallel binding experiments with eHJ Ro-256981. This 
histogram represents the specific binding of eH] Ro-256981 at 16 and 25nM and shows 
a reduced, but not significantly reduced level of binding in the presence of the NR3B 
subunit at both concentrations of radioligand. This data shows that the binding of this 
NR2B-selective antagonist may be affected by the presence of NR3B in the receptor 
complex due to modulation of the Ro-256981 binding site, or a reduction in the number 
ofNR1/NR2B receptors at the cell surface. 
The data presented are generated from the mean ± SD for two individual experiments 
performed in triplicate. 
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Figure 5.18 Histogram representing specific binding data for PH] Ro-256981 in recombinant 
NR1/NR2B and NR1/NR2B/NR3B receptors. The data shown are mean ± SD for two 
individual experiments. Non-specific binding was defined using 1mM ifenprodil. 
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5.2.3.11 Radioligand binding assay investigating the specific binding of eHJ CP-
101606 in recombinant NR1/NR2B and NR1/NR2B/NR3B receptors. 
Parallel binding experiments were carried out with eHJ CP-101606 on NR1/NR2B and 
NR1/NR2BINR3B receptor populations expressed in HEK 293 cells. This histogram 
represents specific binding of eHJ CP-1 01606 at 4 and 9nM and shows a reduction in 
the level of binding in the presence of the NR3B subunit, however the data are not 
significant. This preliminary data may provide further evidence for a modulatory effect 
of the NR3B subunit upon the pharmacology of the receptor complex by altering the 
binding site of CP-101606 or reducing the number of NR1/NR2B receptor sites 
available. 
The results displayed are mean ± SD from two individual experiments carried out in 
triplicate. 
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Figure 5.19 Histogram to represent the specific binding data for PH] CP-101606 in 
recombinant NR1/NR28 and NR1/NR2B/NR38 receptors. The data shows the mean ± SD for 
two individual experiments. Non-specific binding was defined with lmM ifenprodil. 
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Assa~ ( om pound F fft·t·t of\ IU B 
Ifenprodil Trend to Increase 
Cytotoxicity 
Assays COMPOUND No effect/trend to decrease 
% cytoprotection B 
COMPOUND 
A Decrease 
CP-101606 
Trend to Decrease 
Electrophysiology 
0/o current Ro-256981 
Trend to Decrease 
inhibition 
COMPOUND 
B Decrease binding affinity 
Competition 
Radioligand COMPOUND 
Binding A Decrease binding affinity 
Competition 
CP-101606 
Specific Decrease binding affinity 
Binding 
Ro-256981 
Specific Decrease binding affinity 
Binding 
Table 5.1 Summarising the pharmacological influence of the NR3B subunit upon NR2B-
selective antagonists ifenprodil, Ro-256981, CP-101606, COMPOUND A and COMPOUND 
B. 
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5.3 Discussion 
The heteromeric nature of the NMDA receptor complex gives nse to large 
variations in channel characteristics which need to be elucidated before the 
functional implications of such receptors in native tissue can be fully understood. 
The most recently discovered and most poorly characterised NR3 subunits were the 
focus of investigation in this chapter investigating their functional and 
pharmacological modulation ofNR1/NR2A and NR1/NR2B receptor complexes. 
The percentage of cell death in HEK 293 cells eo-expressing various NMDA 
receptor subunit combinations was measured using the promega non-radioactive 
cytotoxicity assay, as previously described by Cik et al., 1995. The membrane 
potential of the HEK293 cells is approximately -10 to -20rn V (Chazot, 
unpublished) and therefore depolarised enough to relieve blockade by magnesium 
in the culture medium and activate the receptors. In the absence of an NMDA 
antagonist the }-glutamate and glycine present in the culture medium were 
sufficient to activate the receptors allowing excessive calcium influx and cell 
mortality. It has previously been shown that calcium influx is a major cause of 
toxicity in HEK 293 cells expressing recombinant NMDA receptors in studies 
using calcium chelators such as EDTA (Cik et al., 1995; Chazot et al., 1999) and 
expression of the mutant NMDAR1-1a (N598Q)/NMDAR2A which reduces 
calcium permeability of the receptors (Cik et al., 1994). 
HEK293 cells transfected without plasmid DNA acted as a negative control and 
resulted in a low background cell toxicity of 3 ± 0.6%. HEK293 cells transfected 
with the NRI subunit alone acted as a positive single-subunit control and showed 9 
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± 1% cell death. Co-transfection of NR l/NR2B receptor sub units resulted in the 
highest incidence of cell death (50± 11%) due to calcium toxicity mediated by}-
glutamate activated NMDA receptor Ca2+ influx. Co-transfection of NR1/NR2A 
subunits to form another diheteromeric complex commonly found in native adult 
tissue (Chazot et al., 1997; Stephenson, 2001) resulted in significantly lower levels 
of cytotoxicity (19 ± 2%) compared to that resulting from NR1/NR2B eo-
expression. This differential degree of cell death may be the result of variations in 
transfection efficiencies within the model system; however, this result is consistent 
with previous work associating NR2B-containing receptors with NMDA-mediated 
excitotoxicity (Fuller et al., 2006; Loftis and Janowsky, 2003; Liu et al., 2007). In 
comparison to the NR2A subunit, NR2B confers increased duration of channel 
opening, increased permeability to calcium and a higher sensitivity to glutamate 
(Fuller et a/, 2006; Cull-Candy et al., 2001). These factors are likely to enhance 
NR2B-containing NMDA receptor activity and therefore result in increased levels 
of cell death. 
Triheteromeric complexes generated from co ... transfection of NR3A with 
NR1/NR2B and NR3B with NR1/NR2B receptor complexes resulted in significant 
reductions in the levels of cell death (29% and 23% cytotoxicity, equating to 42% 
and 54% cytoprotection respectively) in comparison to NR1/NR2B alone. The 
differential level of cytoprotection between the NR3A and NR3B subunit may 
imply that NR3B reduces calcium permeability to a greater extent than NR3A 
therefore potentially having a greater impact in our model. 
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These novel results provide possible evidence that the proposed reduction in Ca2+ 
influx mediated by the NR3 subunits (Nishi et al., 2001; Matsuda et al., 2002, AI-
Hallaq et al., 2002) is sufficient to significantly reduce cytotoxicity and have a 
profound cytoprotective effect in vitro. In these studies despite the likely formation 
of both diheteromeric (NR1/NR2B and NR1/NR3B) and triheteromeric 
(NR1/NR2B/NR3B) complexes from the co-transfection of three subunits 
(Brimcombe et al., 1997), the presence of the NR3 sub units had a significant effect, 
consistent with the findings ofNishi et al., 2001. 
Interestingly, no significant cytoprotection was seen when NR3A and NR3B were 
co-transfected with NR 1/NR2A receptors. This result opposes that which would 
have been expected from previous work by Nishi et a/, 2001 and Matsuda et al., 
2002 who found reduced calcium permeability in recombinant NR1/NR2AINR3B 
receptors in comparison to NR1/NR2A receptors alone. It is possible that in this 
system, the NR3 subunits are not associating with NR1/NR2A receptors and are 
therefore not being expressed at the receptor surface. It is also possible that any 
cytoprotective effect of the NR3 subunits is beyond detection limits when 
compared with the level of cell death resulting from NR1/NR2A receptors which is 
comparatively lower than NR1/NR2B. 
The cytoprotection seen with inclusion of NR3A and NR3B in NR1/NR2B 
receptors may be initial evidence to suggest a mechanism of NR3 retention of 
NR2B-containing receptors within the ER reducing protein trafficking and 
expression at the cell surface which would reduce Ca2+ influx. There may also be 
specific interactions between the NR2B/NR3B-containing receptors and 
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intracellular signalling cascades which alter the internal processing of calcium, 
neutralising excess concentrations with uptake into stores or disrupting CaMKII 
kinase stability, an enzyme linked with NR2B and important for promoting Ca2+ 
influx (Bay er et al., 2001; Lisman et al., 2002). 
The stoichiometry of the heteromeric complex may also play a role in NR3 subunit 
modulation. For example, inclusion of NR3B in the receptor complex may 
substitute for one NR2B subunit, forming a tetramer composed of two NRl 
subunits, one NR2B subunit and one NR3B subunit. This formation would reduce 
the number of NR2B glutamate binding sites, potentially reducing the influence of 
the NR2B subunit and attenuating receptor activation however this hypothesis is 
not supported by the electrophysiological peak current amplitude data. It has also 
been suggested that the NR3A subunit doesn't undergo extensive molecular re-
arrangement upon channel activation, and with NRl forms a narrow vestibule, 
modulating the influx of cations (Wada et al., 2006). The NR3B subunit may 
therefore act similarly, when part of the receptor complex. 
Electrophysiological experiments were then undertaken to further characterise the 
effects of the NR3 subunits on NMDA receptor biophysical properties and 
function. NR3B and its influence on NR1/NR2B receptors was the focus for these 
experiments to reflect receptors present in adult rat tissue and because this receptor 
combination showed the highest degree of cytoprotection. 
The peak amplitudes resulting from NMDA-mediated currents in HEK 293 cells 
co-transfected with NR1/NR2B and those with NR1/NR2BINR3B were measured 
upon application of co-agonists glutamate ( 1 OOJJ.M) and glycine ( 1 OfJ.M). 
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Experiments were carried out in the absence of magnesium to ensure no voltage-
dependent blockade of the receptor channel. Both populations of cells showed 
functional activity with similar fast onset activation and deactivation kinetics 
though no significant difference in peak amplitude was observed between cells co-
transfected with NRIINR2B/NR3B and those with NR1/NR2B. Previous 
electrophysiological studies showed reduced glutamate induced whole-cell current 
in NR1/NR2AINR3A (Ciabarra et al., 1995; Sucher et al., 1995) and 
NR1/NR2AINR3B (Nishi et al., 2001) recombinant receptors, however, in contrast 
Matsuda et al., 2002 found no significant reduction in current amplitudes in cells 
eo-expressing NR1/NR2AINR3B when compared to NR1/NR2A receptors. These 
conflicting results provide evidence to support the theory that NR3 subunits have a 
modulatory rather than a dominant negative (Nishi et al., 2001) role when part of 
the receptor complex and may have diverse interactions with different NR2 
subunits, also evident from the cytotoxicity data. A recent study has highlighted 
the potential for different effects ofNR1 splice variants when investigating in vitro 
interactions. Interestingly, it was noted that eo-expression of NR1-la and NR3B 
with either NR2B or NR2D in Xenopus laevis oocytes resulted in potentiated 
currents, though eo-expression of NR1 (regardless of variant) and NR3B with 
either NR2A or NR2C showed the dominant attenuation of currents previously seen 
(Cavara and Hollmann, 2007) suggesting important differential modulation 
depending upon receptor composition. The electrophysiological studies carried out 
in this chapter were carried out on cells eo-expressing the NR1-la splice variant 
with NR3B and NR2B and therefore the data supports these previous findings as no 
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dominant attenuation of current was observed. These differences in modulatory 
properties conveyed by alternative receptor eo-assemblies may explain the 
discrepancies between the data presented in this chapter and the literature. 
It must also be remembered that expression efficiencies will vary between systems 
and cell labelling with GFP was taken as a marker for successful expression of 
potentially all three cDNA plasmids, but may not be absolute. In future 
experiments, it may be advantageous to tag the NR3B subunit or all three subunits 
with fluorophores, so that cells eo-expressing all subunits could be identified. 
The current/voltage (1/V) relationship of both receptor populations revealed no 
significant alteration to the reversal potential of the receptor channel being -3.9 and 
-3.6mV for NR1/NR2B and NRIINR2BINR3B respectively, a novel finding 
showing that the species of ion permeant to the receptor is the same in the presence 
and absence of NR3B. The IN relationship was then used to measure Ca2+ 
permeability between the two receptor populations. Measuring the reversal 
potential of glutamate induced currents in 3mM and 30mM external calcium 
resulted in a shift in potential of 15.9 ± IO.OmV for NRIINR2B and 21.9 ± 9.0mV 
for NRIINR2BINR3B and therefore no significant reduction in calcium 
permeability of the receptor in the presence ofNR3B. The large variability in these 
measurements may be an indication of variable transfection efficiencies and 
therefore must be considered when drawing conclusions. These findings further 
suggest a differential modulatory effect of NR3B upon NR2B subunits in 
comparison to NR2A as previous research by Matsuda et al., 2002 reported a 
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reduced shift in reversal potential from 16.6 ± 0.6mV for NRIINR2A and 9.3 ± 
0.8mV for NR1/NR2A/NR3B equating with attenuated Ca2+ permeability. 
The conflicting data between the cytotoxicity and electrophysiological experiments 
may be evidence for a different, non-NMDA interaction of the NR3 subunits, such 
as with internal calcium stores, which may reduce intracellular calcium 
concentrations, seen as a cytoprotective effect in whole cell functional assays, 
which would not be detected in NMDA channel physiology. Calcium imaging via 
fluorescence imaging plate reader (FLIPR) was attempted to investigate 
intracellular calcium concentrations in large cell populations, with and without 
NR3B, however the data obtained was inconclusive and is therefore not shown. 
The sensitivity of NR1/NR2B and NRIINR2B/NR3B receptors towards 
magnesium blockade was characterised by IN relationships and percentage 
inhibition of current amplitude in 1 OOJ.I.M and 20J.1M external magnesium. At both 
concentrations of magnesium, blockade ofNRIINR2B receptors remains maximal 
until the membrane potential reaches~ -35mV, however, both 100J.1M and 20J.1M 
Mg2+ blockade are relieved at much lower membrane potentials of ~ -50-60m V in 
receptors containing the NR3B subunit. This data is consistent with previous data 
suggesting the NR3 subunits confer reduced magnesium sensitivity towards the 
receptor complex due to a key amino acid change (asparagine to glycine) within the 
M2 domain (Matsuda et al., 2002). The percentage inhibition of 1 OOJ.I.M 
magnesium was reduced from 83 ± 5% in NRIINR2B receptors to 69 ± 3% in the 
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presence ofNR3B and with 20f.1M Mg2+ from 49 ± 5% to 44 ± 3% though there is 
no statistical difference between receptor populations. 
Implication of NR2B-containing receptor involvement in hyperexcitability of 
NMDA receptors has led to the development of novel subunit selective antagonists 
for therapeutic targeting. The subunit composition of the receptor complex has 
proved to be an important factor for pharmacological affinity of compounds for the 
receptor and for targeting specific sub-populations of receptor in different CNS 
regions. The interactions and influence mediated by the NR3B subunit upon NR2B 
receptor pharmacology is therefore potentially very important particularly for 
regulation and assessment of the impact of receptor targeting in motor neurons, 
where NR3B is predominantly expressed. 
The cytotoxicity assay was performed with HEK293 cells co-transfected with 
NR1/NR2B and NR1/NR2B/NR3B receptors in the presence of three NR2B 
specific antagonists and using no antagonist as a control. 
When no NMDA antagonist was present, NR1/NR2B/NR3B receptors showed a 
significant reduction in cell death compared to NR1/NR2B receptors again 
confirming a cytoprotective property of the NR3B subunit. The addition of 
ifenprodil to cells eo-expressing NR1/NR2B receptors resulted in a reduction in cell 
death to 21% and 17% at 1 f.! M and 1 Of.lM concentrations, showing effective 
antagonism of NR2B-containing receptors. Interestingly, the eo-expression of 
NR3B with NR1/NR2B seemingly increased the sensitivity of ifenprodil, reducing 
cytotoxicity to 16 ± 7%, 18 ± 5% and 9 ± 5% at 1 OOnM, 1 f.!M and 1 Of.!M, 
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respectively. This apparently enhanced binding affinity of ifenprodil for receptors 
containing NR3B may be the result of conformational and/or allosteric changes of 
the ligand binding domain or an impact on the activation state of the NMDA 
receptors as it has been reported that ifenprodil binds with higher affinity towards 
receptors in the activated state (Mutel et al., 1998). Ifenprodil is also reported to 
bind to other non-NMDA receptors such as voltage-gated Ca2+ channels (Church et 
al., 1994) which may be modulated by NR3B and up-regulated, increasing binding 
and reducing intracellular Ca2+ in HEK 293 cells. 
Antagonism with the novel compounds COMPOUND B and COMPOUND A 
resulted in significant reduction in cell death to 23 ± 7% and 16 ± 4%, respectively 
at 1J.1M in cells eo-expressing NR1/NR2B receptors. The addition ofNR3B into 
the receptor complex slightly reduced the sensitivity to COMPOUND B although 
overall the protective effect remained similar to that observed in NR I /NR2B cells. 
In the presence of NR3B, antagonism with COMPOUND A showed reduced 
sensitivity and binding affinity as no significant reduction in cytotoxicity was 
observed. This may be due to an allosteric effect of the inclusion of NR3B in the 
receptor complex, altering the binding site of COMPOUND A and reducing its 
affmity, or it could be due to a reduction in the numbers of NR2B subunit 
expressing on the cell surface, thereby reducing the number of available binding 
sites. 
This data provides initial evidence for differential cytoprotective effects of the two 
novel compounds COMPOUND B and COMPOUND A upon recombinant NMDA 
receptor-mediated cytotoxicity in vitro and potentially shows that COMPOUND A 
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is more sensitive to the presence of alternative subunits, a finding also highlighted 
in chapter 3. The sources of variability seen in these assays should be taken into 
consideration and are likely to result from the natural variability in the health and 
age of the cell cultures. Also, due to physical limitations in the number of assays 
which could be performed at one time, experiments were repeated over a number of 
weeks, increasing the likelihood of variability occurring. 
Whole-cell patch clamp electrophysiology was then used in order to investigate the 
pharmacological effect ofNR3B inclusion in NR1/NR2B receptor complexes upon 
Ro-256981 and CP-101606. Both Ro-256981 and CP-101606 are highly selective 
NR2B-containing receptor antagonists commonly used as tools for receptor 
characterisation. Following agonist activation of receptor currents, application of 
CP-101606 (10f.1M, 300nM and 30nM) displayed fast onset of blockade, but very 
slow, minimal wash-out after several minutes, demonstrating high affinity binding 
to both NR1/NR2B and NR1/NR2B/NR3B complexes. A trend towards reduced 
inhibition in the presence of NR3B with short 10 second application of 300nM 
CP 101606 supports previous findings that this compound binds with higher affinity 
towards only NR2B-containing receptors (Chazot et al., 2002) over receptors 
containing NR2B plus other subunits. Overall however, no significant differences 
in the percentage inhibition were observed implying a distinction between the 
allosteric modulatory effects of the NR2 and NR3B subunits on ligand binding 
domains. 
Application of Ro-256981 (10f.1M) also showed high functional potency towards 
both receptor complexes inhibiting NMDA receptor mediated currents by 
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approximately 1 00%, with fast onset of action and minimal wash-out. At 30nM, 60 
second application of Ro-256981 showed a time-dependent response with 
apparently reduced inhibition ofNR1/NR2B/NR3B receptor-mediated currents (10 
± 7%) in comparison to NR1/NR2B (41 ± 12%). These data show that the 
sensitivity of Ro-256981 may be reduced in the presence of NR3B implying that 
NR3B confers distinct pharmacological changes to the receptor complex in 
comparison to alternative NR2 subunits, although due to the small replicate 
number, further characterisation would be required to confirm results. 
Parallel radioligand binding assays also enabled pharmacological characterisation 
of the influence ofNR3B upon NR2B-selective compounds. COMPOUND A and 
COMPOUND B both show high affinity eH] CP-101606 displacement curves with 
NR1/NR2B receptors (Ki= 5 ± 6nM and 14 ± 11nM respectively) which are shifted 
to the right in the presence of NR3B. In cells eo-expressing NR1, NR2B and 
NR3B, COMPOUND A and COMPOUND B displayed low affinity binding sites 
(12 and 11J.M, respectively), providing further evidence for reduced sensitivity of 
these compounds toward triheteromeric NR1/NR2B/NR3B complexes. 
Interestingly, the presence of the NR3B subunit may also be reducing receptor 
numbers or NR2B subunits at the cell surface, or affecting antagonist binding sites. 
Herein, it is shown that in comparison with NR1/NR2B receptors, eo-expression of 
NR1/NR2B/NR3B reduced the specific binding of both eH] Ro-256981 (3000 to 
2000 fmoles/mg at 25nM) and eH] CP-101606 (1300 to 1000fmoles/mg at 9nM). 
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The pharmacological modifications of antagonist sensitivities in the presence of 
NR3B are likely to be due to physical alteration of the compound binding sites, 
reduced numbers of NR2B subunit expression at the cell surface or alterations in 
functional receptor expression levels. Compound binding sensitivities would be 
reduced if the number of functional receptors reaching the cell surface was lowered 
by changes in receptor trafficking mechanisms or increases in the number of 
receptors undergoing endocytosis. Previous research suggests that receptors 
containing NR3A (sharing large sequence homology with NR3B) undergo rapid 
endocytosis from dendritic plasma membranes during post-natal development. 
Specific removal is regulated by PACSINl/syndapin which binds selectively to 
NPF motifs in the carboxyl terminal of the 3A subunit. (Perez-Otano et a/, 2006). 
It is possible that NR3B shares this binding motif and is similarly internalised 
rapidly, reducing the number ofreceptors and thus binding sites available, however, 
the protein complexes required for this internalisation are likely to be different in 
our model from those of native dendritic membranes. 
This potential reduction in receptor numbers reaching the cell surface or the 
reduced expression of the NR2B subunit supports the cytotoxicity data as a 
reduction in the number of NR2B subunits would probably lower Ca2+ influx into 
the cell thereby reducing toxicity. However, this potential reduction of NR2B at 
the cell surface was not reflected in the channel conductance as no significant 
changes were apparent between the NR1/NR2B and NR1/NR2BINR3B 
populations, therefore further investigation is required. 
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It is evident from the data presented that both NR3A and NR3B have distinct 
modulatory influences on the NMDA receptor complex which may alter receptor 
physiology, pharmacology, subunit expression, transportation and signalling. 
Elucidating these modulations conferred by the NR3 subunits is therefore very 
important for understanding the full extent ofNMDA receptor heterogeneity and its 
implications for receptor function and pharmacological development of new drug 
candidates. 
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Chapter 6 
NMDA subunit expression in a chronic pain model 
6.1 Introduction 
The hyper-excitation of the NMDA receptors within the central nervous system has been 
implicated as a pathogenic mechanism in a wide-range of disease states including 
neurodegenerative conditions, stroke, head trauma, schizophrenia and chronic pain. 
Increasing understanding of the molecular mechanisms behind chronic nociceptive 
signalling via prolonged activation of excitatory neurotransmitters and their receptors 
led to the focus of research upon NMDA receptors, their function and pharmacology. 
Persistence of the nociceptive response is mediated, in part, by synaptic changes and 
long-term potentiation of NMDA receptor signalling, resulting in central sensitisation, 
an enhanced responsiveness of neurons within the spinal cord and brain stem. 
Pharmacological intervention of these signalling pathways may therefore provide 
potentially novel, effective analgesic treatments for chronic pain. As discussed 
previously in chapters I, 4 and 5 the undesirable side-effect profile of broad-range 
NMDA receptor antagonists necessitates the selective targeting of specific receptor 
populations within nociceptive signalling and processing pathways. NR2B-containing 
receptors have since become the focus for NMDA receptor targeting, due to their 
expression patterns and proven involvement in nociceptive transmission (eg, Wei et al., 
200 I; Zhuo., 2002; Nishimura et al., 2004; Wu et al., 2005). 
The development of novel pharmaceutical compounds requires effective animal 
modelling to closely reproduce clinically relevant symptoms and phenotypes of disease. 
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The development ofNR2B-selective compounds has been reliant upon animal models of 
peripheral nerve lesion and inflammation (Karlsson et al., 2002; Wu et al., 2005), nerve 
injury (Dickenson et al., 1997) or subcutaneous injection of an inflammatory mediator 
into the rat hind paw with measurements of inflammation and pain recorded within 
several hours of the insult (Chaplan et al., 1994). These models therefore display 
predominantly acute nociceptive phenotypes and show limite-d success as bases for 
developing chronic therapies in the clinic. A requirement therefore exists for improved 
animal modelling of chronic pain which mimics the more persistent responses displayed 
in the clinic. 
This chapter will discuss and utilise tissue from a novel animal model of chronic 
inflammatory pain, developed by Alex Wilson and colleagues at GlaxoSmithKline 
(Wilson et al., 2005). The model was developed for therapeutic advancement of 
analgesic compounds including NR2B-selective antagonists and aimed to induce the 
peripheral and central sensitisation seen in chronic pain states. Inflammatory pain is 
induced by injection of the inflammatory mediator Freund's Complete Adjuvant (FCA) 
into the left knee joint of adult male Random-Hooded rats with weight bearing and joint 
diameter measurements made daily for up to 90 days post-FCA. 
Previous research has shown changes in NMDA receptor expression including up-
regulation ofNR2B-containing receptors (Wu et al., 2005), down-regulation ofNR2A-
containing receptors (Karlsson et al., 2002) and increased phosphorylation of NR1, 
NR2A and NR2B subunits in dorsal horn neurons (Zou et al., 2000; Gou et al., 2002) 
during inflammatory pain states. This chapter presents novel data investigating NMDA 
receptor subunit expression and phosphorylation states in rat brain and spinal cord tissue 
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from this pain model. NR 1, NR2A, NR2B, NR3B and PSD-95 protein expression and 
phosphorylation of NR2A (pY1325, pY1387) and NR2B (p1252, p1336, p1472) was 
investigated using immunohistochemical analysis (2.2.11 ). Functional NR2B-
containing receptors were mapped using autoradiographical analysis (2.2.22) with the 
NR2B-selective compound eH] Ro-256981, to provide a data set detailing modulation 
ofNMDA receptor complexes during chronic pain states. 
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6.2 Results 
Inflammatory hyperalgesia of the left knee joint was induced in adult male Random 
Hooded rats via injection of 150j.1.l Freund's Complete Adjuvant (containing 1mg/ml 
Mycobacterium tuberculosis). Sham control animals were injected with a saline 
solution. 16 days post-injection the rats were sacrificed and whole brains (n=8 sham, 
n=8 FCA) and spinal cords (n=8 sham, n=8 FCA) dissected and either snap frozen on 
dry ice or fixed in 4% paraformaldehyde until processing. 
6.2.1 Immunohistochemical characterisation of subunit expression in the spinal 
cord of adult male rats subjected to a novel chronic pain model 
Immunohistochemical analysis was carried out on the lumbar and thoracic regions of the 
fixed spinal cord tissue (n=4 sham, n=4 FCA) as detailed in 2.2.11. 
Following cryostat sectioning of the spinal cords (2.2.9.2) and blockade of endogenous 
peroxidase activity, the tissue was probed overnight with primary antibodies from the 
panel previously described in chapter 4; anti-NR1 (1j.1.g/ml), anti-NR2A (2J..Lg/ml), anti-
NR2B (2J..Lg/ml), anti-NR3B(885-899) (2J..Lg/ml) and also anti-PSD-95 (I: 1 000) and 
phosphorylation antibodies anti-NR2A (py1325, py1387) (1: 1000) and anti-NR2B 
(p1252, pl336, p1472) (1:1000) provided as a gift from Professor Seth Grant, Sanger 
Institute. Sections probed without primary antibodies acted as controls (figure 6.1 ). 
Both the sensory (dorsal) and motor (ventral) regions ofthe lumbar and thoracic spinal 
cord were analysed and immunoreactivity of each antibody compared between the sham 
and model (FCA) tissue for changes in expression. 
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Figure 6.1 Schematic (Tolle et al., 1993) and low resolution images (Uu et al., 1994) of the 
cord highlighting the dorsal (outer lamina) and ventral regions (motor neurons) 
investigated in this study (A) and control sections showing the immunoreactivity in tissue 
in the absence of primary antibodies in the lumbar dorsal horn (B), the lumbar ventral horn 
(C), the thoracic dorsal horn (D) and the thoracic ventral horn (E). 
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6.2.1.1 NRl expression 
The ubiquitously expressed NRl subunit showed abundant expression throughout the 
outer laminae of the dorsal horn and large cell bodies of the motor neurons in laminae 
IX in both the thoracic and lumbar regions of the spinal cords. An example of NR 1 
immunoreactivity in thoracic spinal cord is shown in figure 6.1. No detectable change 
in immunoreactivity between the sham and model tissue perhaps indicates that there is 
minimal modulation of the total numbers of NMDA receptors in an inflammatory state 
compared to control tissue, an observation supported by previous results showing no 
change in the number of neurons between control and nerve lesioned animals (Ultenius 
et al., 2006). 
A B 
Figure 6.2 Expression of NR1 protein in the dorsal (A) and ventral (B) horns of the thoracic 
cord in a sham animal probed with anti-NR1 (l!J.g/ml). The outer laminae I, 11, Ill are 
labelled in the dorsal horn (A) and cell bodies of motor neurons (MN) in lamina IX in the 
ventral horn (B). Scale bar represents 100J11D. 
202 
Chapter 6 Heather Chaffey 
6.2.1.2 NR2A expression 
Immunohistochemical analysis of NR2A protein showed immunoreactivity in the 
ventral horns of lumbar cord in both sham and FCA animals. NR2A expression showed 
no apparent changes in immunoreactivity between the sham and FCA tissue, consistent 
with previous research that detected no differences in immunoreactivity of non-
phosphorylated NR2A in a rat model of peripheral nerve injury (Uitenius et al., 2006) 
but contradicting a study which detected reduced NR2A mRNA expression after 
peripheral nerve lesion (Karlsson et al., 2002). Prominent NR2A protein expression 
was detected in the motor neuronal cell bodies of lamina IX in the ventral horn with 
more limited expression in the dorsal horns showing that NR2A plays a role in sensory 
and motor modulation consistent with previous research (Nagy et al., 2004). 
A B 
MN 
MN 
Figure 6.3 Expression of NR2A protein in the ventral horns of lumbar spinal cord in sham (A) 
and FCA model (B) animals, probed with anti-NR2A (2J.lgfml). The cell bodies of the motor 
neurons (MN) within laminae IX show high levels of NR2A protein expression. Scale bar 
represents 100J.1.ID. 
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6.2.1.3 NR2A phosphorylation 
Changes in the phosphorylation of the NR2A subunit between the sham and FCA 
animals was analysed using two antibodies; one which recognised single 
phosphorylation at tyrosine 1325 (p1325) and one which recognised single 
phosphorylation at tyrosine 1387 (p1387). Both tyrosine residues are located in the C-
terminus of the NR2A protein and can be phosphorylated by the Src family of protein 
tyrosine kinases (Lee, 2006). It has been proposed that Src-mediated tyrosine 
phosphorylation of the NR2A subunit potentiates NMDA receptor function by reducing 
tonic Zn2+ inhibition (Zheng et al., 1998). 
Phosphorylation of the NR2A subunit was evident in both the dorsal and ventral horns 
of lumbar and thoracic spinal regions. Immunoreactivity with the anti-py1325 antibody 
showed no detectable changes in NR2A phosphorylation at this residue between the 
sham and FCA animals (figure 6.3). Analysis with the anti-py1387 antibody showed 
initial evidence for enhanced phosphorylation of NR2A at this residue during an 
inflammatory response with increased immunoreactivity of the dorsal and ventral horns 
in the FCA lumbar tissue in comparison with the sham tissue (figure 6.4). However, 
immunoreactivity in the thoracic tissue was unchanged possibly indicating that 
phosphorylation may be confined to the lumbar region at the site of tibial and fibular 
nerve entry into the cord. The over-all immunoreactivity of the phosphorylated subunit 
was reduced possibly because it is detecting only NR2A as part of functional receptors 
at the cell surface which are phosphorylated and at synapses which are not as 
prominently labelled as cell bodies with this technique. 
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Figure 6.4 Expression of phosphorylated NRZA subunit at tyrosine residue 132 5 in the dorsal 
horn of sham (A) and FCA (B) lumbar cord tissue. Weak immunoreactivity is present 
particularly in the outer laminae (1, 11 and Ill) of the dorsal horn. Scale bar represents 
100J1m. 
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Figure 6.5 Expression of phosphorylated NRZA subunit at tyrosine 1387 in the dorsal horn of 
sham (A) and FCA (B) lumbar cord tissue. Initial evidence for increased phosphorylation of 
NR2A at tyrosine 1387 in the outer laminae (I, 11 and Ill) during the inflammatory response. 
Scale bar represents 100J1ID. 
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6.2.1.4 NR2B expression 
NR2B protein expression was concentrated in the outer laminae I, 11 and Ill of the dorsal 
horn and motor neuronal somata in the ventral horn, consistent with previous studies 
(Boyce et al., 1999; Nagy et al., 2004; O'Donnell et al., 2004). No detectable 
differences in immunoreactivity between the sham and FCA tissue suggest that NR2B 
expression is unchanged in the spinal cord under these inflammatory conditions. 
Previous studies have shown up-regulation of forebrain NR2B receptors after 
inflammation (Wu et al., 2005) and up-regulation ofNR2B mRNA in the rat dorsal horn 
following nerve lesion (Karlsson et al., 2002). Figure 6.5 shows NR2B 
immunoreactivity within the dorsal horn of the lumbar cord of both sham and FCA 
animals. 
A B 
11 
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Figure 6.6 Expression ofNR28 protein within the dorsal horns oflumbar spinal cord in sham 
(A) and FCA (B) tissue. NR2B shows expression in the outer laminae (I, 11 and Ill) in both 
sham and model tissue showing involvement in sensory inputs to the cord. Scale bar 
represents lOOJUD. 
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6.2.1.5 NR2B phosphorylation 
Phosphorylation of the NR2B subunit was investigated using three antibodies which 
recognised tyrosine residues Yl252, Y1336 and Y1472 respectively, again located in 
the C-terminal of the protein, which are phosphorylated via the Fyn family of kinases 
(Nakazawa et al., 2001 ). Analysis with all three antibodies revealed phosphorylated 
NR2B subunits in the dorsal and ventral horns throughout the spinal cord. 
Immunoreactivity with anti-pY1252 showed no detectable changes in phosphorylation 
between the sham and FCA tissue (figure 6.6). Immunoreactivity with anti-pY1336 and 
anti-pY1472 showed initial evidence for increased phosphorylation ofthe NR2B subunit 
at these residues in both the dorsal and ventral horns of the lumbar cord of FCA animals 
compared to sham tissue (figure 6.7 and figure 6.8). These findings are consistent with 
previous research which shows increased phosphorylation of NR2B with induction of 
LTP (Nakazawa et al., 2001) and blockade of NR2B receptor internalisation via 
phosphorylation at Y1472 potentiating receptor activity (Prybylowski et al., 2005). 
A B 
11 
Ill 
Figure 6.7 Expression of phosphorylated NR2B at tyrosine 1252 within the dorsal horn of 
lumbar sham {A) and FCA (B) tissue. Similar levels of immunoreactivity suggest no alteration 
in phosphorylation of Nr2B at this residue in the outer laminae I, 11 and Ill of the dorsal 
horns. Scale bar represents 100~m. 
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Figure 6.8 Expression of phosphorylated NR2B at residue y1336 within the dorsal horn of 
lumbar sham (A} and FCA (B) tissue. Initial evidence for increased phosphorylation of NR2B 
at this residue in the outer laminae I, 11 and Ill, suggesting potentiation of sensory NR2B· 
mediated transmission. Scale bar represents 1001JD1. 
A B 
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Figure 6.9 Expression of phosphorylated NR2B at residue y1472 within the dorsal horn of 
lumbar sham (A) and FCA (B) tissue. Initial evidence for enhanced phosphorylation of the 
NR2B subunit at residue 1472, in outer laminae I, 11 and Ill, important for blockade of 
receptor internalisation. Scale bar represents 100~m. 
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6.2.1.6 NR3B expression 
NR3B protein expression was prominent in the motor neuronal cell bodies in lamina IX 
of the ventral horn in all regions of the spinal cord of both sham and FCA animals. 
Somatic motor neuronal expression of NR3B is consistent with previous research 
mapping NR3B protein (Matsuda et al. , 2002) and mRNA (Nishi et al., 2001). 
Moderately high levels of immunoreactivity in the dorsal horns were detected, with 
potentially initial evidence for an increase in NR3B protein expression in the FCA 
animal dorsal horn in laminae I, 11 and Ill (figure 6.9). This provides novel data 
suggesting that inflammatory conditions may up-regulate NR3B expression in sensory 
areas. 
A B 
Figure 6.10 Expression of NRJB protein within the dorsal horns of the lumbar spinal cord in 
sham (A) and FCA (B) tissue. Initial evidence for increased NR3B expression in outer 
laminae I, 11 and Ill following onset of the inflammatory response. Scale bar represents 
1001lJil. 
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6.2.1.7 Post-synaptic density 95 (PSD-95) expression 
Analysis of the post-synaptic density using an anti-PSD-95 antibody revealed very weak 
immunoreactivity, particularly in the dorsal horns, where it may be difficult to detect 
due to its predominantly synaptic localisation. In the ventral horn, the large motor 
neuronal soma show immunoreactivity (figure 6.1 0), supporting previous data 
suggesting that intracellular pools of PSD-95 exist and can exhibit plastic changes and 
movement between synapses. 
A B 
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Figure 6.11 Expression of PSD-95 within the ventral horns of the lumbar cord in sham (A) 
and FCA (B) tissue. Initial evidence for increased expression of PSD-95 in the motor 
neuronal soma (MN) of FCA model tissue (B) in comparison with sham tissue (A). Scale bar 
represents lOOJUD. 
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6.2.1.8 Qualitative summary of NMDA receptor subunit expression and 
phosphorylation state in the lumbar and thoracic regions of spinal cord from 
control and model tissue. 
The data are semi-quantified and shown as the average intensity of immunoreactivity 
detected from parallel experiments in spinal cords from 2-4 sham animals and 2-4 FCA 
treated animals. 
Lumbar coni Thoracic l'ord 
Sham Model Sham Model 
VB DB VB DB VB DB VB DB 
Anti-NRl +++ +++ +++ +++ +++ +++ +++ +++ 
Anti-NR2A +++ ++ +++ ++ ++++ ++ ++++ ++ 
Anti-pyl387 ++ ++ +++ +++ ++ ++ ++ ++ 
Anti-pyl325 ++ ++ ++ ++ ++ +++ ++ ++ 
Anti-NR2B ++ ++ ++ ++ (+) (+) (+) (+) 
Anti-pl252 +++ ++ +++ ++ ++ ++ ++ ++ 
Anti-pl336 + + ++ ++ ++ ++ ++ ++ 
Anti-p1472 ++ + ++ ++ ++ ++ ++ ++ 
Anti-NR3B +++ ++ +++ +++ +++ +++ +++ +++ 
Anti-PSD-95 + (+) + (+) + (+) + (+) 
Table 6.1 Qualitative summary of the average intensity of immunoreactivity detected with 
each of the antibodies, in the lumbar and thoracic regions of the spinal cord. 
( +) =Very weak expression,+= Weak expression, ++ = Moderate expression, 
+++ = Strong expression, ++++ =Very strong expression. 
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6.2.2 Autoradiographical analysis of the distribution and density of NR2B-
containing receptors in the CNS of adult male rats exposed to a chronic pain 
model. 
Following dissection and rapid freezing of the tissue, autoradiography was carried out 
on lumbar and thoracic spinal cord regions and whole brains of FCA treated animals 
compared with sham animals (2.2.22). The NR2B-subtype selective compound eH] 
Ro-256981 was used to map NR2B expression in these tissues, defining non-specific 
binding with ifenprodil (lmM). Following autoradiography, the tissue sections were 
exposed to tritium-sensitive film together with slide-mounted tritium standards, used 
during analysis to calculate optical density values, and thus the concentration of bound 
radioligand (Bq/mg). The autoradiographs were exposed for 5-6 weeks at room 
temperature and developed for 5 minutes 
6.2.2.1 Analysis of autoradiography on the adult rat spinal cord 
Autoradiographical analysis on the adult rat spinal cord showed a high level of specific 
binding within the dorsal and ventral horns of the sham and FCA treated animals (Figure 
6.11 ). Effective displacement of eHJ Ro-256981 using 1 mM ifenprodil (figure 6.11) 
showed specific binding towards NR2B-containing receptors and is consistent with 
previous findings (Sheahan and Chazot, unpublished). 
The outer laminae of the dorsal horn and lamina IX of the ventral horn were regions of 
the spinal cord selected for analysis due to the high level of NR2B expression in these 
areas and their involvement in sensory and motor pathways. 
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Figure 6.12 Representative autoradiograms of adult rat lumbar spinal cord using (3H] Ro-
256981 in sham (A) and FCA treated (B) animals. Representative image showing non-
specific binding defined using ifenprodil (1mM) (C). 
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6.2.2.1.1 Mapping the expression of functional NR2B-containing receptors in the 
spinal cord of sham and FCA treated adult rats using eH] Ro-256981. 
Binding of eH] Ro-256981 within each region ofthe sham and FCA-treated spinal cord 
was compared using optical density measurements to calculate the concentration of 
bound radioligand (Bq/mg). 
eH] Ro-256981 binding in the outer lamina (I and II) of the dorsal horn showed 
prominent distribution of NR2B-containing receptors in this region of the cord 
consistent with previous immunohistochemical findings. Comparing the two regions of 
cord analysed, overall more eH] Ro-256981 binding was evident in the lumbar cord, 
likely to be due to a greater proportion of grey matter, though the density changes 
between the sham and FCA tissue were most evident in the thoracic cord. 
In the lumbar region enhanced NR2B expression was evident in the dorsal horn with 
increased eH] Ro-256981 binding, however, not to a significant level, possibly showing 
that induction of inflammation in this model results in up-regulation of NR2B-
containing receptors. These data are consistent with previous findings in forebrain (Wei 
et al., 2001; Wu et al., 2005) but contradict previous IHC findings, likely either to be 
due to the comparative insensitivity of IHC method or that IHC can't distinguish 
between an individual subunit and those in a functional complex. In the thoracic cord, 
both the dorsal and ventral horns showed increased binding of eH] Ro-256981 in the 
FCA-treated animals in comparison to sham animals. This provides evidence for up-
regulation of NR2B-containing receptor expression or activity in a region other than 
where the initial insult enters the spinal cord. 
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Figure 6.13 Autoradiographical data showing PH] Ro-256981 binding within the dorsal and 
ventral horns of sham and FCA spinal cord. 
Data shown are the mean values ± standard deviation for n=4 sham and n=4 FCA spinal 
cords. Sham and FCA tissue is compared in the dorsal horn of the lumbar cord (A), the 
ventral horn of the lumbar cord (B), the dorsal horn of the thoracic cord (C) and the ventral 
horn of the thoracic cord (D). Levels of PHI Ro-256981 binding are higher in the lumbar 
region than the thoracic region, consistent with NR2B immunoreactivities in IHC 
experiments. 
215 
Chapter 6 Heather Chaffey 
6.2.2.2 Analysis of autoradiography on the adult rat brain 
eH] Ro-256981 autoradiography on sham and FCA-treated rat brain revealed specific 
binding confined to forebrain regions, consistent with data showing minimal NR2B 
subunit expression in the cerebellum (Bradford and Chazot, unpublished, Thompson et 
al., 2000). 
The structures important for nociceptive signalling and processing were selected for 
analysis to determine any up-regulation in NR2B expression as a result of the 
inflammatory response. These structures were the somatosensory cortices, the anterior 
cingulate cortex, the periaqueductal grey, the thalamus and the hippocampal regions 
(CAI, CA2, CA3 and dentate gyrus) and were analysed from horizontal and coronal 
brain slices. 
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Figure 6.14 Representative horizontal (A+B) and coronal (C+D) autoradiograms showing 
pH] Ro-256981 binding within sham and FCA-treated rat brains. Non-specific binding was 
defined using 1mM ifenprodil (E). 
217 
Chapter 6 Heather Chaffey 
6.2.2.2.1 Mapping the expression of functional NR2B-containing receptors in the 
brain of sham and FCA treated adult rats using eH] Ro-256981. 
Binding of eH] Ro-256981 within each region of the sham and FCA-treated whole 
brains was compared using optical density measurements to calculate the concentration 
ofbound radioligand (Bq/mg). 
Overall, the level of eH] Ro-256981 binding in the FCA-treated animals was enhanced 
in comparison to sham tissue showing that this chronic pain model stimulates up-
regulation of NR2B-containing receptors. The somatosensory cortices, the cingulate 
cortex and the periaqueductal grey showed minimal increases in eH] Ro-256981 
binding levels in both the left and right hemispheres. The cingulate cortex and 
periaqueductal grey are components of the descending modulatory pathway of pain 
transmission which act to induce 'endogenous analgesia' and attenuate responses, 
therefore no significant up-regulation of excitatory NR2B-containing receptors may 
imply a reduced role for this subunit in descending transmission. The brain regions 
showing significant increases in eH] Ro-256981 binding were the thalamus, the 
hippocampal regions CA 1, CA3 and the dentate gyrus showing differential, rather than 
universal up-regulation. Interestingly, in CA3 and dentate gyrus, significant changes 
were only detected in the right hemisphere where information from the left knee would 
be processed. Increases in NR2B expression in the hippocampal regions may be 
indicative of the onset of stress-induced plastic changes of pain transmission and would 
thus be more evidence for the induction of chronic conditions in this model. 
218 
Chapter 6 
A 
~2 
~ 
~ 1 
:e 
c 
::c 
..... 
CO 
en 
CD 
&n 
N 
& 
£ 0 
"L 
c 
~ 4000 J• 
![ 
g» 300 
:g 
::c 200 
..... 
CO 
en 
CD 
~ 100 
ti. 
£ 
"L 
0· 
o-
o-
0 
Primary somatosensory cortex 
SHAM FCA 
Right Hemisphere 
SHAM FCA 
Left Hemisphere 
Cingulate cortex 
T 
.... .,-
-.-
. SHAM FCA SHAM FCA 
Right Hemisphere Left Hemisphere 
Heather Chaffey 
B Secondary somatosensory cortex 
~ 
:e 
c 
::c 
..... 
CO 
en 
CD 
&n 
N 500 
& 
£ 
"L SHAM FCA 
Right hemisphere 
D 
SHAM FCA 
Left hemisphere 
Periaqueductal grey 
c; ;i 1250 
--1 ~ 
:e 
c 750 
::c 
..... 
~ 500 
CD 
&n 
N 250 
& 
£ 
"L SHAM FCA 
Right Hemisphere 
SHAM FCA 
Left Hemisphere 
Figure 6.15 Autoradiographical data showing PH] Ro-256981 binding within the whole brain 
of sham and FCA-treated animals. 
Data shown are the means ± standard deviation of between n=3/4 sham and n=3/4 FCA 
whole brains. Sham and FCA tissue is compared in 1° somatosensory cortex (A), the 2° 
somatosensory cortex (B), the cingulate cortex (C), the periaqueductal grey (D). 
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Figure 6.16 Autoradiographical data showing PH] Ro-256981 binding within the whole 
brains of sham and FCA treated animals. 
Data shown are the means ±standard deviation of between n=3/4 sham and n=3/4 FCA 
whole brains. Sham and FCA tissue is compared in hippocampal regions CAt (E), CA2 (F), 
CA3 (G), the dentate gyrus (H).* p=< 0.05 Unpaired Two-tailed T-Test. 
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Figure 6.17 Autoradiographical data showing (3H] Ro-256981 binding within the whole 
brains of sham and FCA-treated animals. 
Data shown are the means ±standard deviation of between n=3/4 sham and n=3/4 FCA 
whole brains. Sham and FCA tissue is compared in the thalamus (I) and all brain regions in 
both hemispheres combined (p=O.OS) (J). * p=<O.OS Unpaired Two tailed T-Test. 
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6.3 Discussion 
The involvement of NMDA receptors in nociceptive transmissions has been widely 
researched (e.g., Fisher et al., 2000, Wei et al., 2001, Wu et al., 2005, Wilson et al., 
2005) with strong evidence to suggest involvement in plastic neuronal changes and 
chronification ofthe response. 
As discussed previously, the pharmacological development of effective analgesics relies 
heavily upon accurate, representative animal models which mimic clinical symptoms. 
This chapter presents novel data showing modulation of NMDA receptor subunit 
expression in an animal model of chronic inflammatory pain (Wilson et al., 2005). The 
model seeks to stimulate onset of peripheral sensitisation as a result of knee joint insult 
and to allow this primary afferent discharge to stimulate centrally mediated changes in 
the spinal cord (central sensitisation), a marker of chronification. This activity-
dependent facilitated transmission of dorsal horn nociceptive neurons occurs due to 
glutamate and neuromodulator activation of multiple intracellular signalling pathways 
via ionotropic and metabotropic glutamate receptors and protein kinases. Synaptic 
efficacy is increased by changes in ion channel activity, such as increased 
phosphorylation, increasing channel open-time, removing magnesium blockade of 
NMDA receptors and promoting receptor trafficking to the membrane (Woolf and 
Salter, 2000). The onset of NMDA receptor modulation, particularly -the increased 
phosphorylation and up-regulation of NR2B-containing receptors, shown in this chapter 
provides some evidence supporting the attainment of chronicity in this model. This is 
consistent with data presented in the initial study where hypersensitivity of the animal 
was maintained over 90 days, despite significant reductions in inflammation, and 
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effective NR2B-selective antagonism was observed suggesting central plastic changes 
had occurred (Wilson et al., 2005). 
In this study, analysis of the lumbar and thoracic regions of the spinal cord and the brain 
was carried out to record ascending and descending modulation of the nociceptive 
response. 
The immunohistochemical data showed abundant NR 1 expression throughout sensory 
and motor regions of sham and FCA-treated tissue, consistent with previous data 
showing no apparent difference in NRl protein or mRNA expression after nerve crush 
injury (Virgo et al., 2000). This data provided evidence to suggest that the overall 
number of NMDA receptors remains unchanged during chronic responses, but that 
receptor composition is altered by the enhancement of activity showing the NMDA 
complex to be a flexible assembly. There were also no apparent bilateral differences 
between the ipsilateral and contralateral sides of the cord. An interesting addition to the 
current data would be to investigate the time at which NMDA modulation begins, to 
gain a more accurate insight into the onset of chronification. 
Expression of NR2A and NR2B protein remained unaltered in FCA treated animals in 
comparison to sham animals providing possible evidence to suggest that the NR2A 
subunit is not replaced by NR2B under such circumstances to enhance receptor 
activation. However, these findings are in contrast to previous work which showed 
reduced NR2A mRNA following peripheral nerve injury and previous research 
showing up-regulation of NR2B mRNA after nerve injury (Virgo et al., 2000), up-
regulation of forebrain NR2B receptors after inflammation (Wu et al., 2005) and a 
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specific 28% increase in NR2B protein expression following colitis (Li et al., 2006). 
Also, the autoradiographical data in this chapter shows increased eH]-Ro256981 
binding towards NR2B-containing receptors possibly indicating up-regulation ofNR2B-
containing receptors in the spinal cord and brain, and therefore sensitivity of the 
immunohistochemical assay must be considered. 
NMDA receptor phosphorylation is a critical mechanism for protein regulation, function 
and involvement in intracellular signal transduction. Initial evidence for enhanced 
phosphorylation of both the NR2A and the NR2B subunit shows that the 
activation/function of the existing subunits may be enhanced in addition to or instead of 
up-regulating the subunit protein. Src-mediated tyrosine phosphorylation of the NR2A 
subunit potentiates NMDA receptor function by reducing tonic Zn2+ inhibition (Zheng et 
al., 1998) therefore phosphorylation at residue y1387 in both the lumbar dorsal and 
ventral horns in FCA-treated tissues suggests enhanced receptor activity in both sensory 
and motor systems. However, immunoreactivity in the thoracic tissue was unchanged 
possibly indicating that NR2A phosphorylation-mediated receptor enhancement is 
confined to the lumbar region at the site of nerve fibre entry into the L4 cord region. 
Fyn-mediated tyrosine phosphorylation of the NR2B subunit at residues y1336 and 
y 14 72 was enhanced again in the lumbar cord in the dorsal and ventral horns, showing 
enhanced receptor activity at the site of afferent entry into the cord, where nociceptive 
afferents from the injured knee synapse with the dorsal horn neurons. Repeating low 
frequency stimulations, causing slow synaptic potentials gradually produce a cumulative 
summation of responses, a phenomenon known as windup. A resulting cumulative 
depolarisation occurs, releasing the voltage-dependent magnesium block on NMDA 
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receptors, inducing increased activation and phosphorylation of receptors increasing the 
action potential response (Thompson et al., 1990; Ji et al., 2003) and leading to early 
onset central sensitisation within the cord. 
These findings are consistent with previous research showing increased phosphorylation 
ofNR2B with induction of LTP (Rosenblum et al., 1996; Nakazawa et al., 2001) and 
imply enhanced receptor activity on sensory and motor neurons and potential onset of 
hyperalgesia (demonstrated by animals in the model upon mechanical stimulation). 
Phosphorylation of the tyrosine residue 1472 is thought to inhibit NR2B-containing 
receptor internalisation thereby potentiating receptor presence at the cell surface and 
augmenting transmissions. Phosphorylation at this residue prevents AP-2 adaptors from 
binding to the critical internalisation sequence YEKL in the C-terminal of NR2B, 
blocking endocytosis and potentiating surface expression (Lee, 2006). This may again 
be evidence to suggest that the NR2B protein itself is not up-regulated, just the 
phosphorylation, holding the receptor at the cell surface for longer, increasing binding. 
Expression of NR3B showed initial evidence of up-regulation in the lumbar cord 
posterior dorsal horn in the FCA-treated animals in comparison to the sham tissue 
suggesting that inflammatory conditions may up-regulate NR3B expression in sensory 
areas. It is possible that this up-regulation of NR3B may have a protective role, to 
counteract and regulate Ca2+ entry into the cells in the event of NR2B-mediated hyper-
activation. Prominent expression in the outer laminae also suggests NR3B involvement 
in afferent terminal transmissions, providing further evidence for a more extensive role 
than previously considered and consistent with recent data (Wee et al., 2007). 
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Expression in the motor neurons in lumbar and thoracic regions (lamina IX) remained 
prominent throughout both the FCA and sham tissues and again no observable 
differences were detected between the ipsilateral and contralateral sides of the cord. 
Expression levels of PSD-95 were low in both the FCA-treated and sham cords, with no 
detectable differences between the comparable sections oftissue. Immunoreactivity was 
most prominent in the soma of motor neurons in lamina IX, likely to be due to the large 
area for staining in these cells and lack of sensitivity in smaller neuronal processes or 
possibly intracellular storage pools of protein. It would be expected that PSD-95 would 
have abundant expression throughout the spinal cord, over-lapping with that of the 
NMDA receptor subunits, in both the posterior and anterior horn due to its vital role as a 
multivalent adaptor and anchoring protein (Garry et al., 2003). A previous study 
showed PSD-95 expression restricted to lamina II of the dorsal horn (Garry et al., 2003), 
therefore these contrasting results may be indicative of detection sensitivity issues as the 
PSD-95 complex is constantly changing and re-locating within the cell according to 
requirement. 
Autoradiographical analysis of sham and FCA-treated spinal cords and whole brains 
enabled detailed, quantifiable mapping of the expression and modulation of NR2B-
containing receptors via the specific binding of the NR2B-selective antagonist eH] Ro-
256981. Transverse sectioning of thoracic and lumbar spinal cords and horizontal and 
coronal sectioning of the brains facilitated specific binding to NR2B-containing 
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receptors in the spinothalamic tracts and higher brain centres important in nociceptive 
processing. 
The spinal cord autoradiograms showed prominent specific radioligand binding in the 
superficial laminae of the dorsal horns and lamina IX ofthe ventral horns (figure 6.12), 
which displayed a similar bilateral distribution, reflecting previously published patterns 
ofNR2B expression (Nagy et al., 2004). This specific binding in the sensory and motor 
regions was analysed to investigate the potential up-regulation of NR2B expression and 
its involvement in both afferent and efferent pathways following nociceptive 
stimulation. 
Comparing the two regions of spinal cord tissue, the overall level of specific eH] Ro 
256981 binding was greater in the lumbar cord than in the thoracic cord probably due to 
the increased grey matter proportions in this region containing a larger quantity of 
neuronal cell bodies and dendrites, but also because this is the site of entry to the cord of 
the afferent neurons from the knee insult. 
In the thoracic cord, eH] Ro-256981 binding was increased in similar proportions in 
both the dorsal and ventral horns, potentially implying an increase in NR2B-containing 
receptors as a result of enhanced transduction, possibly descending as both sensory and 
motor transmissions from higher brain centres to different areas of the cord. 
This data may provide initial evidence for an increase in eH] Ro-256981 binding in 
diseased tissue as a result of either up-regulation of the NR2B subunit, or increased 
NMDA phosphorylation maintaining NR2B-containing receptor expression at the cell 
surface, though further work to increase the number of samples would be required for 
more accurate conclusions. This data is consistent with previously published results 
227 
Chapter 6 Heather Chaffey 
detailing increased expression ofNR2B in lumbar-sacral spinal cord regions after colitis 
(Li et al., 2006) and the genetic enhancement of inflammatory pain by over expression 
offorebrain NR2B receptors (Wei et al., 2001). 
Autoradiographical analysis of sham and FCA-treated rat whole brains revealed NR2B 
expression confined to forebrain regions consistent with previous data (Sheahan and 
Chazot, unpublished; Stephenson, 2001 ). Minimal background binding in the 
cerebellum is consistent with previous fmdings in the laboratory (Sheahan and Chazot, 
unpublished; Bradford and Chazot, unpublished) and may result from an additional 
binding site of eH] Ro-256981. A previous study also showed some NR2B 
immunoreactivity in cell bodies and dendritic arbors of Purkinje cells {Thompson et al., 
2000). 
Analysis of the forebrain areas was concentrated on the structures important for 
nociceptive processing and comprising the sensory-discriminative and emotional-
affective areas of pain perception (Tracey et al., 2002). Structures involved in the 
ascending spinothalamic tract were investigated, with cortical sensory areas, and the 
descending pathway thought to modulate endogenous analgesia. 
To detect any bilateral changes, the left and right hemispheres were analysed separately, 
with a greater proportion of significant modifications being evident in the right 
hemisphere. This observation shows that despite overall increases in eH] Ro-256981 
binding throughout the brain (p=0.05), the resultant modifications occur primarily in the 
contralateral hemisphere directly processing information from the insult on the left knee. 
It would be interesting to see if this hemispheric separation remained throughout a 
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longer time-course to distinguish any patterns of hyper-sensitisation and observe any 
masking of bilateral differences. 
Radioligand binding in the primary and secondary somatosensory cortices was slightly 
increased in the FCA-treated tissue in comparison with the sham brains in both the left 
and right hemispheres, though no significant increase was observed. To perceive acute 
rapid pain in the somatosensory cortex fast conducting, first order neurons enter the 
spinal cord synapsing in the dorsal horn, with second order neurons crossing to the 
contralateral side and forming the axons of the spinothalamic tract. The spinothalamic 
tract ascends to the thalamus terminating in the ventral posterolateral thalamic nucleus 
(VPL) where third order neurons then ascend and pass into the sensory cortex and 
sensations are perceived (Young and Young, 1997). However, in chronic pain, spinal 
cord reorganisation modifies pathways and slower, more chronic pain is transmitted via 
a more diffuse pathway called the spinoreticulothalamic tract which is located more 
medially in the brain stem, synapses in the reticulothalamic system, which projects to 
medial parts of the thalamus and consequently to more widespread regions of the cortex, 
particularly those responsible for an emotional response to pain, such as the limbic 
system, rather than the somatosensory cortex. Therefore the small changes in the 
sensory cortex seen in this model, but the significant changes seen in the hippocampus 
may again provide more evidence for the onset of slower, chronic nociceptive 
transmissions. 
eH] Ro256981 binding in the thalamus was significantly increased in FCA-treated 
tissue in comparison to sham brains providing evidence for increased NR2B expression 
and/or NR2B-containing receptor activation in this model, consistent with up-regulation 
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of forebrain receptors following inflammation (Wu et al., 2005). The thalamus is a 
large nuclear mass forming 80% of the diencephalon (Tortora and Grabowski, 2003), an 
area of the forebrain vital for the integration and dissemination of ascending and 
descending sensory impulses from the spinal cord and brain stem to the cortices (Young 
and Young, 1997) and back again. As previously described, nociceptive transmissions 
ascending the spinal cord arrive in the medial thalamus for processing and dispersal to 
cortical areas responsible for emotional and motor responses. Increased NMDA 
receptor activity in the thalamus therefore provides evidence for the onset of centrally 
mediated enhanced activity and persistent responses in this model. 
eH] Ro-256981 binding to the hippocampal formation showed prominent NR2B 
expression in the neuronal cell bodies of the CAl, CA2 and CA3 fields, and in the 
granular cell layer of the dentate gyrus consistent with previously published data 
(Thompson et al., 2002). Significant increases in eH] Ro-256981 binding were 
apparent in FCA -treated tissue in comparison with sham tissue in the CA3 region where 
some hemispheric differences were again evident. NMDA receptors and their 
involvement in neuronal plasticity, LTP and L TD have been well characterised in the 
hippocampus which is critical for learning and formation of new memories (Bliss and 
L0mo, 1973; Bliss and Collingridge, 1993; Kim et al., 1996; Y ang et al., 2005, Toyoda 
et al., 2006.). The increase in hippocampal NR2B-containing receptor activity in this 
model may be the result of increases in synaptic strength and possibly the onset of L TP 
induced by the summation of excitatory post-synaptic potentials (EPSP), excessive 
membrane depolarisation and enhanced NMDA receptor activation enabling increased 
calcium influx. The calcium signal within the cell is thought to contribute to the 
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plasticity of a synapse inducing either L TP or L TO to increase or reduce synaptic 
strength accordingly (Bienenstock et al., 1982). 
Hippocampal connections with the cingulum and the cortex may transmit perceptions of 
pain and thus form stress responses and fear memories in animals experiencing 
hyperalgesia and mechanical allodynia from external stimuli. Previous findings have 
demonstrated that behavioural stress induced by repeated tail shock in adult rats, 
facilitated LTD in hippocampal CAI regions (Yang et al., 2005) possibly as a 
mechanism to regulate neuronal activity (Zhuo 2002). It is proposed that the stress-
induced increase in corticosterone levels activates glucocorticoid receptors and inhibits 
uptake of synaptically released glutamate, enabling glutamate spill over from the 
synaptic cleft and subsequent activation of extrasynaptic NR2B-containing NMDA 
receptors. It is therefore possible that a similar mechanism of plasticity could arise from 
stress induced by FCA treatment in this model, facilitating increased NR2B-receptor 
activation. 
Small increases in eH] Ro-256981 binding were observed in FCA-treated tissue in 
comparison with sham tissue in the cingulate cortex and periaqueductal grey, possibly 
indicating the onset of descending modulatory inhibition, though no statistically 
significant increases were measured. Overall, the level of radio ligand binding was much 
lower in the periaqueductal grey possibly showing a lower expression level of NR2B-
containing receptors in this region. Supraspinal structures such as the cingulate cortex 
and the periaqueductal grey-rostroventral medulla are part of a descending pathway 
involved with endogenous analgesic control and transmit descending facilitatory 
modulation to the dorsal horn neurons in the spinal cord via glutamate, inhibitory 
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transmitters GABA and glycine, and with the release of endogenous opioids (Zhuo 
2002, Tracey et al., 2002). Connections with reticular formation nuclei inhibit the 
transmission of ascending nociceptive signals via secondary neurons (Young and 
Young, 1997) and peripheral nociceptive signals from descending higher cortical 
pathways can also be controlled. It has been shown that direct electrical stimulation of 
the PAG in humans and in rats can inhibit reflex responses to noxious stimulation 
(Tracey et al., 2002) and therefore this descending pathway may provide potential 
targets for pharmaceutical intervention to stimulate the internal analgesic mechanisms in 
chronic conditions. 
In conclusion, the novel data presented in this chapter provides evidence to suggest the 
attainment of chronic pain in this model, which could therefore be used to provide more 
clinically significant representations of persistent pain. 
Immunohistochemical analysis showing an up-regulation of phosphorylated NR2A and 
NR2B proteins and autoradiographical data detailing the up-regulation and/or increased 
expression of NR2B-containing receptors in both the spinal cord and forebrain in this 
model confirm the critical involvement of NMDA receptor modulation in nociceptive 
transmissions and therefore support the pharmacological targeting of NR2B-containing 
receptors for analgesia. 
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Chapter 7 
OveraU discussion and further work 
This thesis has investigated the physiological flexibility of the NMDA receptor, 
analysing subunit expression and assessing changes in receptor physiology and 
pharmacology conveyed by the distinct modulatory properties of its component 
subunits. 
The work contained herein was focused on investigation of three main hypotheses: to 
investigate the potential of selective pharmacological targeting of NR2B-containing 
receptors and to characterise two novel NR2B-selective antagonists, to investigate 
the influence of the NR3 subunits upon receptor physiology and NR2B-selective 
antagonist function, and to investigate changes in NMDA receptor physiology during 
chronic pain states. 
7.1 Characterisation of COMPOUND A and COMPOUND B 
In chapter 3, characterisation of the two novel NR2B-selective antagonists 
COMPOUND A and COMPOUND B, revealed that both compounds displayed a 
high affinity for native and recombinant receptors composed exclusively of 
NR1/NR2B subunits. Low affinity displacement of eH] Ro-256981 suggests that 
the novel compounds are sensitive to the presence of alternative NR2 or NR3 
subunits or interacting proteins in the receptor complex, or that they have possibly 
distinct but overlapping binding sites to that of the Roche compound. 
High affinity competitive antagonism with eHJ CP-101606 showed that 
COMPOUND A and COMPOUND B compete for the same NR1/NR2B receptor 
populations and are likely to compete for the same binding sites on the receptor 
complex. Incomplete displacement with COMPOUND B suggests that CP-101606 
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binds to an alternative receptor population or non-NMDA receptor component in the 
native tissue to which COMPOUND A also binds, but COMPOUND B does not, 
implying different interactions between the two novel compounds. These data 
provide evidence that these novel antagonists potentially show an advanced 
selectivity profile in comparison to the most effective NR2B antagonists currently in 
the public domain, sharing properties with the Pfizer compound CP-1 01606 and 
showing higher selectivity than the Roche antagonist Ro-256981 (Represented in 
figure 7.1 ). 
Distinct displacement patterns of eHJ MK-801 demonstrated the potential for 
differential modulation of the channel pore between the two compounds, showing 
that COMPOUND B binding effects open-channel probability and may have some 
allosteric interaction with the channel pore MK-801 binding site. Therefore 
COMPOUND B may have a distinct mode of action and possibly site of action to 
COMPOUND A. 
Ro-256981 
K,=9.4nM 
j \ 
CP-101606 COMPOUND A COMPOUND 8 
r· /<~~~~=// ~;=~ 
MK-801 binding 
site 
1 
V 
NR1/NR2B 
Figure 7.1 Schematic diagram showing the binding affinities and selectivity towards NR2B· 
containing receptors of Ro-256981, CP-101606, COMPOUND A and COMPOUND B, and the 
potential allosteric interaction of COMPOUND B with the channel pore. 
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Investigating the functional effects of the two novel compounds with cytotoxicity 
assays revealed differential antagonistic effects of COMPOUND A and 
COMPOUND B in recombinant NR1/NR2B receptors. Effective cytoprotection was 
evident for both compounds at lJ.!M concentration. To further characterize these 
novel NR2B antagonists, whole-cell patch clamp electrophysiology could be carried 
out as a functional assay to look at binding efficacy, effectiveness of current 
inhibition and reversible inhibition. Site-directed mutagenesis studies could also be 
carried out to analyse the binding sites of each compound in detail. 
7.2 Expression and differential cytoprotective effects ofNR3 subunits 
To further enhance the understanding of the impact of alternative subunits upon 
NR2B receptor populations and NR2B-selective antagonists, interactions with the 
NR3 subunits were investigated. It has been shown that the NR3 subunits are 
expressed predominantly in motor neurons but more recent studies suggest a wider 
distribution throughout the brain (Wee et al., 2007, Nilsson et al., 2007), particularly 
in the human and therefore their impact upon NMDA receptor physiology and 
pharmacology is important to understand. 
This thesis presents novel data, showing the eo-expression of the NR3B subunit with 
NRl, NR2A and NR2B protein in adult rat and human spinal cord, in the motor and 
possibly sensory regions and provides putative evidence for their eo-assembly in 
these structures. Further work in this area would be fundamental to understand the 
native interactions of the NR3B subunit in the spinal cord and the brain. In future 
experiments lumbar/thoracic spinal cord homogenate should be used for 
solubilisation to maximize receptor subunit expression, particularly of NR2B and 
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NR3B. Direct immunoprecipitation with the anti-NR3B antibody may be a more 
effective tool than immunopurification, though it would be important to confirm 
antibody specificity using tissue from knock-out mice (Neimann et al., 2007). It 
would also be very interesting to investigate any potential changes in native NR3B 
eo-assemblies in human tissue both from normal patients and from patients who 
have suffered a neurodegenerative illness. 
Chapter 5 presents novel evidence for a differential cytoprotective effect of the NR3 
subunits upon NRIINR2A and NR1/NR2B receptors in vitro, highlighting the 
potential for different interactions and effects within native receptor populations. 
Ca2• 
NR1/NR2A 
caz• 
NR1/NR2A/NR3A 
No 
cytoprotection 
Ca2• 
NR1/NR2A/NR3B 
No 
cytoprotection 
caz• 
NR1/NR2B 
caz• 
NR1/NR2B/NR3A 
21% reduction in 
cytotoxicity 
Ca2' 
NR1/NR2B/NR3B 
27% reduction in 
cytotoxicity 
Figure 7.2 A schematic diagram showing the differential protective effect of the NR3 
subunits upon the proposed NMDA-mediated calcium toxicity in NR1/NR2A and 
NR1/NR2B receptors. 
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A significant reduction in cell death when both NR3A and NR3B are eo-expressed 
with NR1/NR2B receptors may indicate an endogenous mechanism triggered to 
counteract the hyper-excitation of the NR2B-containing NMDA receptors and 
reduce cytotoxicity in native systems. Indeed, initial evidence for an increase in 
NR3B expression throughout the spinal cord presented in the rat model of chronic 
pain, shows that this endogenous protective mechanism may be induced in 
pathological conditions. 
From this work, it was possible to hypothesise that neurodegenerative conditions 
mediated in part by NMDA calcium toxicity may develop from defective NR3 
expression. Recently a study was published suggesting that 10% of the normal 
European-American population lacks NR3B due to a homozygous occurrence of a 
null allele in the gene (Niemann et al., 2007). The question arising about the 
phenotypic consequences of this genetic loss was partly answered in the same study 
which looked specifically at ALS (motor neuron disease). The researchers reported 
no obvious impairment of motor neuronal function or increased susceptibility for 
ALS in the absence of NR3B suggesting that 'NR3B is functionally redundant' 
(Niemann et al., 2007) in humans. However, species differences are clearly apparent 
as animal models have shown that NR3B knockout mice develop progressive paresis 
and die at P5 with loss of motor neurons in the spinal cord (Qu et al., 2004) and 
genetic ablation ofNR3B in mice showed a moderate but significant impairment of 
motor co-ordination and enhanced anxiety-like behaviour consistent with effects of 
NR3B loss in higher brain centers such as the hippocampus and amygdala (Niemann 
et al., 2007). 
These apparent variations between species therefore require further investigation, to 
confirm the role of NR3B in the receptor complex. It would be interesting to 
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investigate the cytoprotective effects of human recombinant receptor combinations 
in the presence and absence of NR3B and compare them with the rodent studies. 
Also more expression and purification studies are required to map NR3B expression 
in rodents, monkeys and humans to see if there is an evolutionary stage at which 
NR3B became redundant, confirming or refuting the recent publication. It would 
also be interesting to see if expression levels of NR3A are increased as a 
compensatory mechanism in individuals lacking the NR3B subunit as recent studies 
showed NR3A expression in the adult human (Eriksson et al., 2002; Niemann et al., 
2007) whereas only minimal expression in the adult rodent is evident (Sucher et al., 
1995). 
To further investigate the cytoprotective properties of the NR3A and NR3B subunits 
it would be interesting to repeat the cytotoxicity assays co-transfecting both NR3A 
and NR3B with NR1!NR2B receptors, to see if a combination of both NR3 subunits 
enhances the cytoprotective effect. The recent studies showing NR3A expression in 
the adult human (Eriksson et al., 2002; Niemann et al., 2007), suggest that 
potentially both NR3A and NR3B could be expressed together in the same receptor 
complex. 
7.3 Physiological impact of NR3B in NR1/NR2B receptors 
In chapter 5, electrophysiological analysis of the physiological impact of NR3B 
upon NR1/NR2B receptors showed that current amplitudes and calcium 
permeabilities remained unchanged in this system, contrasting with literature 
previously published on eo-expression of NR1/NR2AINR3B (Nishi et al., 2001; 
Matsuda et al., 2002). However, recent work, published only in abstract form, 
suggests that receptor currents are significantly altered depending on eo-expression 
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of NRl splice variant, suggesting that NRl-la expressiOn with NR2B/NR3B 
potentiates currents, whilst expression with NR2AINR3B attenuates currents (Cavara 
and Hollmann, 2007). Whilst this study supports the electrophysiological data 
presented in this thesis, it contradicts the cytotoxicity data which suggests 
suppression of receptor activity. It is therefore apparent that further research is 
required to explain these contradictions in the current data set and it may become 
evident that NR3B interacts with other protein complexes in the cell to reduce 
internal calcium concentrations. Repetition of these studies using single channel 
electrophysiology could enable more detailed study of the differences in receptor 
channel activity imposed by NR3B and may reduce the potential for subtle changes 
in whole receptor populations measured with whole-cell assays. Further experiments 
using FLIPR analysis could also be used to measure intracellular calcium 
concentrations in large cell populations expressing various combinations of rodent 
and human NR3 subunits. Effective subunit tagging before transfection could also 
ensure that measurements were taken from cells eo-expressing all three subunits and 
transfection with different NRl splice variants should be investigated. Tracking the 
movement of NR3B within a cell or neuron may indicate whether it interacts with 
alternative intracellular complexes, and purification of NR3B from the cell surface, 
may indicate any non-NMDA associations. 
7.4 Pharmacological impact ofNR3B in NR1/NR2B receptors 
Novel pharmacological interactions of the NR3B subunit with NR1/NR2B 
containing receptors were also presented in this thesis, providing evidence for 
potentially important modifications of compound interaction. eo-expression of 
NR3B in the receptor complex appeared to enhance the apparent affinity of the 
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NR2B-antagonist ifenprodil for the receptor complex, increasing the level of 
cytoprotection conveyed by this compound. Furthermore, in the cytotoxicity assay 
COMPOUND A sensitivity appeared reduced in the presence of NR3B, with no 
significant reduction in cytotoxicity measured. Interestingly, in binding assays, the 
inclusion of NR3B in the receptor complex appeared to reduce binding affinities of 
COMPOUND A, COMPOUND B, CP-101606 and Ro-256981 to the receptor. 
These data provide initial evidence to suggest a potentially important 
pharmacological impact of the NR3B subunit upon NR2B-selective antagonists. 
t 
ICOI\~POlJND A binding+ 
l---ICOI\o~P01JND B binding + 
1Ro-<t569:111 binding + 
,._,.-,,u ..... uo binding + 
NR1/NR2B NR1/NR2B/NR3B 
2x LIVBP binding sites lx LIVBP binding site 
Potential allosteric 
modulation by NR3B 
Figure 7.3 A schematic diagram showing that the inclusion of an NR3B subunit into the 
receptor complex may have an allosteric effect upon the LIVBP binding domain of the 
NR2B-selective antagonists. 
To expand upon these findings it would be important to repeat the binding 
experiments and the cytotoxicity assays with wider concentration ranges of the five 
compounds and to repeat the binding assays with ifenprodil for direct comparison. 
Surface binding experiments, using cross-linking reagents could show if the 
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expression ofNR2B at the cell surface is reduced upon inclusion ofNR3B. Whole-
cell electrophysiology could be carried out to analyse the effects of all five 
compounds towards recombinant receptors and site-directed mutagenesis studies 
could be used to investigate and compare the binding sites of each antagonist. 
It may also be possible to culture motor neurons and sensory neurons in vitro and 
see if they respond differently to the antagonists thereby investigating whether the 
NR3B subunit has similar effects in native neurons as in receptors expressed in HEK 
293cells. It would also be interesting to see if eo-expression of NR3A with 
NR1/NR2B affected the antagonists in a similar manner to NR3B. 
7.5 NMDA receptor modulation in a chronic pain model 
Autoradiographical and immunohistochemical analysis of rat spinal cord and whole 
brain from a chronic pain model showed initial evidence for increased NR3B 
expression and NR2A phosphorylation in comparison to controls, suggesting 
increased NMDA receptor activity and up-regulation of NR3B as an endogenous 
cytoprotective mechanism. Increased binding of eHJ Ro-256981 and increased 
phosphorylation of NR2B in comparison to control tissue also provides evidence for 
increased expression of NR2B and/or potentiation of NR2B-containing receptor 
activity via inhibition of endocytosis. These modulations to NMDA receptor 
activity, induced by persistent nociceptive inputs, suggest attainment of a level of 
central sensitization and chronicity in this model. 
This work provides evidence for a simultaneous increase in NR2B receptor activity 
in both the dorsal and the ventral horns of the spinal cord, particularly in the thoracic 
region showing hyperactivity and increased sensitivity in both sensory and motor 
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systems. Also, significant increases in eH] Ro-256981 binding in the thalamus and 
hippocampus show the onset of increased receptor activity in supraspinal structures 
and the recruitment of emotional brain centers during chronic pain states, possibly 
effecting memory formation in these animals and relaying the onset of stress and 
fear. 
These physiological changes in receptor properties and the up-regulation of NR2B-
receptors at the cell surface in chronic pain states are consistent with previous 
publications and provide further evidence to support the targeting of NR2B-
containing receptors for analgesia. 
Chronic pain 
pathway 
1=-=-1---f 
Figure 7.4 A schematic diagram showing the pathway of chronic pain transmission from 
the spinal cord, through the brainstem and into the cortex (Anaesthesia, UK 
www.frca.co.uk) and the changes in the NMDA receptor which may contribute to the 
persistent response. 
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To confirm the results presented in this thesis, the assays could be repeated using a 
larger number of animals and replicates for each study. Perfusion fixation may 
increase the quality of the tissue for immunohistochemistry, the whole brains should 
be analysed and the immunoreactivity in the tissue could be quantified using a slice 
densitometer (Ultenius et al., 2006) to avoid subjective conclusions. It would also 
be interesting to compare tissue from this model with that from an acute model, and 
analyse different time-points during the experiment to determine the stage at which 
persistent pain occurs and where NMDA involvement is enhanced. It would also be 
interesting to perform high resolution studies to see if up-regulation of receptor 
activity is concentrated synaptically or extrasynaptically. 
7.6 Overall :fmdings 
• The novel compounds presented in this thesis are high affinity, selective 
NR2B antagonists, which have potential to be developed as clinical 
analgesics following further investigations into their side effect profile and 
effectiveness in vivo. 
• The NR3 subunits show differential cytoprotective properties when eo-
expressed within recombinant NMDA receptor complexes, providing 
significant cytoprotection towards NR1/NR2B receptors but not to 
NR1/NR2A receptors, though the mechanism by which this reduction in 
cytotoxicity is mediated requires further investigation. 
• The inclusion of NR3B in NR1/NR2B receptor complexes appears to 
modulate the binding affinities of some NR2B-selective antagonists, possibly 
by allosterically altering their binding sites. 
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• The up-regulation of NR3B and NR2B subunit expression and increased 
phosphorylation ofNR2B and NR2A provides evidence for NMDA receptor 
subtype involvement in the onset of persistent pain and further supports 
NR2B-subunit targeting for analgesic development. From the evidence 
published (Wilson et al., 2005) and the work presented in this thesis, this 
chronic pain model appears to provide an effective mimic of clinical 
symptoms of long-term inflammatory pain, and therefore would provide an 
essential tool for assessing future drug candidates. 
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